Nitric oxide-generating vasodilators and 8-bromo-cycli mitogenesis and proliferation of cultured rat vascular s

Journal of Clinical Investigation 83, 1774-1777

DOI: 10.1172/jci114081

Citation Report

#	Article	IF	CITATIONS
1	Antiproliferative action of cyclic GMP-elevating vasodilators in cultured rabbit aortic smooth muscle cells. Atherosclerosis, 1989, 80, 143-147.	0.8	133
2	Inhibition by nitric oxide and nitric oxide-producing vasodilators of DNA synthesis in vascular smooth muscle cells. European Journal of Pharmacology, 1990, 189, 347-353.	2.6	223
3	Vasoactive Peptides and Their Receptors. Journal of Vascular Research, 1990, 27, 137-145.	1.4	6
4	The endothelin explosion. A pathophysiological reality or a biological curiosity?. Circulation, 1990, 81, 2022-2025.	1.6	33
5	Endothelial Control of Vascular Tone and Growth. Clinical and Experimental Hypertension, 1990, 12, 897-902.	0.3	16
6	Persistent dysfunction of regenerated endothelium after balloon angioplasty of rabbit iliac artery Circulation, 1990, 81, 1667-1679.	1.6	169
7	Serum-induced proliferation of rabbit aortic smooth muscle cells from the contractile state is inhibited by 8-Br-CAMP but not 8-Br-cGMP. Atherosclerosis, 1990, 82, 113-123.	0.8	108
8	Regulatory Functions of the Vascular Endothelium. New England Journal of Medicine, 1990, 323, 27-36.	27.0	1,809
9	Nitric oxide-generating vasodilators inhibit mitogenesis and proliferation of BALBc 3T3 fibroblasts by a cyclic GMP-independent mechanism. Biochemical and Biophysical Research Communications, 1990, 171, 474-479.	2.1	139
10	Endothelial control of vascular tone in large and small coronary arteries. Journal of the American College of Cardiology, 1990, 15, 519-527.	2.8	178
11	Biotransformation of organic nitrates to nitric oxide by vascular smooth muscle and endothelial cells. Biochemical and Biophysical Research Communications, 1991, 180, 286-293.	2.1	151
12	Coronary atherosclerosis: Current therapeutic approaches and future trends. Life Sciences, 1991, 49, 689-705.	4.3	18
13	Effects of cyclic nucleotides and phorbol myristate acetate on proliferation of pig aortic endothelial cells. British Journal of Pharmacology, 1991, 102, 101-106.	5 <b>.</b> 4	16
14	POSTER COMMUNICATIONS. British Journal of Pharmacology, 1991, 102, 159P.	5.4	1
15	Inhibition by prostacyclin and carbacyclins of endothelin-induced DNA synthesis in cultured vascular smooth muscle cells. Prostaglandins Leukotrienes and Essential Fatty Acids, 1991, 44, 237-239.	2.2	8
16	Hypertension, endothelium, and cardiovascular risk factors. American Journal of Medicine, 1991, 90, \$13-\$18.	1.5	27
17	C-Type natriuretic peptide is a growth inhibitor of rat vascular smooth muscle cells. Biochemical and Biophysical Research Communications, 1991, 177, 927-931.	2.1	190
18	Stimulation by D-glucose of the direct conversion of arginine to citrulline in enterocytes isolated from pig jejunum. Biochemical and Biophysical Research Communications, 1991, 177, 1171-1177.	2.1	27

#	Article	IF	CITATIONS
19	Clearance receptor-binding atrial natriuretic peptides inhibit mitogenesis and proliferation of rat aortic smooth muscle cells. Biochemical and Biophysical Research Communications, 1991, 179, 1606-1613.	2.1	86
20	Suppression of lymphocyte proliferation through the nitric oxide synthesizing pathway. Journal of Surgical Research, 1991, 50, 403-409.	1.6	128
21	Influence of 8-(N,N-Diethylamino)octyl-3,4,5-trimethoxybenzoate (TMB-8) on cell cycle progression and proliferation of cultured arterial smooth muscle cells. Biochemical Pharmacology, 1991, 41, 1045-1054.	4.4	18
22	Impairment of Endothelium-Dependent Pulmonary-Artery Relaxation in Chronic Obstructive Lung Disease. New England Journal of Medicine, 1991, 324, 1539-1547.	27.0	507
23	Nitric oxide and nitric oxideâ€generating compounds inhibit hepatocyte protein synthesis. FASEB Journal, 1991, 5, 2085-2092.	0.5	229
24	Southwestern Internal Medicine Conference: Hormonal and Local Factors in Hypertension. American Journal of the Medical Sciences, 1991, 301, 412-420.	1.1	8
25	Role of endothelium-derived relaxing factor in regulation of vascular tone and remodeling. Update on humoral regulation of vascular tone Hypertension, 1991, 17, 909-916.	2.7	40
27	Endothelium-derived relaxing and contracting factors: Perspectives in nephrology. Kidney International, 1991, 39, 575-590.	5.2	97
28	The endothelial L-arginine/nitric oxide pathway and the renal circulation. Klinische Wochenschrift, 1991, 69, 603-609.	0.6	23
29	St Cyres lecture. Endothelium in control Heart, 1991, 65, 116-125.	2.9	148
30	Different activation of the endothelial L-arginine and cyclooxygenase pathway in the human internal mammary artery and saphenous vein Circulation Research, 1991, 68, 52-60.	4.5	201
31	Increased blood flow inhibits neointimal hyperplasia in endothelialized vascular grafts Circulation Research, 1991, 69, 1557-1565.	4.5	230
32	Hypercholesterolemia enhances macrophage recruitment and dysfunction of regenerated endothelium after balloon injury of the rabbit iliac artery Circulation, 1991, 84, 755-767.	1.6	70
33	Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin Hypertension, 1991, 18, 558-563.	2.7	362
34	Management of the patient with intermittent claudication. Vascular Medicine Review, 1991, vmr-2, 19-31.	0.3	1
35	Pharmacology of smooth muscle cell replication Hypertension, 1992, 20, 713-736.	2.7	227
36	Vaso-active factors in pregnancy. Fetal and Maternal Medicine Review, 1992, 4, 15-36.	0.3	9
37	Loss of the coronary microvascular response to acetylcholine in cardiac transplant patients Circulation, 1992, 86, 1156-1164.	1.6	82

#	Article	IF	CITATIONS
38	Platelet-derived growth factor suppresses and fibroblast growth factor enhances cytokine-induced production of nitric oxide by cultured smooth muscle cells. Effects on cell proliferation Circulation Research, 1992, 71, 1088-1100.	4.5	169
39	Interferon-gamma and tumor necrosis factor synergize to induce nitric oxide production and inhibit mitochondrial respiration in vascular smooth muscle cells Circulation Research, 1992, 71, 1268-1276.	4.5	262
40	Atherosclerosis or lipoprotein-induced endothelial dysfunction. Potential mechanisms underlying reduction in EDRF/nitric oxide activity Circulation, 1992, 85, 1927-1938.	1.6	441
41	Atrial natriuretic polypeptide as a novel antigrowth factor of endothelial cells Hypertension, 1992, 19, 758-761.	2.7	123
42	Pulmonary vasodilatory action of endogenous atrial natriuretic factor in rats with hypoxic pulmonary hypertension. Effects of monoclonal atrial natriuretic factor antibody Circulation Research, 1992, 70, 184-192.	4.5	30
43	Inhibition of proliferation, but not of Ca2+ mobilization, by cyclic AMP and GMP in rabbit aortic smooth-muscle cells. Biochemical Journal, 1992, 288, 527-532.	3.7	115
44	A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. British Journal of Pharmacology, 1992, 105, 771-772.	<b>5.</b> 4	219
45	Endotheliumâ€dependent increase in vascular sensitivity to phenylephrine in longâ€ŧerm streptozotocin diabetic rat aorta. British Journal of Pharmacology, 1992, 107, 983-990.	5.4	58
46	Prevention of intimal thickening after endothelial removal by a nonpeptide angiotensin II receptor antagonist, losartan. British Journal of Pharmacology, 1992, 106, 665-671.	5.4	67
47	<i>In vitro</i> effect of oestradiol on thymidine uptake in pulmonary vascular smooth muscle cell: role of the endothelium. British Journal of Pharmacology, 1992, 107, 679-683.	5 <b>.</b> 4	47
48	Kinins mediate the antiproliferative effect of ramipril in rat carotid artery. Biochemical and Biophysical Research Communications, 1992, 182, 283-288.	2.1	140
50	Dietary Supplementation With l-Arginine Ameliorates the Progression of Renal Disease in Rats With Subtotal Nephrectomy. American Journal of Kidney Diseases, 1992, 20, 168-176.	1.9	111
51	Bioassay of EDRF from internal mammary arteries: Implications for early and late bypass graft patency. Annals of Thoracic Surgery, 1992, 54, 1078-1084.	1.3	74
52	Interferon- $\hat{I}^3$ inhibits proliferation of rat vascular smooth muscle cells by nitric oxide generation. Biochemical and Biophysical Research Communications, 1992, 188, 409-415.	2.1	118
53	The Prevention of Heart Failure — A New Agenda. New England Journal of Medicine, 1992, 327, 725-727.	27.0	102
54	Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors. Biochemical Pharmacology, 1992, 44, 857-866.	4.4	76
55	Effect of nitric oxide on mitogenesis and proliferation of cerebellar glial cells. Brain Research, 1992, 592, 208-212.	2.2	45
56	C-type natriuretic peptide inhibits growth factor-dependent DNA synthesis in smooth muscle cells. American Journal of Physiology - Cell Physiology, 1992, 263, C1001-C1006.	4.6	101

#	Article	IF	Citations
57	Vascular effects of systemic hypertension. American Journal of Cardiology, 1992, 69, 3-7.	1.6	39
58	Mechanisms of action and efficacy of nitrates in heart failure. American Journal of Cardiology, 1992, 70, B88-B92.	1.6	9
59	Pathophysiology of ischemia in patients with coronary artery disease. Progress in Cardiovascular Diseases, 1992, 35, 27-39.	3.1	17
60	The 1991 Ulf von Euler Lecture:The <scp>l</scp> â€arginine: nitric oxide pathway. Acta Physiologica Scandinavica, 1992, 145, 201-227.	2.2	673
61	Endogenous and exogenous nitrates. Acta Anaesthesiologica Scandinavica, 1992, 36, 7-10.	1.6	18
62	Differential antimitogenic effectiveness of atrial natriuretic peptides in primary versus subcultured rat aortic smooth muscle cells: Relationship to expression of ANF-C receptors. Journal of Cellular Physiology, 1993, 154, 28-38.	4.1	36
63	The effect of nitric oxide-donating vasodilators on monocyte chemotaxis and intracellular cGMP concentrations in vitro. European Journal of Clinical Pharmacology, 1993, 45, 53-58.	1.9	72
64	Physiological aspects of vascular endothelial cell interactions in hypertension and atherosclerosis. Acta Anaesthesiologica Scandinavica, 1993, 37, 10-15.	1.6	4
65	The endothelium as a target and mediator of cardiovascular disease. European Journal of Clinical Investigation, 1993, 23, 670-685.	3.4	96
66	Nitric oxide synthases in the cardiovascular system. Trends in Cardiovascular Medicine, 1993, 3, 104-110.	4.9	48
67	Distribution and metabolism of NG-nitro-L-arginine and NG-nitro-L-arginine methylester in canine blood in vitro. Naunyn-Schmiedeberg's Archives of Pharmacology, 1993, 347, 342-345.	3.0	22
68	Local contractile and growth modulators in the myocardium. Clinical Cardiology, 1993, 16, 5-9.	1.8	24
69	Post-MI remodeling. Clinical Cardiology, 1993, 16, 21-24.	1.8	16
70	Cytokine-induced expression of an inducible type of nitric oxide synthase gene in cultured vascular smooth muscle cells. FEBS Letters, 1993, 318, 213-217.	2.8	109
71	Antiproliferative effect of esculetin on vascular smooth muscle cells: possible roles of signal transduction pathways. European Journal of Pharmacology, 1993, 237, 39-44.	3.5	45
72	Mechanisms of nitrosothiol-induced antimitogenesis in aortic smooth muscle cells. European Journal of Pharmacology, 1993, 237, 243-249.	3.5	51
73	L-arginine inhibits neointimal formation following balloon injury. Life Sciences, 1993, 53, PL387-PL392.	4.3	40
74	Antiatherosclerotic effects of oral cicaprost in experimental hypercholesterolemia in rabbits. Atherosclerosis, 1993, 103, 93-105.	0.8	15

#	Article	IF	CITATIONS
75	Oestradiol inhibits smooth muscle cell proliferation of pig coronary artery. British Journal of Pharmacology, 1993, 109, 612-617.	5.4	160
76	Inhalational nitric oxide: A selective pulmonary vasodilator for treatment of persistent pulmonary hypertension of the newborn. Journal of Pediatrics, 1993, 123, 76-79.	1.8	19
77	The L-Arginine-Nitric Oxide Pathway. New England Journal of Medicine, 1993, 329, 2002-2012.	27.0	5,659
78	Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus Circulation, 1993, 88, 2510-2516.	1.6	1,046
79	Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science, 1993, 262, 1274-1277.	12.6	1,670
80	Changes in protein kinase activity within 30â€,min of induced differentiation in Friend erythroleukemia cells. Biochemistry and Cell Biology, 1993, 71, 1-6.	2.0	2
81	Calcium Antagonists and ACE Inhibitors. Drugs, 1993, 46, 121-132.	10.9	30
82	Essential hypertension: a renal disease? A review and update of the evidence Hypertension, 1993, 21, 380-390.	2.7	70
84	Effect of cocaine on macromolecular syntheses and cell proliferation in cultured glial cells. Neuroscience, 1993, 57, 467-472.	2.3	22
85	Inhaled nitric oxide in chronic obstructive lung disease. Lancet, The, 1993, 341, 307-308.	13.7	42
86	Chapter 5 Vascular lesion formation. Cardiovascular Pathology, 1993, 2, 43-52.	1.6	7
87	Long-term oral nitrate therapy prevents chronic ventricular remodeling in the dog. Journal of the American College of Cardiology, 1993, 21, 514-522.	2.8	70
88	Growth regulatory properties of endothelins. Peptides, 1993, 14, 385-399.	2.4	338
89	Insulin stimulates endothelin binding and action on cultured vascular smooth muscle cells Endocrinology, 1993, 133, 1092-1097.	2.8	86
90	Angiotensin-Converting Enzyme Inhibition and Renal Protection. Archives of Internal Medicine, 1993, 153, 2426.	3.8	61
91	Molecular mechanisms of nitric oxide regulation. Potential relevance to cardiovascular disease Circulation Research, 1993, 73, 217-222.	4.5	325
92	Captopril inhibits endothelin-1 secretion from endothelial cells through bradykinin Hypertension, 1993, 21, 921-924.	2.7	81
93	Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation Circulation Research, 1993, 72, 1202-1210.	4.5	209

#	Article	IF	CITATIONS
94	SIN-1 reduces platelet adhesion and platelet thrombus formation in a porcine model of balloon angioplasty Circulation, 1993, 87, 590-597.	1.6	82
95	Anti-Atherogenic Effect of Nuts: Is the Answer NO?. Archives of Internal Medicine, 1993, 153, 896.	3.8	33
96	Endothelial Regulation of Vascular Tone and Growth. American Journal of Hypertension, 1993, 6, 283S-293S.	2.0	102
97	Nitric oxide regulates luteinizing hormone-releasing hormone secretion Endocrinology, 1993, 133, 2399-2402.	2.8	213
98	Lysophosphatidylcholine causes cGMP-dependent verapamil-sensitive Ca2+ influx in vascular smooth muscle cells. American Journal of Physiology - Cell Physiology, 1993, 264, C885-C893.	4.6	30
99	Hemodynamic actions of insulin. American Journal of Physiology - Endocrinology and Metabolism, 1994, 267, E187-E202.	3.5	330
100	Chaos and Fractals in Vascular Biology. Vascular Medicine Review, 1994, vmr-5, 161-182.	0.3	13
101	Long-term infusion of kallikrein attenuates renal injury in Dahl salt-sensitive rats Hypertension, 1994, 24, 770-778.	2.7	123
102	Is NO an endogenous antiatherogenic molecule?. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994, 14, 653-655.	3.9	198
103	Pleiotropic regulation of vascular smooth muscle tone by cyclic GMP-dependent protein kinase Hypertension, 1994, 23, 1141-1147.	2.7	181
104	Antiproliferative effect of desferrioxamine on vascular smooth muscle cells in vitro and in vivo Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994, 14, 299-304.	3.9	58
105	Enhanced endothelial adhesiveness in hypercholesterolemia is attenuated by L-arginine Circulation, 1994, 89, 2176-2182.	1.6	292
106	Long-term inhibition of NO synthesis promotes atherosclerosis in the hypercholesterolemic rabbit thoracic aorta. PGH2 does not contribute to impaired endothelium-dependent relaxation Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994, 14, 746-752.	3.9	227
107	Beneficial effect of SPM-5185, a cysteine-containing nitric oxide donor, in rat carotid artery intimal injury Circulation Research, 1994, 75, 77-84.	4.5	80
108	Spinal cord infarcts during long-term inhibition of nitric oxide synthase in rats Stroke, 1994, 25, 1666-1673.	2.0	59
109	17Î <sup>2</sup> -Estradioi and Endotheilal Nitric Oxide Synthase. Endothelium: Journal of Endothelial Cell Research, 1994, 2, 203-208.	1.7	17
110	Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994, 14, 753-759.	3.9	443
111	Ethinyl estradiol acutely attenuates abnormal coronary vasomotor responses to acetylcholine in postmenopausal women Circulation, 1994, 89, 52-60.	1.6	504

#	Article	IF	CITATIONS
112	Relative effects of alpha 1-adrenoceptor blockade, converting enzyme inhibitor therapy, and angiotensin II subtype $1$ receptor blockade on ventricular remodeling in the dog. Circulation, $1994$ , $90$ , $3034-3046$ .	1.6	98
113	Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat Circulation, 1994, 89, 2273-2282.	1.6	415
114	Long-term oral administration of L-arginine reduces intimal thickening and enhances neoendothelium-dependent acetylcholine-induced relaxation after arterial injury Circulation, 1994, 90, 1357-1362.	1.6	125
115	Endothelioma Cells Express and Secrete Endothelin-1 and Inhibit Platelet Aggregation through Nitric Oxide Formation. Endothelium: Journal of Endothelial Cell Research, 1994, 2, 125-137.	1.7	0
116	Sympathetic baroreceptor responses after chronic NG-nitro-L-arginine methyl ester treatment in conscious rats Hypertension, 1994, 23, 982-986.	2.7	48
117	L-arginine improves endothelium-dependent vasorelaxation and reduces intimal hyperplasia after balloon angioplasty Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994, 14, 938-943.	3.9	95
118	Potential importance of tissue angiotensin-converting enzyme inhibition in preventing neointima formation Circulation, 1994, 90, 449-455.	1.6	124
119	Mononuclear cells from dogs with acute lung allograft rejection cause contraction of pulmonary arteries Circulation, 1994, 90, 952-958.	1.6	18
120	Effect of prolonged nitrate therapy on left ventricular remodeling after canine acute myocardial infarction Circulation, 1994, 89, 2297-2307.	1.6	78
121	Long-term nitric oxide synthase inhibition and distensibility of carotid artery in intact rats Hypertension, 1994, 23, 967-970.	2.7	42
122	Inhibition of inducible nitric oxide synthase in macrophages by oxidized low-density lipoproteins Circulation Research, 1994, 74, 318-328.	4.5	77
123	Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions Hypertension, 1994, 23, 1121-1131.	2.7	1,015
124	Coronary vasomotor responses: Role of endothelium and nitrovasodilators. Cardiovascular Drugs and Therapy, 1994, 8, 601-610.	2.6	47
125	Advanced glycosylation endproducts: Role in diabetic and non-diabetic vascular disease. Drug Development Research, 1994, 32, 77-89.	2.9	27
126	Endogenous nitric oxide attenuates ethanol-induced perturbation of hepatic circulation in the isolated perfused rat liver. Hepatology, 1994, 20, 961-965.	7.3	42
127	The Emerging Concept of Vascular Remodeling. New England Journal of Medicine, 1994, 330, 1431-1438.	27.0	1,408
128	Nitric oxide release from rat aortic smooth muscle cells is not attenuated by angiotensin converting enzyme inhibitors. European Journal of Pharmacology, 1994, 269, 319-323.	2.6	7
129	Endothelial-dependent coronary vasomotor responsiveness in postmenopausal women with and without estrogen replacement therapy. American Journal of Cardiology, 1994, 73, 951-952.	1.6	182

#	Article	IF	CITATIONS
130	Has the problem of heart failure been solved?. American Journal of Cardiology, 1994, 73, C40-C43.	1.6	0
131	Nitric Oxide and the Cardiovascular System. Journal of Cardiac Surgery, 1994, 9, 361-371.	0.7	70
132	Induction of nitric oxide synthase in rat immune complex glomerulonephritis. Kidney International, 1994, 45, 1215-1219.	5.2	93
133	From Apoptosis to Autoimmunity: Insights from the Signaling Pathways Leading to Proliferation or to Programmed Cell Death. Immunological Reviews, 1994, 142, 53-91.	6.0	40
134	SUPPRESSION OF NITRIC OXIDE PRODUCTION BY CYCLOSPORIN A AND FK506A IN RAT VASCULAR SMOOTH MUSCLE CELLS. Clinical and Experimental Pharmacology and Physiology, 1994, 21, 231-233.	1.9	38
135	Endothelial nitric oxide and cardiovascular disease. Journal of Internal Medicine, 1994, 235, 317-327.	6.0	94
136	Nitric oxide and nitrovasodilators: Similarities, differences and potential interactions. Journal of the American College of Cardiology, 1994, 24, 555-566.	2.8	88
137	Dietary arginine prevents atherogenesis in the coronary artery of the hypercholesterolemic rabbit. Journal of the American College of Cardiology, 1994, 23, 452-458.	2.8	119
138	Dietary vitamin E increases the resistance to lipoprotein oxidation and attenuates endothelial dysfunction in the cholesterol-fed rabbit. Atherosclerosis, 1994, 110, 241-249.	0.8	31
139	The effect of transluminal endothelial seeding on myointimal hyperplasia following angioplasty. European Journal of Vascular Surgery, 1994, 8, 423-434.	0.9	22
140	Chronic changes in blood flow alter endothelium-dependent responses in autogenous vein grafts in dogs. Journal of Vascular Surgery, 1994, 20, 765-773.	1.1	32
141	p53 expression in nitric oxide-induced apoptosis. FEBS Letters, 1994, 355, 23-26.	2.8	367
142	Functional evidence that balloon angioplasty results in transient nitric oxide synthase induction. European Journal of Pharmacology, 1994, 255, 81-89.	3.5	25
143	Spontaneous nitric oxide release accounts for the potent pharmacological actions of FK409. European Journal of Pharmacology, 1994, 257, 123-130.	3.5	108
144	Role of NO in vascular smooth muscle and cardiac muscle function. Trends in Pharmacological Sciences, 1994, 15, 255-259.	8.7	90
145	Inhibition of platelet activity by S-nitrosoglutathione during coronary angioplasty. Lancet, The, 1994, 344, 1458-1460.	13.7	210
146	Effect of N <sup>G</sup> â€monomethylâ€Lâ€arginine on kininâ€induced vasodilation in the human forearm British Journal of Clinical Pharmacology, 1994, 38, 307-310.	2.4	56
147	Abolition of flowâ€dependent EDRF release before that evoked by agonists in hypercholesterolaemic rabbits. British Journal of Pharmacology, 1994, 113, 190-194.	5.4	10

#	Article	IF	CITATIONS
148	Increase of an endogenous inhibitor of nitric oxide synthesis in serum of high cholesterol fed rabbits. Life Sciences, 1994, 54, 753-758.	4.3	104
149	Elastase enhances cAMP accumulation and the inhibition of DNA synthesis induced by OP-41483, a stable prostacyclin analogue, in vascular smooth muscle cells. Atherosclerosis, 1994, 110, 111-117.	0.8	4
150	Physiological and pathophysiological roles of nitric oxide. Microsurgery, 1994, 15, 693-702.	1.3	43
151	Nitric Oxide in the Kidney: Synthesis, Localization, and Function. American Journal of Kidney Diseases, 1994, 24, 112-129.	1.9	282
152	Nitric Oxide (NO) in the Cardiovascular System: Role in Atherosclerosis and Hypercholesterolemia. Blood Pressure, 1994, 3, 279-282.	1.5	19
153	Progress in Understanding the Mechanism and Function of Cyclic GhAP-Dependent Protein Kinase. Advances in Pharmacology, 1994, 26, 115-170.	2.0	68
154	Paradoxic Pulmonary Vasoconstriction in Response to Acetylcholine in Patients With Primary Pulmonary Hypertension. Chest, 1994, 106, 385-390.	0.8	38
155	Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 4072-4076.	7.1	57
156	Metallothionein protects against the cytotoxic and DNA-damaging effects of nitric oxide  Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 4452-4456.	7.1	234
157	Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 1137-1141.	7.1	747
158	Endothelium-Dependent Regulation of the Cardiovascular System Internal Medicine, 1995, 34, 939-946.	0.7	30
159	cGMP Signaling through cAMP- and cGMP-Dependent Protein Kinases. Advances in Pharmacology, 1995, 34, 305-322.	2.0	89
160	Local regulation of the coronary circulation in health and disease: role of nitric oxide and endothelin. European Heart Journal, 1995, 16, 51-58.	2.2	29
161	Nitric oxide stimulates tyrosine phosphorylation in murine fibroblasts in the absence and presence of epidermal growth factor. Biochemical Journal, 1995, 305, 613-619.	3.7	55
162	Mechanism of anti-proliferation caused by YC-1, an indazole derivative, in cultured rat A10 vascular smooth-muscle cells. Biochemical Journal, 1995, 306, 787-792.	3.7	25
163	Inhaled Nitric Oxide, Clinical Rationale and Applications. Advances in Pharmacology, 1995, 34, 439-456.	2.0	16
164	Nitric Oxide Donors: A Continuing Opportunity in Drug Design. Advances in Pharmacology, 1995, 34, 383-398.	2.0	39
165	The Role of Growth Factors in Vascular Cell Development and Differentiation. International Review of Cytology, 1995, 161, 1-48.	6.2	42

#	Article	IF	CITATIONS
166	Nitric Oxide Donors: Biochemical Pharmacology and Therapeutics. Advances in Pharmacology, 1995, 34, 361-381.	2.0	35
167	Neointima formation is promoted by surgical preparation and inhibited by cyclic nucleotides in human saphenous vein organ cultures. Journal of Thoracic and Cardiovascular Surgery, 1995, 109, 2-12.	0.8	52
168	Nitric oxide and its role in the cardiovascular system. Progress in Cardiovascular Diseases, 1995, 38, 87-104.	3.1	514
169	The role of endothelium-derived vasoactive substances in the pathophysiology of exercise intolerance in patients with congestive heart failure. Progress in Cardiovascular Diseases, 1995, 38, 23-50.	3.1	66
170	Angiotensin-converting enzyme inhibitors reduce neointimal thickening and maintain endothelial nitric oxide function in rabbit carotid arteries. American Journal of Cardiology, 1995, 76, 24E-27E.	1.6	19
171	Structural Changes in Cardiovascular Disease. American Journal of Cardiology, 1995, 76, 34E-37E.	1.6	16
172	Human endothelial cells bioactivate organic nitrates to nitric oxide: implications for the reinforcement of endothelial defence mechanisms. European Journal of Clinical Investigation, 1995, 25, 737-745.	3.4	33
173	Synergistic interaction of interleukin-1? and growth factors in primary cultures of rat aortic smooth muscle cells. Journal of Cellular Physiology, 1995, 164, 644-657.	4.1	27
174	Ventricular remodeling: insights from pharmacologic interventions with angiotensin-converting enzyme inhibitors. Molecular and Cellular Biochemistry, 1995, 147, 51-55.	3.1	23
175	Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis. Molecular and Cellular Biochemistry, 1995, 147, 89-97.	3.1	65
176	Demonstration of endothelium-mediated increase in vascular smooth muscle cGMP, in a flexible coculture model. Cytotechnology, 1995, 17, 237-244.	0.7	0
177	Nitric oxide and endothelin in pathophysiological settings. Pediatric Nephrology, 1995, 9, 235-244.	1.7	44
178	Vascular protective effects of ACE inhibitors and calcium antagonists: Theoretical basis for a combination therapy in hypertension and other cardiovasular diseases. Cardiovascular Drugs and Therapy, 1995, 9, 509-523.	2.6	32
179	Alterations of vasomotor regulation in atherosclerosis. Cardiovascular Drugs and Therapy, 1995, 9, 55-63.	2.6	11
180	Nitric oxide as a vascular modulator. Blood Reviews, 1995, 9, 262-269.	5.7	9
181	Impaired endothelial function in patients with nephritic range proteinuria. Kidney International, 1995, 48, 544-550.	5.2	40
182	Nitric oxide triggers a switch to growth arrest during differentiation of neuronal cells. Nature, 1995, 375, 68-73.	27.8	484
183	ACCELERATED ENDOTHELIAL REGENERATION AND INTIMAL HYPERPLASIA FOLLOWING A REPEATED DENUDATION OF RABBIT CAROTID ARTERIES: MORPHOLOGICAL AND IMMUNOHISTOCHEMICAL STUDIES. Clinical and Experimental Pharmacology and Physiology, 1995, 22, 748-754.	1.9	7

#	Article	IF	CITATIONS
184	Dietary nitroprusside alleviates atherosclerosis in hypercholesterolemic Japanese quail (Coturnix) Tj ETQq0 0 0 rgE 151-154.	BT /Overlo	ck 10 Tf 50 7 2
185	Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 $\hat{l}^2$ . European Journal of Pharmacology, 1995, 290, 69-73.	2.6	86
186	Ouabain enhances nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin- $1\hat{l}^2$ . European Journal of Pharmacology, 1995, 288, 379-383.	2.6	10
187	Nitric oxide regulates angiotensin II receptors in vascular smooth muscle cells. European Journal of Pharmacology, 1995, 288, 219-229.	2.6	64
188	Cyclic GMP as a Second Messenger in the Cardiovascular System International Heart Journal, 1995, 36, 127-177.	0.6	9
189	Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB Journal, 1995, 9, 1319-1330.	0.5	710
190	Effects of magnesium on nitric oxide synthase activity in endothelial cells. American Journal of Physiology - Cell Physiology, 1995, 269, 1-1.	4.6	0
191	Regulation of endothelial cell nitric oxide synthase mRNA expression by shear stress. American Journal of Physiology - Cell Physiology, 1995, 269, C1371-C1378.	4.6	485
192	Effects of magnesium on nitric oxide synthase activity in endothelial cells. American Journal of Physiology - Cell Physiology, 1995, 269, 1-1.	4.6	0
193	Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines Journal of Clinical Investigation, 1995, 96, 60-68.	8.2	1,559
194	Endothelin Receptor Subtype B Mediates Autoinduction of Endothelin-1 in Rat Mesangial Cells. Journal of Biological Chemistry, 1995, 270, 6997-7003.	3.4	74
195	<i>MRF4</i> , <i>Myf-5</i> , and <i>myogenin</i> mRNAs in the adaptive responses of mature rat muscle. American Journal of Physiology - Cell Physiology, 1995, 269, 1-1.	4.6	42
196	Pathophysiology of smooth muscle in hypertension. Canadian Journal of Physiology and Pharmacology, 1995, 73, 574-584.	1.4	33
197	The role of nitric oxide in female reproduction. Fetal and Maternal Medicine Review, 1995, 7, 175-205.	0.3	10
198	Induction and Stabilization of $\hat{\mathbb{I}}^{\mathbb{B}}\hat{\mathbb{I}}^{\pm}$ by Nitric Oxide Mediates Inhibition of NF- $\hat{\mathbb{I}}^{\mathbb{B}}$ B. Journal of Biological Chemistry, 1995, 270, 14214-14219.	3.4	651
199	Nitric Oxide Inhibits Macrophage-Colony Stimulating Factor Gene Transcription in Vascular Endothelial Cells. Journal of Biological Chemistry, 1995, 270, 17050-17055.	3.4	157
200	Cyclic GMP-dependent Protein Kinase Blocks Pertussis Toxin-sensitive Hormone Receptor Signaling Pathways in Chinese Hamster Ovary Cells. Journal of Biological Chemistry, 1995, 270, 9052-9059.	3.4	62
201	Endogenous Nitric Oxide in Cardiovascular Disease and Transplantation. Annals of Medicine, 1995, 27, 395-406.	3.8	52

#	Article	IF	CITATIONS
202	Natriuretic peptide-augmented induction of nitric oxide synthase through cyclic guanosine 3',5'-monophosphate elevation in vascular smooth muscle cells Endocrinology, 1995, 136, 2135-2142.	2.8	42
203	Nitric oxide increases cellular glutathione levels in rat lung fibroblasts American Journal of Respiratory Cell and Molecular Biology, 1995, 13, 442-448.	2.9	39
204	Clinical Applications of Inhaled Nitric Oxide in Children with Pulmonary Hypertension. Advances in Pharmacology, 1995, 34, 475-504.	2.0	26
205	Nitric Oxide-Induced Cytotoxicity: Involvement of Cellular Resistance to Oxidative Stress and the Role of Glutathione in Protection. Pediatric Research, 1995, 37, 41-49.	2.3	112
206	Middle T antigen-transformed endothelial cells exhibit an increased activity of nitric oxide synthase Journal of Experimental Medicine, 1995, 181, 9-19.	8.5	38
207	Renal hypertensive angiopathyComparison between chronic NO suppression and DOCA-salt intoxication. American Journal of Hypertension, 1995, 8, 167-176.	2.0	32
208	Changes of Vascular Architecture Independent of Blood Pressure in Experimental Uremia. American Journal of Hypertension, 1995, 8, 409-417.	2.0	123
209	Endothelial Cell Signaling and Endothelial Dysfunction. American Journal of Hypertension, 1995, 8, 28S-41S.	2.0	81
210	Involvement of nitric oxide in IFN- $\hat{1}^3$ -mediated reduction of microvessel smooth muscle cell proliferation. Molecular Immunology, 1995, 32, 965-973.	2.2	22
211	Nitric oxide regulation of ADP-ribosylation of G proteins in hypertension. Medical Hypotheses, 1995, 44, 159-164.	1.5	21
212	NO in the lung. Respiration Physiology, 1995, 101, 109-120.	2.7	62
213	Accumulation of endogenous inhibitors for nitric oxide synthesis and decreased content of Lâ€arginine in regenerated endothelial cells. British Journal of Pharmacology, 1995, 115, 1001-1004.	5.4	118
214	Pathophysiology of congenital diaphragmatic hernia X: Localization of nitric oxide synthase in the intima of pulmonary artery trunks of lambs with surgically created congenital diaphragmatic hernia. Journal of Pediatric Surgery, 1995, 30, 5-9.	1.6	36
215	$17\hat{l}^2$ -Estradiol inhibits the voltage-dependent L-type Ca2+ currents in aortic smooth muscle cells. European Journal of Pharmacology, 1995, 294, 625-635.	3.5	131
216	Nitric oxide: An overview. American Journal of Surgery, 1995, 170, 292-303.	1.8	147
217	Combined captopril and isosorbide dinitrate during healing after myocardial infarction. Journal of the American College of Cardiology, 1995, 25, 1089-1096.	2.8	25
218	Effect of captopril and enalapril on left ventricular geometry, function and collagen during healing after anterior and inferior myocardial infarction in a dog model. Journal of the American College of Cardiology, 1995, 25, 1718-1725.	2.8	44
219	Inhaled nitric oxide and hemodynamic evaluation of patients with pulmonary hypertension before transplantation. Journal of the American College of Cardiology, 1995, 25, 1656-1664.	2.8	113

#	Article	IF	CITATIONS
220	Vascular Actions of Insulin in Health and Disease. Applied Physiology, Nutrition, and Metabolism, 1995, 20, 127-154.	1.7	19
221	Nitric Oxide and Vascular Disease. New England Journal of Medicine, 1995, 333, 251-253.	27.0	104
222	New Approaches to the Prevention of Atherosclerosis. Drugs, 1995, 50, 440-453.	10.9	22
223	Nitric oxide inhibition of endothelial cell mitogenesis and proliferation*. Surgery, 1995, 118, 274-279.	1.9	69
224	FK409, a new nitric-oxide donor, suppresses smooth muscle proliferation in the rat model of balloon angioplasty. Atherosclerosis, 1995, 117, 97-106.	0.8	65
225	Nitric oxideâ€" biological mediator, modulator and factor of injury: its role in the pathogenesis of atherosclerosis. Atherosclerosis, 1995, 118, S69-S80.	0.8	116
226	The pathogenesis of cardiovascular disease: role of the endothelium as a target and mediator. Atherosclerosis, 1995, 118, S81-S90.	0.8	122
227	Role of endothelium in the human uterine arteries during normal menstrual cycle. British Journal of Pharmacology, 1995, 114, 902-908.	5.4	22
228	Antiproliferative effects of A02011â€1, an adenylyl cyclase activator, in cultured vascular smooth muscle cells of rat. British Journal of Pharmacology, 1995, 114, 1227-1235.	5.4	11
229	Oxidized Low-density Lipoprotein Decreases the Expression of Endothelial Nitric Oxide Synthase. Journal of Biological Chemistry, 1995, 270, 319-324.	3.4	473
230	Advanced glycosylation end products in diabetic renal and vascular disease. American Journal of Kidney Diseases, 1995, 26, 875-888.	1.9	183
231	Nitroglycerin decreases medial smooth muscle cell proliferation after arterial balloon injury. Journal of Vascular Surgery, 1995, 21, 499-504.	1.1	13
232	Pharmacology of Cardiac and Vascular Remodeling. Annual Review of Pharmacology and Toxicology, 1995, 35, 509-539.	9.4	30
233	Cigarette smoking increases the development of intimal hyperplasia after vascular injury. Journal of Vascular Surgery, 1996, 23, 401-409.	1.1	26
234	Urokinase treatment preserves endothelial and smooth muscle function in experimental acute arterial thrombosis. Journal of Vascular Surgery, 1996, 23, 851-859.	1.1	18
235	The l-arginineâ€"nitric oxide pathway: role in atherosclerosis and therapeutic implications. Atherosclerosis, 1996, 127, 1-11.	0.8	151
236	Epicardial coronary arteries are not adequately sized in hypertensive patients. Journal of the American College of Cardiology, 1996, 27, 115-123.	2.8	28
237	Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. Journal of the American College of Cardiology, 1996, 27, 567-574.	2.8	957

#	ARTICLE	IF	CITATIONS
238	Task force 1. Pathogenesis of coronary disease: The biologic role of risk factors. Journal of the American College of Cardiology, 1996, 27, 964-976.	2.8	181
239	Differentiated Properties and Proliferation of Arterial Smooth Muscle Cells in Culture. International Review of Cytology, 1996, 169, 183-265.	6.2	220
240	Nitric oxide inhibits Leydig cell steroidogenesis Endocrinology, 1996, 137, 5337-5343.	2.8	197
241	Vascular reactivity in mesenteric resistance arteries following chronic nitric oxide synthase inhibition in Wistar rats. British Journal of Pharmacology, 1996, 117, 341-346.	5.4	53
242	Adenosine inhibitory effect on enhanced growth of aortic smooth muscle cells from streptozotocinâ€induced diabetic rats. British Journal of Pharmacology, 1996, 118, 783-789.	5.4	21
243	Intimal hyperplasia in human uterine arteries accompanied by impaired synergism between prostaglandin I <sub>2</sub> and nitric oxide. British Journal of Pharmacology, 1996, 119, 1072-1078.	5.4	12
244	Role of endothelial cells in restenosis after coronary angioplasty. Fundamental and Clinical Pharmacology, 1996, 10, 234-242.	1.9	26
245	MENOPAUSE AND RISK OF CARDIOVASCULAR DISEASE. Thrombosis Research, 1996, 84, 1-19.	1.7	25
246	Impairment of endothelium dependent relaxation in the diabetic rat heart: mechanisms and implications. Diabetes Research and Clinical Practice, 1996, 31, S143-S155.	2.8	50
247	Nitric oxide inhibits cell growth in cultured human thyrocytes. Life Sciences, 1996, 59, PL227-PL234.	4.3	15
248	Antiproliferative effect in rat vascular smooth muscle cells by osthole, isolated from Angelica pubescens. European Journal of Pharmacology, 1996, 298, 191-197.	3.5	52
249	Regulation of growth of cultured smooth muscle cells from diabetic rats by interleukin- $1\hat{l}^2$ : role of nitric oxide. European Journal of Pharmacology, 1996, 311, 79-86.	3.5	1
250	Perindopril Treatment Prevents the Loss of Endothelial Nitric Oxide Function and Development of Neo-intima in Rabbits. Journal of Molecular and Cellular Cardiology, 1996, 28, 1985-1994.	1.9	11
251	Deficiency in nitric oxide bioactivity in epicardial coronary arteries of cigarette smokers. Journal of the American College of Cardiology, 1996, 28, 1161-1167.	2.8	131
252	Arginine restores nitric oxide activity and inhibits monocyte accumulation after vascular injury in hypercholesterolemic rabbits. Journal of the American College of Cardiology, 1996, 28, 1573-1579.	2.8	75
253	Nitric oxide and murine coxsackievirus B3 myocarditis: Aggravation of myocarditis by inhibition of nitric oxide synthase. Journal of the American College of Cardiology, 1996, 28, 1610-1615.	2.8	46
254	Cardiovascular Effects of Exercise: Role of Endothelial Shear Stress. Journal of the American College of Cardiology, 1996, 28, 1652-1660.	2.8	352
255	Increasing cAMP antagonizes hypertrophic response to angiotensin II without affecting Ras and MAP kinase activation in vascular smooth muscle cells. FEBS Letters, 1996, 397, 89-92.	2.8	19

#	Article	IF	CITATIONS
256	Nitric Oxide Regulates Cell Proliferation during Drosophila Development. Cell, 1996, 87, 639-649.	28.9	247
257	Nitroprusside Ameliorates Lung Allograft Reperfusion Injury. Annals of Thoracic Surgery, 1996, 62, 791-797.	1.3	58
258	Effect of cilostazol, a cAMP phosphodiesterase inhibitor, on nitric oxide production by vascular smooth muscle cells. European Journal of Pharmacology, 1996, 314, 197-202.	3.5	43
259	Reduced expression of basic fibroblast growth factor and its receptor mRNAs and proteins in portal hypertensive esophageal mucosa: A mechanism responsible for muscularis mucosae thinning and variceal rupture. Surgery, 1996, 119, 424-430.	1.9	5
260	Vascular inducible nitric oxide synthase gene therapy: Requirement for guanosine triphosphate cyclohydrolase I. Surgery, 1996, 120, 315-321.	1.9	36
261	Expression of VCAM-1 in rabbit iliac arteries is associated with vasodilator dysfunction of regenerated endothelium following balloon injury. Atherosclerosis, 1996, 122, 59-67.	0.8	26
262	Eicosanoids, fatty acids and restenosis following coronary artery bypass graft surgery and balloon angioplasty. Prostaglandins Leukotrienes and Essential Fatty Acids, 1996, 54, 385-402.	2.2	30
263	The endothelium of resistance arteries: physiology and role in hypertension. Prostaglandins Leukotrienes and Essential Fatty Acids, 1996, 54, 17-25.	2.2	8
264	Neural and endothelial control of the peripheral circulationâ€"Implications for anesthesia: Part II, endothelium-mediated effects in the normal and diseased circulation. Journal of Cardiothoracic and Vascular Anesthesia, 1996, 10, 159-171.	1.3	18
265	[14] Cyclic GMP-dependent protein kinase in nitric oxide signaling. Methods in Enzymology, 1996, 269, 149-166.	1.0	61
266	RAYNAUD'S PHENOMENON. Rheumatic Disease Clinics of North America, 1996, 22, 765-781.	1.9	87
267	Atherosclerosis and the vascular biology of aging. Aging Clinical and Experimental Research, 1996, 8, 221-234.	2.9	44
268	Vascular Gene Transfer of the Human Inducible Nitric Oxide Synthase: Characterization of Activity and Effects on Myointimal Hyperplasia. Molecular Medicine, 1996, 2, 211-225.	4.4	107
269	Nitric Oxide in Vascular Remodeling International Heart Journal, 1996, 37, 431-445.	0.6	15
270	Regression or Progression. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 44-50.	2.4	174
271	Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 10022-10027.	7.1	226
272	Chronic hypoxia upregulates endothelial and inducible NO synthase gene and protein expression in rat lung. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1996, 270, L164-L170.	2.9	132
273	Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone Journal of Clinical Investigation, 1996, 97, 1916-1923.	8.2	2,179

#	Article	IF	CITATIONS
274	Role of Nitric Oxide in Allograft Rejection. , 1996, , 237-257.		2
275	17Â-Estradiol inhibits proliferation and migration of human vascular smooth muscle cells: similar effects in cells from postmenopausal females and in males. Cardiovascular Research, 1996, 32, 980-985.	3.8	28
276	Modulation of Endothelial Cell Nitric Oxide Synthase Expression. Japanese Circulation Journal, 1996, 60, 815-821.	1.0	15
277	Restorative Effect of Shosaikoto (Kampo Medicine) on Diminution of Nitric Oxide Synthesis in Murine Peritoneal Macrophages Induced by Hypercholesterolemia Biological and Pharmaceutical Bulletin, 1996, 19, 1468-1473.	1.4	7
278	Shosaikoto (Kampo Medicine) Protects Macrofage Function from Suppression by Hypercholesterolemia Biological and Pharmaceutical Bulletin, 1996, 19, 652-654.	1.4	2
279	Biological Basis of Angiogenesis and Vascular Remodeling. Shear stress and vascular formation Folia Pharmacologica Japonica, 1996, 107, 141-152.	0.2	1
280	Vascular reactivity of arterial coronary artery bypass grafts—implications for their performance. Clinical Cardiology, 1996, 19, 165-171.	1.8	11
281	Endogenous cardiac vasoactive factors modulate endothelin production by cardiac fibroblasts in culture. Endocrine, 1996, 5, 95-102.	2.2	3
282	Redox modulation of tyrosine phosphorylation-dependent signal transduction pathways. Free Radical Biology and Medicine, 1996, 21, 323-333.	2.9	222
283	Attenuation of nitric oxide synthase gene expression in rat lung induced by hypoxia. Journal of Tongji Medical University, 1996, 16, 148-151.	0.1	1
284	Autocrine growth inhibition of IL- $1\hat{1}^2$ -treated cultured human aortic smooth muscle cells: Possible role of nitric oxide. Heart and Vessels, 1996, 11, 223-228.	1.2	2
285	Paracrine effect of human vascular endothelial cells on human vascular smooth muscle cell proliferation: Transmembrane co-culture method. Heart and Vessels, 1996, 11, 229-233.	1.2	21
286	Alteration in the pulsatility index values of the internal carotid and middle cerebral arteries after suspension of postmenopausal hormone replacement therapy: A randomized crossover study. American Journal of Obstetrics and Gynecology, 1996, 175, 606-611.	1.3	41
287	Flow-induced vasodilation of the human brachial artery is impaired in patients < 40 years of age with coronary artery disease. American Journal of Cardiology, 1996, 78, 1210-1214.	1.6	301
288	New concepts of the renin-angiotensin system $\hat{a}\in$ " Implications for vascular and endovascular surgery. European Journal of Vascular and Endovascular Surgery, 1996, 11, 393-401.	1,5	1
289	EXPLANTED VEIN GRAFTS WITH AN INTACT ENDOTHELIUM DEMONSTRATE REDUCED FOCAL EXPRESSION OF ENDOTHELIAL NITRIC OXIDE SYNTHASE SPECIFIC TO ATHEROSCLEROTIC SITES. , 1996, 179, 197-203.		33
290	Regulation of endothelin receptors by nitric oxide in cultured rat vascular smooth muscle cells., 1996, 166, 469-479.		68
291	Hypoxia decreases constitutive nitric oxide synthase transcript and protein in cultured endothelial cells., 1996, 167, 469-476.		108

#	Article	IF	CITATIONS
292	Endothelium: the main actor in the remodelling of the retinal microvasculature in diabetes. Diabetologia, 1996, 39, 739-744.	6.3	27
293	Prevention of ventricular remodeling after myocardial infarction and in congestive heart failure. Heart Failure Reviews, $1996$ , $1$ , $115-129$ .	3.9	23
294	Regression of established ventricular remodeling: A therapeutic goal in ventricular dysfunction?. Heart Failure Reviews, 1996, 1, 131-137.	3.9	0
295	Dynamics of vascular remodeling: An overview and bibliography. Journal of Thrombosis and Thrombolysis, 1996, 3, 71-86.	2.1	1
296	FK409, a Novel Spontaneous NO Releaser: Comparative Pharmacological Studies with ISDN. Cardiovascular Drug Reviews, 1996, 14, 148-165.	4.1	4
297	Increased expression of inducible nitric oxide synthase in psoriatic skin and cytokine-stimulated cultured keratinocytes. British Journal of Dermatology, 1996, 134, 643-648.	1.5	115
298	Vasoactive hormones and renal sclerosis. Kidney International, 1996, 49, 578-597.	5.2	180
299	REGULATION OF EXPRESSION OF THE ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE. Clinical and Experimental Pharmacology and Physiology, 1996, 23, 251-255.	1.9	56
300	Nitric oxide Annals of the Rheumatic Diseases, 1996, 55, 7-20.	0.9	96
301	Contribution of Sustained Ca2+ Elevation for Nitric Oxide Production in Endothelial Cells and Subsequent Modulation of Ca 2+ Transient in Vascular Smooth Muscle Cells in Coculture. Journal of Biological Chemistry, 1996, 271, 5647-5655.	3.4	86
302	State-of-the-Art Review: Nitric Oxide and Restenosis. Clinical and Applied Thrombosis/Hemostasis, 1996, 2, 7-10.	1.7	9
303	Selective Impairment of Nitric Oxide Dependent Vasodilation in Young Adults with Hypercholesterolemia. European Journal of Cardiovascular Prevention and Rehabilitation, 1996, 3, 465-471.	2.8	4
304	Nitric Oxide Attenuates Vascular Smooth Muscle Cell Activation by Interferon-Î <sup>3</sup> . Journal of Biological Chemistry, 1996, 271, 11317-11324.	3.4	121
305	Platelet-derived Growth Factor Regulates Vascular Smooth Muscle Cell Proliferation by Inducing Cationic Amino Acid Transporter Gene Expression. Journal of Biological Chemistry, 1996, 271, 11838-11843.	3.4	66
306	Chapter 7. Inhibitors of Types I and V Phosphodiesterase: Elevation of cGMP as a Therapeutic Strategy. Annual Reports in Medicinal Chemistry, 1996, , 61-70.	0.9	14
307	Nitric Oxide and Endothelial Regulation of Vascular Tone. Methods in Neurosciences, 1996, , 215-227.	0.5	5
308	THE VASCULAR BIOLOGY OF NITRIC OXIDE AND ITS ROLE IN ATHEROGENESIS. Annual Review of Medicine, 1996, 47, 365-375.	12.2	231
309	Long-Term Treatment of Atherosclerotic Minipigs with Isosorbide Dinitrate Restores Nitric Oxide Release from Endothelial Cells, and Inhibits Vascular Smooth Muscle Cell Proliferation. Endothelium: Journal of Endothelial Cell Research, 1996, 4, 235-245.	1.7	5

#	Article	IF	Citations
310	Adenoviral gene transfer of nitric oxide synthase: High level expression in human vascular cells. Cardiovascular Research, 1996, 32, 962-972.	3.8	67
311	Mechanisms and prevention of restenosis: from experimental models to clinical practice. Cardiovascular Research, 1996, 31, 835-846.	3.8	106
312	The Nitric Oxide–Cyclic GMP Signaling System. , 1996, , 257-268.		24
313	Control of Skeletal Muscle Blood Flow During Dynamic Exercise. Sports Medicine, 1996, 21, 119-146.	6.5	72
314	Mechanisms of Neointima Formation—Lessons from Experimental Models. Vascular Medicine, 1997, 2, 179-189.	1.5	54
315	Lipid Profile and Peripheral Vascular Disease in Arseniasis-Hyperendemic Villages in Taiwan. Angiology, 1997, 48, 321-335.	1.8	57
316	The Link Among Nitric Oxide Synthase Activity, Endothelial Function, and Aortic and Ventricular Hypertrophy in Hypertension. Hypertension, 1997, 29, 235-241.	2.7	163
317	Endothelial dysfunction of conduit arteries in insulin-dependent diabetes mellitus without microalbuminuria. Cardiovascular Research, 1997, 34, 164-168.	3.8	53
318	?-Arginine inhibits smooth muscle cell proliferation of vein graft intimal thickness in hypercholesterolemic rabbits. Cardiovascular Research, 1997, 36, 429-436.	3.8	38
319	NO: COPD and beyond. Thorax, 1997, 52, S16-S21.	5.6	18
320	Carbon Monoxide Controls the Proliferation of Hypoxic Vascular Smooth Muscle Cells. Journal of Biological Chemistry, 1997, 272, 32804-32809.	3.4	299
321	Induction of the Cyclin-dependent Kinase Inhibitor p21 by Nitric Oxide-generating Vasodilator in Vascular Smooth Muscle Cells. Journal of Biological Chemistry, 1997, 272, 10050-10057.	3.4	151
322	The Effect of Nitric Oxide Release Rates on the Oxidation of Human Low Density Lipoprotein. Journal of Biological Chemistry, 1997, 272, 21647-21653.	3.4	70
323	Local Delivery of an Ultra-short-acting Nitric Oxide- releasing Compound, DMHD/NO, Is Highly Effective in Inhibiting Acute Platelet-Thrombus Formation on Injured Arterial Strips. Journal of Cardiovascular Pharmacology and Therapeutics, 1997, 2, 181-193.	2.0	4
324	Nitric oxide function in atherosclerosis. Mediators of Inflammation, 1997, 6, 3-21.	3.0	60
325	Just Say NO. Chest, 1997, 111, 4-7.	0.8	2
326	Role of Nitric Oxide in the Regulation of Osteoblast Metabolism. Plastic and Reconstructive Surgery, 1997, 100, 670-673.	1.4	13
327	Basal Nitric Oxide Production is Not Reduced in Patients with Noninsulin-Dependent Diabetes Mellitus. Vascular Medicine, 1997, 2, 302-305.	1.5	21

#	Article	IF	CITATIONS
328	Inhibition of nitric oxide in rats. Regulation of cardiovascular structure and expression of insulin-like growth factor I and its receptor messenger RNA. Journal of Hypertension, 1997, 15, 751-759.	0.5	13
329	Cellular changes induced by chronic nitric oxide inhibition in intact rat basilar arteries revealed by confocal microscopy. Journal of Hypertension, 1997, 15, 1685-1693.	0.5	37
330	Dual cell cycle-specific mechanisms mediate the antimitogenic effects of nitric oxide in vascular smooth muscle cells. Journal of Hypertension, 1997, 15, 275-283.	0.5	55
331	Nitric oxide reversibly inhibits the epidermal growth factor receptor tyrosine kinase. Biochemical Journal, 1997, 326, 369-376.	3.7	86
332	Diabetic-induced endothelial dysfunction in rat aorta: role of hydroxyl radicals. Cardiovascular Research, 1997, 34, 145-156.	3.8	165
333	Female Sex Hormones and Cardiovascular Disease in Women <sup>1</sup> . Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3913-3918.	3.6	116
334	The antiatherogenic potential of blocking the renin-angiotensin system. Expert Opinion on Investigational Drugs, 1997, 6, 1651-1658.	4.1	1
335	Smooth Muscle Cell Proliferation in Response to Co-culture with Venous and Arterial Endothelial Cells. Journal of Vascular and Interventional Radiology, 1997, 8, 375-381.	0.5	16
336	Tranilast inhibits the growth of rat mesangial cells. European Journal of Pharmacology, 1997, 324, 283-287.	3.5	6
337	$17\hat{l}^2$ -oestradiol reduces cardiac leukocyte accumulation in myocardial ischaemia reperfusion injury in rat. European Journal of Pharmacology, 1997, 335, 185-192.	3.5	98
338	Serotonin inhibits nitric oxide synthesis in rat vascular smooth muscle cells stimulated with interleukin-1. European Journal of Pharmacology, 1997, 338, 97-104.	3.5	18
339	Endothelin levels decrease after oral and nonoral estrogen in postmenopausal women with increased cardiovascular risk factors. Fertility and Sterility, 1997, 67, 273-277.	1.0	74
340	Effects of nitric oxide on cholesterol metabolism in macrophages. Atherosclerosis, 1997, 129, 193-198.	0.8	3
341	Effects of nitric oxide and superoxide on relaxation in human artery and vein. Atherosclerosis, 1997, 133, 77-86.	0.8	64
342	Pathophysiology of Atherosclerotic Vascular Disease. Disease Management and Health Outcomes, 1997, 2, 1-8.	0.4	1
343	Cardioprotective Mechanisms of ACE Inhibition. Drugs, 1997, 54, 1-11.	10.9	10
344	Endothelial Dysfunction and Atherothrombotic Occlusive Disease. Drugs, 1997, 54, 41-50.	10.9	12
345	Endothelial Dysfunction and Hypertension. Drugs, 1997, 53, 30-41.	10.9	57

#	Article	IF	CITATIONS
346	NITRIC OXIDE SYNTHASE: Role in the Genesis of Vascular Disease. Annual Review of Medicine, 1997, 48, 489-509.	12.2	652
347	Nitric Oxide Modulates Basal and Endothelin-induced Coronary Artery Vascular Smooth Muscle Cell Proliferation and Collagen Levels. Journal of Molecular and Cellular Cardiology, 1997, 29, 1779-1789.	1.9	77
348	The Mechanism of Inhibition of DNA Synthesis in Articular Chondrocytes from Young and Old Rats by Nitric Oxide. Nitric Oxide - Biology and Chemistry, 1997, 1, 218-225.	2.7	13
349	Quantitative Measurement for Endothelial Constitutive Nitric Oxide Synthase in Cultured Human Endothelial Cells. Nitric Oxide - Biology and Chemistry, 1997, 1, 226-233.	2.7	6
350	Nitric Oxide and Apoptosis: Another Paradigm for the Double-Edged Role of Nitric Oxide. Nitric Oxide - Biology and Chemistry, 1997, 1, 275-281.	2.7	296
351	Is there a rationale for combining angiotensinconverting enzyme inhibitors and calcium antagonists in cardiovascular disease?. American Heart Journal, 1997, 134, s31-s47.	2.7	13
352	The role of nitric oxide in the regulation of aldosterone synthesis by adrenal glomerulosa cells. Journal of Steroid Biochemistry and Molecular Biology, 1997, 61, 47-53.	2.5	48
353	Pharmacologic control of smooth muscle cells in allografts. Transplant Immunology, 1997, 5, 267-275.	1.2	4
354	An arginine analog inhibits responses of both the endothelium and smooth muscle of canine in situ vein grafts. Vascular, 1997, 5, 169-175.	0.5	2
355	Internal mammary artery graft function is not affected in hypertensive patients on therapy. Vascular, 1997, 5, 367-375.	0.5	4
357	Menopause and post-menopause. Bailliere's Clinical Endocrinology and Metabolism, 1997, 11, 311-340.	1.0	45
359	Quinapril Inhibits c-Myc Expression and Normalizes Smooth Muscle Cell Proliferation in Spontaneously Hypertensive Rats. American Journal of Hypertension, 1997, 10, 1147-1152.	2.0	14
360	Surgical implications of vascular endothelial physiology. Surgery, 1997, 122, 516-526.	1.9	18
361	Inducible nitric oxide synthase is upregulated in human transplant coronary artery disease. Transplantation Proceedings, 1997, 29, 2579-2580.	0.6	7
362	Endothelial Cell Injury in Cardiovascular Surgery: The Intimal Hyperplastic Response. Annals of Thoracic Surgery, 1997, 63, 582-591.	1.3	138
363	Nitric Oxide Synthase and Adenylyl and Guanylyl Cyclase Activity in Porcine Interposition Vein Grafts. Annals of Thoracic Surgery, 1997, 63, 470-476.	1.3	52
364	The Intimal Hyperplastic Response. Annals of Thoracic Surgery, 1997, 64, S38-S46.	1.3	13
365	Prolonged inhibition of nitric oxide synthesis in Yoshida hyperlipidemic rat: Aorta functional and structural properties. Life Sciences, 1997, 60, 1249-1262.	4.3	3

#	Article	IF	CITATIONS
366	Preserved Endothelial Function in Patients With Severe Hypertriglyceridemia and Low Functional Lipoprotein Lipase Activity. Journal of the American College of Cardiology, 1997, 29, 964-968.	2.8	86
367	Vascular endothelial dysfunction. Progress in Cardiovascular Diseases, 1997, 39, 325-342.	3.1	150
368	Reduced glutathione prevents nitric oxide-induced apoptosis in vascular smooth muscle cells. Biochimica Et Biophysica Acta - Molecular Cell Research, 1997, 1359, 143-152.	4.1	55
369	NO-donors and angina pectoris: more than just symptomatic treatment?. Netherlands Journal of Medicine, 1997, 50, 180-183.	O <b>.</b> 5	3
370	Biology of the Endothelium. Clinical Cardiology, 1997, 20, II-3.	1.8	243
371	Endothelial Function and Oxidant Stress. Clinical Cardiology, 1997, 20, II-11.	1.8	168
372	Vasculoprotective and Cardioprotective Mechanisms of Angiotensinâ€Converting Enzyme Inhibition: The Homeostatic Balance Between Angiotensin II and Nitric Oxide. Clinical Cardiology, 1997, 20, II-18.	1.8	15
373	Structural properties of rat mesenteric small arteries after 4-wk exposure to elevated or reduced blood flow. American Journal of Physiology - Heart and Circulatory Physiology, 1997, 273, H1699-H1706.	3.2	73
374	Endothelin-1 Inhibits Nitric Oxide Synthesis in Vascular Smooth Muscle Cells. Hypertension, 1997, 29, 65-69.	2.7	103
375	Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats Journal of Clinical Investigation, 1997, 99, 278-287.	8.2	305
376	Mechanisms of natriuretic-peptide-induced growth inhibition of vascular smooth muscle cells. Cardiovascular Research, 1997, 35, 158-167.	3.8	76
377	Role of inhibition of nitric oxide production in monocrotaline-induced pulmonary hypertension. Journal of Applied Physiology, 1997, 82, 1493-1498.	2.5	39
378	Nitric Oxide Synthases and Cardiac Muscle. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 1846-1858.	2.4	251
379	The Antiadhesive and Antithrombotic Effects of the Nitric Oxide Donor SIN-1 Are Combined With a Decreased Vasoconstriction in a Porcine Model of Balloon Angioplasty. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 1806-1812.	2.4	14
380	Increased Blood Flow Induces Regression of Intimal Hyperplasia. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 2245-2249.	2.4	153
381	Role of Angiotensin II and Bradykinin on Aortic Collagen Following Converting Enzyme Inhibition in Spontaneously Hypertensive Rats. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 3196-3201.	2.4	89
382	Expression and Function of Recombinant Endothelial NO Synthase in Coronary Artery Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 2405-2412.	2.4	53
383	<i>N</i> -α-Tosyl- <scp>I</scp> -Lysine Chloromethylketone Prevents Expression of iNOS in Vascular Smooth Muscle by Blocking Activation of NF-ÎB. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 672-679.	2.4	19

#	Article	IF	CITATIONS
384	Natriuretic Peptide Family as a Novel Antimigration Factor of Vascular Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 731-736.	2.4	43
385	NITRIC OXIDE DEFICIENCY INDUCES MYOCARDIAL INFARCTION IN HYPERCHOLESTEROLAEMIC STROKE-PRONE SPONTANEOUSLY HYPERTENSIVE RATS. Clinical and Experimental Pharmacology and Physiology, 1997, 24, 344-348.	1.9	13
386	RAPID REVERSAL OF ENDOTHELIAL DYSFUNCTION IN HYPERCHOLESTEROLAEMIC RABBITS TREATED WITH SIMVASTATIN AND PRAVASTATIN. Clinical and Experimental Pharmacology and Physiology, 1997, 24, 948-953.	1.9	24
387	Pharmacological Treatment and Mechanisms of Insulin Resistance Annals of the New York Academy of Sciences, 1997, 827, 170-177.	3.8	4
388	Hyperhomocyst(e)inemia and Atherothrombosis. Annals of the New York Academy of Sciences, 1997, 811, 48-59.	3.8	90
389	Nitric Oxide in the Vasculature: Physiology and Pathophysiology. Annals of the New York Academy of Sciences, 1997, 811, 60-69.	3.8	302
390	Clinical Trials to Prevent Restenosis after Percutaneous Coronary Revascularization. Annals of the New York Academy of Sciences, 1997, 811, 255-288.	3.8	17
391	Dissociation of lipopolysaccharide-mediated induction of nitric oxide synthase and inhibition of DNA synthesis in RAW 264.7 macrophages and rat aortic smooth muscle cells. British Journal of Pharmacology, 1997, 120, 1439-1444.	5.4	25
392	The involvement of tumour necrosis factor- $\hat{l}\pm$ in the protective effects of $17\hat{l}^2$ oestradiol in splanchnic ischaemia-reperfusion injury. British Journal of Pharmacology, 1997, 121, 1782-1788.	5 <b>.</b> 4	20
393	Prolonged effect of a novel S-nitrosated glyco-amino acid in endothelium-denuded rat femoral arteries: potential as a slow release nitric oxide donor drug. British Journal of Pharmacology, 1997, 122, 1617-1624.	5.4	39
394	Inhibition of platelet-derived growth factor receptor tyrosine kinase by atrial natriuretic peptide. Kidney International, 1997, 52, 356-362.	5 <b>.</b> 2	8
395	Relaxin: A pleiotropic hormone. General Pharmacology, 1997, 28, 13-22.	0.7	225
396	Effect of nicotine on the intimal hyperplasia after endothelial removal of the rabbit carotid artery. General Pharmacology, 1997, 28, 653-659.	0.7	44
397	Regulation of vascular tone and endothelial function and its alterations in cardiovascular disease. Bailliere's Clinical Anaesthesiology, 1997, 11, 531-560.	0.2	3
398	Lipoprotein Modification by Advanced Glycosylation Endproducts (AGEs): Role in Atherosclerosis. Trends in Cardiovascular Medicine, 1997, 7, 39-47.	4.9	3
399	Prevention of Restenosis. Trends in Cardiovascular Medicine, 1997, 7, 90-94.	4.9	6
400	Current status of inhaled nitric oxide therapy in the perinatal period. Early Human Development, 1997, 47, 247-262.	1.8	4
401	The influence of surgical preparation on cyclic nucleotide synthesis in an organ culture of human saphenous vein. European Journal of Vascular and Endovascular Surgery, 1997, 13, 72-78.	1.5	18

#	ARTICLE	IF	CITATIONS
402	The biology of restenosis. Progress in Cardiovascular Diseases, 1997, 40, 107-116.	3.1	197
403	Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention. Progress in Cardiovascular Diseases, 1997, 40, 141-158.	3.1	91
404	Low-density lipoprotein and oxidised low-density lipoprotein: Their role in the development of atherosclerosis., 1997, 74, 55-72.		57
405	Heparin-binding angiogenic growth factors in pregnancy. Placenta, 1997, 18, 215-258.	1.5	13
406	Inhaled nitric oxide in the neonate with cardiac disease. Seminars in Perinatology, 1997, 21, 441-455.	2.5	84
407	ESTROGENS AND ATHEROSCLEROSIS. Annual Review of Pharmacology and Toxicology, 1997, 37, 477-515.	9.4	145
408	The effect of chronic treatment with NO donors during intimal thickening and fatty streak formation. BioFactors, 1997, 6, 209-215.	5.4	6
409	Title is missing!. Molecular and Cellular Biochemistry, 1997, 176, 13-20.	3.1	4
410	The physiology and pathophysiology of the nitric oxide/superoxide system. Herz, 1997, 22, 158-172.	1.1	131
411	The Role of Nitric Oxide in Vascular Biology and Pathobiology. Annals of Vascular Surgery, 1997, 11, 307-314.	0.9	25
412	Compartmentalized coculture of porcine arterial endothelial and smooth muscle cells on a microporous membrane. In Vitro Cellular and Developmental Biology - Animal, 1997, 33, 92-103.	1.5	20
413	Endothelium-derived factors of veins: Implications in development of venous disease. International Journal of Angiology, 1997, 6, 110-114.	0.6	4
414	Endothelial function: strategies for early intervention. , 1998, 12, 125-134.		13
415	Inducible nitric oxide synthase and atherosclerosis. Clinical Cardiology, 1998, 21, 473-476.	1.8	15
416	In Situ Flow Activates Endothelial Nitric Oxide Synthase in Luminal Caveolae of Endothelium with Rapid Caveolin Dissociation and Calmodulin Association. Journal of Biological Chemistry, 1998, 273, 34724-34729.	3.4	268
417	Control of Vascular Smooth Muscle Cell Growth in Fowl. General and Comparative Endocrinology, 1998, 112, 115-128.	1.8	9
418	Hemodialysis and L-arginine, but not D-arginine, correct renal failure-associated endothelial dysfunction. Kidney International, 1998, 53, 1068-1077.	5.2	110
419	Modulation of angiotensin-converting enzyme by nitric oxide. British Journal of Pharmacology, 1998, 124, 291-298.	5.4	90

#	Article	IF	CITATIONS
420	Inhibitory effects of mesoionic 3-aryl substituted oxatriazole-5-imine derivatives on vascular smooth muscle cell mitogenesis and proliferationin vitro. British Journal of Pharmacology, 1998, 125, 402-408.	5 <b>.</b> 4	15
421	Effect of DMPPO, a phosphodiesterase type 5 inhibitor, on hypoxic pulmonary hypertension in rats. British Journal of Pharmacology, 1998, 125, 681-688.	5.4	23
422	Effects of nitric oxide on proliferation and differentiation of rat brown adipocytes in primary cultures. British Journal of Pharmacology, 1998, 125, 888-894.	5.4	96
423	Nitrates in Left Ventricular Dysfunction and Congestive Heart Failure. American Journal of Cardiology, 1998, 81, 54A-56A.	1.6	1
424	Nitrates and Left Ventricular Remodeling. American Journal of Cardiology, 1998, 81, 57A-67A.	1.6	3
425	Prevention of ventricular remodeling. Translational Research, 1998, 131, 124-129.	2.3	2
426	Heparin And Nonanticoagulant Heparin Preserve Regional Myocardial Contractility After Ischemia-Reperfusion Injury: Role Of Nitric Oxide. Journal of Thoracic and Cardiovascular Surgery, 1998, 115, 440-449.	0.8	23
427	Perivascular Delivery Of A Nitric Oxide Donor Inhibits Neointimal Hyperplasia In Vein Grafts Implanted In The Arterial Circulation. Journal of Thoracic and Cardiovascular Surgery, 1998, 115, 604-614.	0.8	69
428	Sequential increases and decreases in blood flow stimulates progressive intimal thickening. European Journal of Vascular and Endovascular Surgery, 1998, 16, 301-310.	1.5	48
429	Efficient Inhibition of Intimal Hyperplasia by Adenovirus-Mediated Inducible Nitric Oxide Synthase Gene Transfer to Rats and Pigs in Vivo. Journal of the American College of Surgeons, 1998, 187, 295-306.	0.5	219
430	Retinoic acid-induced differentiation in a human neuroblastoma cell line is associated with an increase in nitric oxide synthesis. Journal of Cellular Physiology, 1998, 174, 99-106.	4.1	31
431	The contribution of nitric oxide to renal vascular wall thickening in rats with I-NAME-induced hypertension. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1998, 433, 549-557.	2.8	12
433	Expression of cGMP-dependent protein kinase I and its substrate VASP in neointimal cells of the injured rat carotid artery. European Journal of Clinical Investigation, 1998, 28, 416-423.	3.4	32
434	Review Article Erratic behavior of nitric oxide within the immune system: illustrative review of conflicting data and their immunopharmacological aspects. International Journal of Immunopharmacology, 1998, 20, 319-343.	1.1	25
435	The effect of occult diabetic status and oral glucose intake on brachial artery vasoactivity in patients with peripheral vascular disease. Vascular, 1998, 6, 584-589.	0.5	3
436	Role of nitric oxide in the haemodynamic effects of growth hormone. Growth Hormone and IGF Research, 1998, 8, 163-165.	1.1	10
437	Nitric oxide inhibits Oct-1 DNA binding activity in cultured vascular smooth muscle cells. Life Sciences, 1998, 62, 739-749.	4.3	16
438	Aspirin and salicylate enhances the induction of inducible nitric oxide synthase in cultured rat smooth muscle cells. Life Sciences, 1998, 63, 429-439.	4.3	21

#	Article	IF	Citations
439	Pancreatic transplantation reverses endothelial dysfunction in experimental diabetes mellitus. Surgery, 1998, 123, 89-95.	1.9	12
440	Endothelial-Dependent Dynamic and Antithrombotic Properties of Porcine Aortic and Pulmonary Valves. Annals of Thoracic Surgery, 1998, 65, 986-992.	1.3	24
441	Hypoxia Increases Vasodilator Release From Internal Mammary Artery and Saphenous Vein Grafts. Annals of Thoracic Surgery, 1998, 65, 1220-1225.	1.3	17
442	Determination of nitrite/nitrate in human biological material by the simple Griess reaction. Clinica Chimica Acta, 1998, 274, 177-188.	1.1	511
443	Association of the Missense Glu298Asp Variant of the Endothelial Nitric Oxide Synthase Gene With Myocardial Infarction. Journal of the American College of Cardiology, 1998, 31, 1506-1510.	2.8	314
444	Chronic l-arginine treatment increases cardiac cyclic guanosine 5′-monophosphate in rats with aortic stenosis: effects on left ventricular mass and beta-adrenergic contractile reserve. Journal of the American College of Cardiology, 1998, 32, 528-535.	2.8	13
445	Pharmacologic Manipulation of Restenosis. Journal of Vascular and Interventional Radiology, 1998, 9, 291-294.	0.5	0
446	Is smooth muscle growth in primate arteries regulated by endothelial nitric oxide synthase?. Journal of Vascular Surgery, 1998, 28, 514-521.	1.1	19
447	Inhibition of NO Synthesis Induces Inflammatory Changes and Monocyte Chemoattractant Protein-1 Expression in Rat Hearts and Vessels. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 1456-1464.	2.4	111
448	Free Radical Generators Cause Changes in Endothelial and Inducible Nitric Oxide Synthases and Endothelin-1 Immunoreactivity in Endothelial Cells from Hyperlipidemic Rabbits. Molecular Genetics and Metabolism, 1998, 63, 191-197.	1.1	35
449	Cardiovascular risk continuum: implications of insulin resistance and diabetes. American Journal of Medicine, 1998, 105, 4S-14S.	1.5	146
450	Differential Inhibitory Effects of Three Nitric Oxide Donors on Ornithine Decarboxylase Activity in Human Colon Carcinoma Cells. Biochemical Pharmacology, 1998, 55, 1235-1239.	4.4	13
451	Evidence that angiotensin II, endothelins and nitric oxide regulate mitogen-activated protein kinase activity in rat aorta. European Journal of Pharmacology, 1998, 347, 337-346.	3.5	21
452	Dietary l-arginine decreases myointimal cell proliferation and vascular monocyte accumulation in cholesterol-fed rabbits. Atherosclerosis, 1998, 136, 67-77.	0.8	86
453	Inhibitory effect of inducible type nitric oxide synthase on oxidative modification of low density lipoprotein by vascular smooth muscle cells. Atherosclerosis, 1998, 136, 51-57.	0.8	41
454	Transforming growth factor-beta 1 and ascorbate regulate proliferation of cultured smooth muscle cells by independent mechanisms. Atherosclerosis, 1998, 140, 25-34.	0.8	55
455	Nitric oxide and endothelin in the development of cardiac allograft vasculopathy. Potential targets for therapeutic interventions. Atherosclerosis, 1998, 140, 1-14.	0.8	36
456	Improvement in the endothelium-dependent relaxation in hypercholesterolemic rabbits treated with vitamin E. Atherosclerosis, 1998, 140, 333-339.	0.8	13

#	Article	IF	CITATIONS
457	Pathogenesis of atherosclerosis. Pathophysiology, 1998, 5, 43.	2.2	0
458	Hemagglutinating virus of Japan-liposome–mediated gene transfer of endothelial cell nitric oxide synthase inhibits intimal hyperplasia of canine vein grafts under conditions of poor runoff. Journal of Vascular Surgery, 1998, 27, 135-144.	1.1	70
459	Pharmacological Approaches to the Prevention of Restenosis After Coronary Angioplasty. Drugs and Aging, 1998, 13, 291-301.	2.7	25
460	Upregulation of Endothelial Nitric Oxide Synthase by HMG CoA Reductase Inhibitors. Circulation, 1998, 97, 1129-1135.	1.6	1,736
461	Overexpression of Inducible Nitric Oxide Synthase by Neointimal Smooth Muscle Cells. Circulation Research, 1998, 82, 21-29.	4.5	127
462	Local Adenovirus-Mediated Transfer of Human Endothelial Nitric Oxide Synthase Reduces Luminal Narrowing After Coronary Angioplasty in Pigs. Circulation, 1998, 98, 919-926.	1.6	186
463	Calcium and Protein Kinase C Mediate High-Glucose-Induced Inhibition of Inducible Nitric Oxide Synthase in Vascular Smooth Muscle Cells. Hypertension, 1998, 31, 289-295.	2.7	48
464	Endothelial NO Synthase Is Increased in Regenerating Endothelium After Denuding Injury of the Rat Aorta. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 1312-1321.	2.4	52
465	Cyclic GMP–Dependent Protein Kinase Inhibits Osteopontin and Thrombospondin Production in Rat Aortic Smooth Muscle Cells. Circulation Research, 1998, 82, 139-146.	4.5	70
466	Acute Host-Mediated Endothelial Injury After Adenoviral Gene Transfer in Normal Rabbit Arteries. Circulation Research, 1998, 82, 1253-1262.	4.5	76
467	Endothelial Nitric Oxide Synthase Gene Polymorphism and Acute Myocardial Infarction. Hypertension, 1998, 32, 521-526.	2.7	325
468	Adenovirus-mediated Gene Transfer of cGMP-dependent Protein Kinase Increases the Sensitivity of Cultured Vascular Smooth Muscle Cells to the Antiproliferative and Pro-apoptotic Effects of Nitric Oxide/cGMP. Journal of Biological Chemistry, 1998, 273, 34263-34271.	3.4	148
469	Regulation of Angiotensin II Receptor Expression by Nitric Oxide in Rat Adrenal Gland. Hypertension, 1998, 32, 527-533.	2.7	74
470	Thrombin Stimulates Vascular Smooth Muscle Cell Polyamine Synthesis by Inducing Cationic Amino Acid Transporter and Ornithine Decarboxylase Gene Expression. Circulation Research, 1998, 83, 217-223.	4.5	37
471	LDLs Impair Vasomotor Function of the Coronary Microcirculation. Circulation Research, 1998, 83, 404-414.	4.5	110
472	Cardiac Angiotensin II Receptors Are Upregulated by Long-Term Inhibition of Nitric Oxide Synthesis in Rats. Circulation Research, 1998, 83, 743-751.	4.5	115
473	Aspirin Improves Endothelial Dysfunction in Atherosclerosis. Circulation, 1998, 97, 716-720.	1.6	260
474	Endothelial Function and Common Carotid Artery Wall Thickening in Patients With Essential Hypertension. Hypertension, 1998, 32, 25-32.	2.7	131

#	Article	IF	CITATIONS
475	Estradiol Therapy Combined With Progesterone and Endothelium-Dependent Vasodilation in Postmenopausal Women. Circulation, 1998, 98, 1158-1163.	1.6	272
476	Enhanced Monocyte Tissue Factor Response After Experimental Balloon Angioplasty in Hypercholesterolemic Rabbit: Inhibition With Dietary <scp>I</scp> -Arginine. Circulation, 1998, 98, 1776-1782.	1.6	41
477	Transfection of Inducible Nitric Oxide Synthase Gene Causes Apoptosis in Vascular Smooth Muscle Cells. Circulation, 1998, 98, 1212-1218.	1.6	97
478	Exacerbated Transplant Arteriosclerosis in Inducible Nitric Oxide–Deficient Mice. Circulation, 1998, 97, 2059-2065.	1.6	128
479	Atrial Natriuretic Peptide Has Different Effects on Contractility and Intracellular pH in Normal and Hypertrophied Myocytes From Pressure-Overloaded Hearts. Circulation, 1998, 98, 2760-2764.	1.6	45
480	Overexpression of Human Endothelial Nitric Oxide Synthase in Rat Vascular Smooth Muscle Cells and in Balloon-Injured Carotid Artery. Circulation Research, 1998, 82, 862-870.	4.5	103
481	Review of Alterations in Endothelial Nitric Oxide Production in Diabetes. Hypertension, 1998, 31, 1047-1060.	2.7	338
482	Human Endothelial Nitric Oxide Synthase Gene Transfer Inhibits Vascular Smooth Muscle Cell Proliferation and Neointima Formation After Balloon Injury in Rats. Circulation, 1998, 97, 1274-1281.	1.6	229
483	Atherosclerosis and the Two Faces of Endothelial Nitric Oxide Synthase. Circulation, 1998, 97, 108-112.	1.6	274
484	Endothelial Dysfunction: Implications for Therapy of Cardiovascular Diseases. Annals of Pharmacotherapy, 1998, 32, 459-470.	1.9	28
485	Nitric Oxide in Hypertension: Relationship With Renal Injury and Left Ventricular Hypertrophy. Hypertension, 1998, 31, 189-193.	2.7	68
486	Early Impairment of Renal Hemodynamic Reserve in Patients With Asymptomatic Heart Failure Is Restored by Angiotensin II Antagonism. Circulation, 1998, 98, 2849-2854.	1.6	65
487	Inducible Nitric Oxide Synthase Expression in Smooth Muscle Cells and Macrophages of Human Transplant Coronary Artery Disease. Circulation, 1998, 97, 2338-2345.	1.6	69
488	Apolipoprotein E Inhibits Platelet-derived Growth Factor-induced Vascular Smooth Muscle Cell Migration and Proliferation by Suppressing Signal Transduction and Preventing Cell Entry to G1 Phase. Journal of Biological Chemistry, 1998, 273, 20156-20161.	3.4	129
489	Distribution of Inflammatory Cells in Atherosclerotic Plaques Relates to the Direction of Flow. Circulation, 1998, 98, 2000-2003.	1.6	155
490	Captopril Treatment and its Withdrawal Prevents Impairment of Endothelium-Dependent Responses in the Spontaneously Hypertensive Rat. Clinical and Experimental Hypertension, 1998, 20, 847-866.	1.3	18
491	Does Nitric Oxide Regulate Smooth Muscle Cell Proliferation?. Journal of Vascular Research, 1998, 35, 135-142.	1.4	74

#	Article	IF	CITATIONS
493	Asymmetric Dimethylarginine (ADMA): A Novel Risk Factor for Endothelial Dysfunction. Circulation, 1998, 98, 1842-1847.	1.6	1,088
494	Natriuretic Factors and Nitric Oxide Suppress Plasminogen Activator Inhibitor-1 Expression in Vascular Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 1771-1779.	2.4	108
495	Adventitial Expression of Recombinant eNOS Gene Restores NO Production in Arteries Without Endothelium. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 1231-1241.	2.4	61
496	Increased Angiotensin II Type 1 Receptor Expression in Hypercholesterolemic Atherosclerosis in Rabbits. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 1433-1439.	2.4	129
497	Effect of Atherosclerosis on Endothelium-Dependent Inhibition of Platelet Activation in Humans. Circulation, 1998, 98, 17-24.	1.6	122
498	Downregulation of Angiotensin II Type 1 Receptor Gene Transcription by Nitric Oxide. Hypertension, 1998, 31, 342-346.	2.7	215
499	Endothelial regrowth after arterial injury: from vascular repair to therapeutics. Cardiovascular Research, 1998, 38, 54-68.	3.8	62
500	Mechanisms Offsetting the Beneficial Effects of Antihypertensive Drugs: A Problem Increasingly Considered but Incompletely Understood. Clinical Research and Regulatory Affairs, 1998, 15, 47-67.	2.1	0
501	Low Nitric Oxide Production in Patients with Chronic Renal Failure. Nephron, 1998, 79, 265-268.	1.8	69
502	Cardiovascular effect of L-arginine. Current Opinion in Nephrology and Hypertension, 1998, 7, 63-70.	2.0	56
503	Effect of Chronic Nitric Oxide Deficiency on Angiotensin II–Induced Hypertrophy of Rat Basilar Artery. Stroke, 1998, 29, 1031-1036.	2.0	10
504	The role of endothelium in human hypertension. Current Opinion in Nephrology and Hypertension, 1998, 7, 203-210.	2.0	36
505	Monocyte–vascular smooth muscle cell interaction enhances nitric oxide production. Cardiovascular Research, 1998, 37, 820-825.	3.8	16
506	Autoregulation of Angiogenesis by Cells of the Vessel Wall. International Review of Cytology, 1998, 185, 1-43.	6.2	64
507	Nitric oxide $\hat{a}\in$ " cyclic GMP pathway regulates vascular smooth muscle cell phenotypic modulation: implications in vascular diseases. Acta Physiologica Scandinavica, 1998, 164, 507-515.	2.2	63
508	Prolonged Inhaled NO Attenuates Hypoxic, but Not Monocrotaline-Induced, Pulmonary Vascular Remodeling in Rats. Anesthesia and Analgesia, 1998, 86, 74-81.	2.2	13
509	Nitric oxide synthase gene polymorphisms, blood pressure and aortic stiffness in normotensive and hypertensive subjects. Journal of Hypertension, 1998, 16, 31-35.	0.5	155
510	Prolonged Inhaled NO Attenuates Hypoxic, but Not Monocrotaline-Induced, Pulmonary Vascular Remodeling in Rats. Anesthesia and Analgesia, 1998, 86, 74-81.	2.2	30

#	ARTICLE	IF	Citations
511	Chronic Blockade of Nitric Oxide-Synthase and Endothelin Receptors During Pregnancy in the Rat: Effect on Pregnancy Outcome. Journal of the Society for Gynecologic Investigation, 1998, 5, 132-139.	1.7	0
512	Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling Journal of Clinical Investigation, 1998, 101, 731-736.	8.2	727
513	Increased endothelial NOS in lambs with increased pulmonary blood flow and pulmonary hypertension. American Journal of Physiology - Heart and Circulatory Physiology, 1998, 275, H1643-H1651.	3.2	60
514	Endothelium and acute coronary syndromes. Clinical Chemistry, 1998, 44, 1799-1808.	3.2	89
515	Chronic Blockade of Nitric Oxide Synthase and Endothelin Receptors During Pregnancy in the Rat: Effect on Reactivity of the Uterine Artery In Vitro. Journal of the Society for Gynecologic Investigation, 1998, 5, 288-295.	1.7	6
516	Vascular Remodelling in Diabetic Retinopathy. , 1998, 14, 113-124.		1
517	Nitric oxide production by cultured human aortic smooth muscle cells: stimulation by fluid flow. American Journal of Physiology - Heart and Circulatory Physiology, 1998, 274, H616-H626.	3.2	56
518	Effects of a chronic high-salt diet on large artery structure: role of endogenous bradykinin. American Journal of Physiology - Heart and Circulatory Physiology, 1998, 274, H1423-H1428.	3.2	27
519	NO decreases phosphorylation of focal adhesion proteins via reduction of Ca in rat aortic smooth muscle cells. American Journal of Physiology - Heart and Circulatory Physiology, 1998, 274, H1613-H1619.	3.2	9
520	Central nitric oxide attenuates the baroreceptor reflex in conscious rabbits. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1998, 274, R1142-R1149.	1.8	29
521	Myocardial ischemia-reperfusion injury is exacerbated in absence of endothelial cell nitric oxide synthase. American Journal of Physiology - Heart and Circulatory Physiology, 1999, 276, H1567-H1573.	3.2	183
522	Tumor Suppressor p53 But Not cGMP Mediates NO-Induced Expression of p21Waf1/Cip1/Sdi1 in Vascular Smooth Muscle Cells. Molecular Pharmacology, 1999, 56, 938-946.	2.3	34
523	The Effect of Local Delivery of IBMX on the Neointimal Proliferation in Rat Carotid Balloon Injury Model. Sunhwan'gi, 1999, 29, 1097.	0.3	0
524	?-Arginine and ?-NAME have no effects on the reendothelialization process after arterial balloon injury. Cardiovascular Research, 1999, 43, 731-738.	3.8	12
525	Impairment of EDR by a long-term PDGF treatment in organ-cultured rabbit mesenteric artery. American Journal of Physiology - Heart and Circulatory Physiology, 1999, 277, H318-H323.	3.2	9
526	NO alters cell shape and motility in aortic smooth muscle cells via protein tyrosine phosphatase 1B activation. American Journal of Physiology - Heart and Circulatory Physiology, 1999, 277, H1014-H1026.	3.2	26
527	Mechanisms of MAPK activation by bradykinin in vascular smooth muscle cells. American Journal of Physiology - Cell Physiology, 1999, 277, C253-C261.	4.6	93
528	Region-specific antiproliferative effect of VIP and PACAP-(1—38) on rabbit enteric smooth muscle. American Journal of Physiology - Renal Physiology, 1999, 276, G303-G310.	3.4	9

#	Article	IF	CITATIONS
529	Maintained upregulation of pulmonary eNOS gene and protein expression during recovery from chronic hypoxia. American Journal of Physiology - Heart and Circulatory Physiology, 1999, 276, H699-H708.	3.2	61
530	Leukocyte-endothelial cell interactions in nitric oxide synthase-deficient mice. American Journal of Physiology - Heart and Circulatory Physiology, 1999, 276, H1943-H1950.	3.2	136
531	Endothelial cell regrowth and morphology after balloon catheter injury of alloxan-induced diabetic rabbits. American Journal of Physiology - Heart and Circulatory Physiology, 1999, 277, H740-H748.	3.2	12
532	Endothelial cell nitric oxide production in acute chest syndrome. American Journal of Physiology - Heart and Circulatory Physiology, 1999, 277, H1579-H1592.	3.2	28
533	Differential regulation of DNA synthesis by nitric oxide and hydroxyurea in vascular smooth muscle cells. American Journal of Physiology - Heart and Circulatory Physiology, 1999, 277, H1799-H1807.	3.2	7
534	Unaltered vasoconstrictor responsiveness after iNOS inhibition in lungs from chronically hypoxic rats. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1999, 276, L122-L130.	2.9	25
535	E-4010, a selective phosphodiesterase 5 inhibitor, attenuates hypoxic pulmonary hypertension in rats. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1999, 277, L225-L232.	2.9	17
536	Antiproliferative effects of NO and ANP in cultured human airway smooth muscle. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1999, 277, L910-L918.	2.9	36
537	Distribution and function of recombinant endothelial nitric oxide synthase in transplanted hearts. Cardiovascular Research, 1999, 42, 720-727.	3.8	8
538	Vitamin E and vascular homeostasis: implications for atherosclerosis. FASEB Journal, 1999, 13, 965-975.	0.5	144
539	Highly efficient liposome-mediated gene transfer of inducible nitric oxide synthase in vivo and in vitro in vascular smooth muscle cells. Cardiovascular Research, 1999, 43, 808-822.	3.8	12
540	Modulation of Expression of Endothelial Nitric Oxide Synthase by Nordihydroguaiaretic Acid, a Phenolic Antioxidant in Cultured Endothelial Cells. Molecular Pharmacology, 1999, 56, 116-123.	2.3	58
541	Mechanism of Structural Remodelling of the Rat Aorta During Long-Term NG-Nitro-L-arginine Methyl Ester Treatment. The Japanese Journal of Pharmacology, 1999, 81, 99-106.	1.2	5
542	Role of Hemodynamics in Pulmonary Vascular Remodeling. American Journal of Respiratory and Critical Care Medicine, 1999, 159, 361-364.	5.6	88
543	Nitric oxide and the proliferation of vascular smooth muscle cells. Cardiovascular Research, 1999, 43, 580-594.	3.8	237
544	Continuous Perivascular <scp>I</scp> -Arginine Delivery Increases Total Vessel Area and Reduces Neointimal Thickening After Experimental Balloon Dilatation. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 767-776.	2.4	29
545	Inhaled Nitric Oxide: A Premature Remedy for Chronic Lung Disease?. Pediatrics, 1999, 103, 667-669.	2.1	12
546	Increase in Prostaglandin E $<$ sub $>$ 2 $<$ /sub $>$ Production by Interleukin- $1\hat{l}^2$ in Arterial Smooth Muscle Cells Derived From Patients With Moyamoya Disease. Circulation Research, 1999, 85, 912-918.	4.5	49

#	ARTICLE	IF	CITATIONS
547	Decreased Neointimal Thickening After Arterial Wall Injury in Inducible Nitric Oxide Synthase Knockout Mice. Circulation Research, 1999, 85, 1192-1198.	4.5	102
548	Protection by Shear Stress From Collar-Induced Intimal Thickening. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 2609-2614.	2.4	23
549	<i>N</i> -Acetyl- <scp>l</scp> -Cysteine Enhances Interleukin-1β–Induced Nitric Oxide Synthase Expression. Hypertension, 1999, 34, 574-579.	2.7	41
550	Effect of Treatment on Flow-Dependent Vasodilation of the Brachial Artery in Essential Hypertension. Hypertension, 1999, 33, 575-580.	2.7	92
551	Effects of dietary l-arginine on the reactivity of canine coronary arteries. Vascular Medicine, 1999, 4, 211-217.	1.5	9
552	Antiproliferative Actions of Angiotensin-(1-7) in Vascular Smooth Muscle. Hypertension, 1999, 34, 950-957.	2.7	127
553	Bradykinin in the Heart. Circulation, 1999, 100, 2305-2307.	1.6	34
554	Nitric Oxide and C-Type Atrial Natriuretic Peptide Stimulate Primary Aortic Smooth Muscle Cell Migration via a cGMP-Dependent Mechanism. Circulation Research, 1999, 84, 655-667.	4.5	80
555	Apoptosis, Coronary Arterial Remodeling, and Myocardial Infarction After Nitric Oxide Inhibition in SHR. Hypertension, 1999, 34, 609-616.	2.7	54
556	Different Contributions of Endothelin-A and Endothelin-B Receptors in the Pathogenesis of Deoxycorticosterone Acetate–Salt–Induced Hypertension in Rats. Hypertension, 1999, 33, 759-765.	2.7	113
557	Nitric Oxide Synthase Gene Therapy Rapidly Reduces Adhesion Molecule Expression and Inflammatory Cell Infiltration in Carotid Arteries of Cholesterol-Fed Rabbits. Circulation, 1999, 99, 2979-2982.	1.6	123
558	Nitric Oxide Controls Src Kinase Activity through a Sulfhydryl Group Modification-mediated Tyr-527-independent and Tyr-416-linked Mechanism. Journal of Biological Chemistry, 1999, 274, 25821-25826.	3.4	153
559	Superoxide Anion Generation, Superoxide Dismutase Activity, and Nitric Oxide Release in Human Internal Mammary Artery and Saphenous Vein Segments. Journal of Cardiovascular Pharmacology and Therapeutics, 1999, 4, 249-257.	2.0	15
560	Role of Endothelial Nitric Oxide Synthase in Endothelial Cell Migration. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 1156-1161.	2.4	272
561	The 1998 Nobel prize in Medicine: clinical implications for 1999 and beyond. Vascular Medicine, 1999, 4, 57-60.	1.5	6
562	Enhanced Nitric Oxide-Mediated Vascular Relaxation in Radial Artery Compared With Internal Mammary Artery or Saphenous Vein. Circulation, 1999, 100, II-322-II-327.	1.6	71
563	Autoimmunity and Vascular Involvement in Systemic Sclerosis (SSc). Autoimmunity, 1999, 31, 195-214.	2.6	103
564	<i>L</i> -Arginine Availability Is Not Limiting for Nitric Oxide Generation from Recombinant Endothelial Nitric Oxide Synthase. Journal of Vascular Research, 1999, 36, 437-444.	1.4	3

#	ARTICLE	IF	CITATIONS
565	Vascular Gene Transfer. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 196-207.	2.4	48
566	Local <scp>I</scp> -Arginine Delivery After Balloon Angioplasty Reduces Monocyte Binding and Induces Apoptosis. Circulation, 1999, 100, 1830-1835.	1.6	35
567	Preferential Impairment of Nitric Oxide–Mediated Endothelium-Dependent Relaxation in Human Cervical Arteries After Irradiation. Circulation, 1999, 100, 635-641.	1.6	120
568	Posttranscriptional Regulation of Endothelial Nitric Oxide Synthase During Cell Growth. Circulation Research, 1999, 85, 588-595.	4.5	72
569	Natriuretic Peptides and Nitric Oxide Induce Endothelial Apoptosis via a cGMP–Dependent Mechanism. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 140-146.	2.4	102
570	Cyclooxygenase-2 Is Widely Expressed in Atherosclerotic Lesions Affecting Native and Transplanted Human Coronary Arteries and Colocalizes With Inducible Nitric Oxide Synthase and Nitrotyrosine Particularly in Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 646-655.	2.4	281
571	A Missense Mutation of the Nitric Oxide Synthase (eNOS) Gene (Glu298Asp) in Five Patients with Coronary Artery Disease. Angiology, 1999, 50, 671-676.	1.8	7
572	Perlecan Mediates the Antiproliferative Effect of Apolipoprotein E on Smooth Muscle Cells. Journal of Biological Chemistry, 1999, 274, 36403-36408.	3.4	47
573	Inducible nitric oxide synthase and vascular injury. Cardiovascular Research, 1999, 43, 650-657.	3.8	132
574	Identification of Flow-dependent Endothelial Nitric-oxide Synthase Phosphorylation Sites by Mass Spectrometry and Regulation of Phosphorylation and Nitric Oxide Production by the Phosphatidylinositol 3-Kinase Inhibitor LY294002. Journal of Biological Chemistry, 1999, 274, 30101-30108.	3.4	296
575	The ETA-Receptor Antagonist LU 135252 Prevents the Progression of Established Pulmonary Hypertension Induced by Monocrotaline in Rats. Journal of Cardiovascular Pharmacology and Therapeutics, 1999, 4, 33-39.	2.0	17
576	Down-regulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated hypertension. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 13357-13362.	7.1	272
577	The vasodilator action of nebivolol in forearm vasculature of subjects with essential hypertension. British Journal of Clinical Pharmacology, 1999, 48, 460-463.	2.4	108
578	ENDOTHELIAL CELL RESPONSES TO HYPOXIC STRESS. Clinical and Experimental Pharmacology and Physiology, 1999, 26, 74-84.	1.9	309
579	RELATIONSHIPS BETWEEN THE ENDOTHELIN AND NITRIC OXIDE PATHWAYS. Clinical and Experimental Pharmacology and Physiology, 1999, 26, 247-252.	1.9	62
580	Urea induces macrophage proliferation by inhibition of inducible nitric oxide synthesis11See Editorial by Himmelfarh, p. 754 Kidney International, 1999, 56, 581-588.	5.2	41
581	Augmentative Effect of Pulsatility on the Wall Shear Stress in Tube Flow. Artificial Organs, 1999, 23, 727-731.	1.9	16
582	Adenovirus-mediated kallikrein gene transfer inhibits neointima formation via increased production of nitric oxide in rat artery. Immunopharmacology, 1999, 44, 137-143.	2.0	18

#	Article	IF	CITATIONS
583	Role for NADPH/NADH Oxidase in the Modulation of Vascular Tonea. Annals of the New York Academy of Sciences, 1999, 874, 386-400.	3.8	92
584	Accelerated intimal hyperplasia and increased endogenous inhibitors for NO synthesis in rabbits with alloxanâ€nduced hyperglycaemia. British Journal of Pharmacology, 1999, 126, 211-218.	5.4	94
585	Growth-inhibitory effect of cyclic GMP- and cyclic AMP-dependent vasodilators on rat vascular smooth muscle cells: effect on cell cycle and cyclin expression. British Journal of Pharmacology, 1999, 126, 349-357.	5.4	41
586	N-substituted analogues of S-nitroso- N -acetyl-D ,L -penicillamine: chemical stability and prolonged nitric oxide mediated vasodilatation in isolated rat femoral arteries. British Journal of Pharmacology, 1999, 126, 639-648.	5.4	48
587	Cyclosporin A and tacrolimus (FK506) suppress expression of inducible nitric oxide synthase in vitro by different mechanisms. British Journal of Pharmacology, 1999, 128, 337-344.	5.4	55
588	PF9404C, a new slow NO donor with beta receptor blocking properties. British Journal of Pharmacology, 1999, 128, 1713-1722.	5.4	9
589	Structure and function of cGMP-dependent protein kinases., 1999, 135, 105-149.		175
590	Signal transduction by cGMP-dependent protein kinases and their emerging roles in the regulation of cell adhesion and gene expression., 1999, 135, 173-209.		58
592	Involvement of nitric oxide in the inhibition of aortic smooth muscle cell proliferation by calcium dobesilate. International Journal of Angiology, 1999, 8, S5-S10.	0.6	7
593	Expression of nitric oxide synthase isoforms (NOS II and NOS III) in adult rat lung in hyperoxic pulmonary hypertension. Cell and Tissue Research, 1999, 295, 317-329.	2.9	32
594	Cyclic GMP-Dependent Protein KinasesUnderstanding in Vivo Functions by Gene Targeting., 1999, 82, 355-372.		72
595	Vascular sodium pump endothelial modulation and alterations in some pathological processes and aging., 1999, 84, 249-271.		45
596	Insulin signaling in the arterial wall. American Journal of Cardiology, 1999, 84, 21-24.	1.6	180
597	Impairment of endothelium-dependent relaxation in the arteries cultured with fetal bovine serum. European Journal of Pharmacology, 1999, 366, 237-242.	3.5	11
598	Effects of treatment with FK409, a nitric oxide donor, on collar-induced intimal thickening and vascular reactivity. European Journal of Pharmacology, 1999, 374, 33-39.	3.5	6
599	The roles of the guanylate cyclase-stimulating ligands nitric oxide and atrial natriuretic peptide in the regulation of blood flow in the human fetal placental circulation. Placenta, 1999, 20, 311-327.	1.5	0
600	Endothelium-derived agents in Pericyte function/dysfunction. Progress in Retinal and Eye Research, 1999, 18, 511-527.	15.5	52
601	Inducible nitric oxide synthase expression in vascular and glomerular structures of human chronic allograft nephropathy., 1999, 187, 345-350.		24

#	Article	IF	CITATIONS
602	Hemodynamic Shear Stress and Its Role in Atherosclerosis. JAMA - Journal of the American Medical Association, 1999, 282, 2035.	7.4	2,852
603	Vegan proteins may reduce risk of cancer, obesity, and cardiovascular disease by promoting increased glucagon activity. Medical Hypotheses, 1999, 53, 459-485.	1.5	96
604	Vascular effects of isoprostanes after endothelial damage. Prostaglandins Leukotrienes and Essential Fatty Acids, 1999, 61, 369-372.	2.2	15
605	Distribution and prevalence of inducible nitric oxide synthase in atherosclerotic vessels of long-term cholesterol-fed rabbits. Atherosclerosis, 1999, 142, 335-344.	0.8	66
606	Role of nitric oxide in restenosis after experimental balloon angioplasty in the hypercholesterolemic rabbit: effects on neointimal hyperplasia and vascular remodeling. Journal of the American College of Cardiology, 1999, 33, 876-882.	2.8	63
607	The potent platelet inhibitory effects of S-nitrosated albumin coating of artificial surfaces. Journal of the American College of Cardiology, 1999, 33, 1408-1414.	2.8	58
608	Inhibition of estrogen receptor function promotes porcine coronary artery smooth muscle cell proliferation. Steroids, 1999, 64, 472-480.	1.8	11
609	TCV-116 reduces chronic rejection in a rat heterotopic cardiac transplant model. Transplantation Proceedings, 1999, 31, 106-107.	0.6	7
610	Opposing actions of angiotensins on angiogenesis. Life Sciences, 1999, 66, 67-76.	4.3	85
611	Arterial and Venous Smooth Muscle Cell Proliferation in Response to Co-culture with Arterial and Venous Endothelial Cells. Journal of Vascular and Interventional Radiology, 1999, 10, 1051-1057.	0.5	20
612	The Critical Role of Mechanical Forces in Blood Vessel Development, Physiology and Pathology. Journal of Vascular Surgery, 1999, 29, 1104-1151.	1.1	53
613	The small heat shock-related protein–20 is an actin-associated protein. Journal of Vascular Surgery, 1999, 29, 326-333.	1.1	<b>7</b> 3
614	iNOS Overexpression and Inhibition of Vascular Smooth Muscle Cell Proliferation. Journal of Vascular and Interventional Radiology, 1999, 10, 971-973.	0.5	0
615	Impaired brachial artery endothelial function is not predicted by elevated triglycerides. Journal of the American College of Cardiology, 1999, 33, 2038-2043.	2.8	53
616	Reciprocal changes in endothelial and inducible nitric oxide synthase expression following carotid angioplasty in the pig. Atherosclerosis, 1999, 145, 17-32.	0.8	23
617	Nitric oxide inhibits proliferation of human endothelial cells via a mechanism independent of cGMP. Atherosclerosis, 1999, 144, 49-57.	0.8	79
618	Activation of Mitogen-activated Protein Kinase Pathways by Cyclic GMP and Cyclic GMP-dependent Protein Kinase in Contractile Vascular Smooth Muscle Cells. Journal of Biological Chemistry, 1999, 274, 34301-34309.	3.4	131
619	A Common Variant of the Endothelial Nitric Oxide Synthase (Glu <sup>298</sup> â†'Asp) Is a Major Risk Factor for Coronary Artery Disease in the UK. Circulation, 1999, 100, 1515-1520.	1.6	497

#	Article	IF	CITATIONS
620	Mechanism of SNAP Potentiating Antiproliferative Effect of Calcitonin Gene-related Peptide in Cultured Vascular Smooth Muscle Cells. Journal of Molecular and Cellular Cardiology, 1999, 31, 1599-1606.	1.9	17
621	Oral Administration ofl-Arginine Reduces Intimal Hyperplasia in Balloon-Injured Rat Carotid Arteries. Journal of Surgical Research, 1999, 82, 17-23.	1.6	29
622	Pharmacology and Cardiovascular Implications of the Kinin-Kallikrein System. The Japanese Journal of Pharmacology, 1999, 79, 403-426.	1.2	40
623	Mechanism of Structural Remodelling of the Rat Aorta During Long-Term <i>N</i> <sup>G</sup> -Nitro-L-arginine Methyl Ester Treatment. The Japanese Journal of Pharmacology, 1999, 81, 99-106.	1.2	37
624	Vitamin K2 (Menatetrenone) Induces iNOS in Bovine Vascular Smooth Muscle Cells. No Relationship between Nitric Oxide Production and .GAMMACarboxylation Journal of Nutritional Science and Vitaminology, 1999, 45, 711-723.	0.6	13
625	Enhanced angiotensin-converting enzyme activity and impaired endothelium-dependent vasodilation in aortae from hypertensive rats: evidence for a causal link. Clinical Science, 1999, 97, 165-174.	4.3	21
626	Cytokine-Stimulated Nitric Oxide Production in the Human Renal Proximal Tubule and Its Modulation by Natriuretic Peptides: A Novel Immunomodulatory Mechanism?. Nephron Experimental Nephrology, 1999, 7, 438-448.	2.2	52
627	Blood Flow in the Internal Carotid and Middle Cerebral Arteries: Effects of Continuous Oral Conjugated Equine Estrogens Administration with Monthly Progestogen Supplementation on Postmenopausal Women. Menopause, 1999, 6, 225-229.	2.0	11
628	Interactions among ACE, kinins and NO. Cardiovascular Research, 1999, 43, 549-561.	3.8	148
629	Linkage analysis of endothelial nitric oxide synthase gene with human blood pressure. Journal of Hypertension, 1999, 17, 1431-1436.	0.5	13
630	Endothelial Function and Dysfunction. , 1999, , 49-70.		1
632	Effect of Ascorbic Acid on Endothelial Dysfunction of Epicardial Coronary Arteries in Chronic Smokers Assessed by Cold Pressor Testing. Cardiology, 2000, 94, 239-246.	1.4	23
633	Cyclic nucleotides in smooth muscle. Advances in Organ Biology, 2000, 8, 181-213.	0.1	2
636	Mechanisms of the pro- and anti-oxidant actions of nitric oxide in atherosclerosis. Cardiovascular Research, 2000, 47, 465-474.	3.8	92
637	Nitric Oxide–Induced Increase in p21 Sdi1/Cip1/Waf1 Expression During the Cell Cycle in Aortic Adventitial Fibroblasts. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 27-34.	2.4	29
638	Study on the Relationship Between Plasma Nitrite and Nitrate Level and Salt Sensitivity in Human Hypertension. Circulation, 2000, 101, 856-861.	1.6	234
639	Endothelial Dysfunction in the Pulmonary Vascular Bed. American Journal of the Medical Sciences, 2000, 320, 223-232.	1.1	36
640	Vascular Protection. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 1512-1520.	2.4	140

#	Article	IF	CITATIONS
641	Endothelial dysfunctions: common denominators in vascular disease. Current Opinion in Clinical Nutrition and Metabolic Care, 2000, 3, 453-467.	2.5	45
642	High CA repeat numbers in intron 13 of the endothelial nitric oxide synthase gene and increased risk of coronary artery disease. Pharmacogenetics and Genomics, 2000, 10, 133-140.	5.7	66
643	Protective effect of inducible type nitric oxide synthase against intracellular oxidative stress caused by advanced glycation end-products in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats. Journal of Hypertension, 2000, 18, 1071-1079.	0.5	13
644	Endothelial dysfunctions: common denominators in vascular disease. Current Opinion in Lipidology, 2000, 11, 9-23.	2.7	105
645	Extracellular Adenosine Induces Apoptosis of Human Arterial Smooth Muscle Cells via A <sub>2b</sub> -Purinoceptor. Circulation Research, 2000, 86, 76-85.	4.5	90
646	Impaired endothelial function in arterial hypertension and hypercholesterolemia. Journal of Hypertension, 2000, 18, 363-374.	0.5	142
647	eNOS inhibition of proliferation: a role for p21Sdi1/Cip1/Waf1 and p27kip1. Cardiovascular Research, 2000, 47, 640-641.	3.8	1
648	The role of protein kinase C in the development of the complications of diabetes. Vitamins and Hormones, 2000, 60, 149-193.	1.7	54
649	Nutritional aspects and possible pathological mechanisms of hyperhomocysteinaemia: an independent risk factor for vascular disease. Proceedings of the Nutrition Society, 2000, 59, 221-237.	1.0	32
650	Nitric oxide in the pathogenesis of vascular disease. Journal of Pathology, 2000, 190, 244-254.	4.5	531
651	Effects of ACE inhibition and bradykinin antagonism on cardiovascular changes in uremic rats. Kidney International, 2000, 58, 153-161.	5.2	26
652	Endothelial cell dysfunction and nitric oxide synthase. Kidney International, 2000, 58, 1360-1376.	5.2	50
653	Type 2 diabetes and atherosclerosis. Diabetes, Obesity and Metabolism, 2000, 2, S21-S30.	4.4	15
654	A pivotal role of nitric oxide in endothelial cell dysfunction. Acta Physiologica Scandinavica, 2000, 168, 33-40.	2.2	32
655	Dual regulatory effects of nitric oxide on plasminogen activator inhibitor type $\hat{a} \in f1$ expression in endothelial cells. FEBS Journal, 2000, 267, 1001-1007.	0.2	33
656	Nitric oxide-generating polymers reduce platelet adhesion and smooth muscle cell proliferation. Biomaterials, 2000, 21, 2273-2278.	11.4	162
657	S-Nitrosoglutathione reduces nonocclusive thrombosis rate following balloon overstretch injury and intracoronary irradiation of porcine coronary arteries. International Journal of Radiation Oncology Biology Physics, 2000, 48, 1167-1174.	0.8	11
658	Pentaerythrityl tetranitrate attenuates structural changes in conduit arteries evoked by long-term NO-synthase inhibition. British Journal of Pharmacology, 2000, 130, 450-456.	5.4	12

#	ARTICLE	IF	CITATIONS
659	Participation of kinins in the captopril-induced inhibition of intimal hyperplasia caused by interruption of carotid blood flow in the mouse. British Journal of Pharmacology, 2000, 130, 1076-1082.	5 <b>.</b> 4	11
660	Sâ€Nitrosothiols cause prolonged, nitric oxideâ€mediated relaxation in human saphenous vein and internal mammary artery: therapeutic potential in bypass surgery. British Journal of Pharmacology, 2000, 131, 1236-1244.	5.4	54
661	Lipoprotein Modulation of Subendothelial Heparan Sulfate Proteoglycans (Perlecan) and Atherogenicity. Trends in Cardiovascular Medicine, 2000, 10, 60-65.	4.9	56
662	Intimal growth and neovascularization in human stenotic vein grafts1. Journal of the American College of Surgeons, 2000, 191, 264-271.	0.5	29
663	Regulation of Placental Vascular Endothelial Growth Factor (VEGF) and Placenta Growth Factor (PIGF) and Soluble Flt-1 by Oxygen— A Review. Placenta, 2000, 21, S16-S24.	1.5	296
664	Nitric oxide synthase gene therapy in vascular pathology. Seminars in Perinatology, 2000, 24, 51-54.	2.5	15
665	Inhaled nitric oxide. Seminars in Perinatology, 2000, 24, 55-58.	2.5	4
666	Nitric oxide donors and angiotensin-converting enzyme inhibitors act in concert to inhibit human angiotensin-converting enzyme activity and platelet aggregation in vitro. European Journal of Pharmacology, 2000, 406, 15-23.	3.5	19
667	Atherosclerosis risk factors: the possible role of homocysteine. Molecular and Cellular Biochemistry, 2000, 207, 143-148.	3.1	28
668	Chronic treatment with FK506 increases p70 S6 kinase activity associated with reduced nitric oxide synthase activity in rabbit hearts. Cardiovascular Drugs and Therapy, 2000, 14, 329-336.	2.6	6
669	Inhibition of nitric oxide synthesis induces coronary vascular remodeling and cardiac hypertrophy associated with the activation of p70 S6 kinase in rats. Cardiovascular Drugs and Therapy, 2000, 14, 533-542.	2.6	20
670	Brugia malayi: Localization of Nitric Oxide Synthase in a Lymphatic Filariid. Experimental Parasitology, 2000, 94, 92-98.	1.2	19
671	A novel S-nitrosothiol (RIG200) causes prolonged relaxation in dorsal hand veins with damaged endothelium. Clinical Pharmacology and Therapeutics, 2000, 68, 75-81.	4.7	14
672	Molecular mechanisms of estrogen actions on the vasculature. Journal of Nuclear Cardiology, 2000, 7, 500-508.	2.1	32
673	Insulin and the vasculature. Current Hypertension Reports, 2000, 2, 148-153.	3.5	33
674	Nitric oxide and vascular responses in Type I diabetes. Diabetologia, 2000, 43, 137-147.	6.3	110
675	Pathogenetic mechanisms of cardiac allograft vasculopathy $\hat{A}-$ impact of nitric oxide. Clinical Research in Cardiology, 2000, 89, IX24-IX27.	1.1	4
676	Role of Nitric Oxide in the Regulation of Blood Flow. , 2000, , 483-502.		3

#	Article	IF	CITATIONS
677	EXERCISE AND VASCULAR ENDOTHELIAL FUNCTION. Japanese Journal of Physical Fitness and Sports Medicine, 2000, 49, 225-236.	0.0	0
678	Inhibition of angiogenesis decreases alveolarization in the developing rat lung. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2000, 279, L600-L607.	2.9	572
679	Effects of homocysteine on endothelial nitric oxide production. American Journal of Physiology - Renal Physiology, 2000, 279, F671-F678.	2.7	182
680	Role of Nitric Oxide in the Pathogenesis of Chronic Pulmonary Hypertension. Physiological Reviews, 2000, 80, 1337-1372.	28.8	225
681	Cross talk of shear-induced production of prostacyclin and nitric oxide in endothelial cells. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 278, H233-H238.	3.2	82
682	Early abnormalities of pulmonary vascular development in the Fawn-Hooded rat raised at Denver's altitude. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2000, 279, L283-L291.	2.9	48
683	B1 and B2 bradykinin receptors on adventitial fibroblasts of cerebral arteries are coupled to recombinant eNOS. American Journal of Physiology - Heart and Circulatory Physiology, 2000, 278, H367-H372.	3.2	14
684	Inhibition of NOS enhances pulmonary vascular changes in stroke-prone spontaneously hypertensive rats. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2000, 278, L81-L89.	2.9	5
685	Cell growth modulates nitric oxide synthase expression in fetal pulmonary artery endothelial cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2000, 278, L131-L138.	2.9	12
686	BK <sub>Ca</sub> channel activation by membrane-associated cGMP kinase may contribute to uterine quiescence in pregnancy. American Journal of Physiology - Cell Physiology, 2000, 279, C1751-C1759.	4.6	70
687	Antioxidants and the bioactivity of endothelium-derived nitric oxide. Cardiovascular Research, 2000, 47, 426-435.	3.8	112
688	Ascorbic Acid and Glutathione Modulate the Biological Activity of S- Nitrosoglutathione. Hypertension, 2000, 36, 291-295.	2.7	40
689	Expression and Function of Recombinant Endothelial Nitric Oxide Synthase in Human Endothelial Cells. Journal of Vascular Research, 2000, 37, 449-456.	1.4	16
690	Inducible nitric oxide synthase (iNOS) expression upregulates p21 and inhibits vascular smooth muscle cell proliferation through p42/44 mitogen-activated protein kinase activation and independent of p53 and cyclic guanosine monophosphate. Journal of Vascular Surgery, 2000, 31, 1214-1228.	1.1	113
691	Enalapril and Losartan Augment Endogenous Nitric Oxide Release in Takayasu's Arteritis. Angiology, 2000, 51, 69-75.	1.8	11
692	Temporal Events Underlying Arterial Remodeling After Chronic Flow Reduction in Mice. Circulation Research, 2000, 86, 1160-1166.	4.5	60
693	Characterization of an Upstream Enhancer Region in the Promoter of the Human Endothelial Nitric-oxide Synthase Gene. Journal of Biological Chemistry, 2000, 275, 40732-40741.	3.4	56
694	Cyclic GMP-dependent Protein Kinase Signaling Pathway Inhibits RhoA-induced Ca2+ Sensitization of Contraction in Vascular Smooth Muscle. Journal of Biological Chemistry, 2000, 275, 21722-21729.	3.4	541

#	Article	IF	Citations
695	Cyclic GMP–Dependent Protein Kinase Expression in Coronary Arterial Smooth Muscle in Response to Balloon Catheter Injury. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 2192-2197.	2.4	71
696	Nitric Oxide Inhalation Decreases Pulmonary Artery Remodeling in the Injured Lungs of Rat Pups. Circulation Research, 2000, 87, 140-145.	4.5	69
697	Regulation of Endothelial Nitric Oxide Synthase Expression by Albumin-Derived Advanced Glycosylation End Products. Circulation Research, 2000, 86, E50-4.	4.5	98
698	Endothelin-1 Inhibits Apoptosis of Vascular Smooth Muscle Cells Induced by Nitric Oxide and Serum Deprivation via MAP Kinase Pathway. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 989-997.	2.4	90
699	Lysophosphatidylcholine Inhibits Endothelial Cell Migration and Proliferation via Inhibition of the Extracellular Signal–Regulated Kinase Pathway. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 1006-1012.	2.4	64
700	Periadventitial Inducible Nitric Oxide Synthase Expression and Intimal Thickening. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 1896-1902.	2.4	32
701	Physical Training Improves Flow-Mediated Dilation in Patients With the Polymetabolic Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 551-555.	2.4	144
702	<i>N</i> -Acetyl- <scp>I</scp> -Cysteine Potentiates Interleukin- $1\hat{l}^2$ Induction of Nitric Oxide Synthase. Hypertension, 2000, 35, 914-918.	2.7	32
703	Effects of L-arginine on Vascular Smooth Muscle Cell Proliferation and Apoptosis after Balloon Injury. Scandinavian Cardiovascular Journal, 2000, 34, 28-32.	1.2	24
704	Effect of nitric oxide on proliferation of human retina pigment epithelial cells. Eye, 2000, 14, 899-902.	2.1	5
705	eNOS gene transfer to vascular smooth muscle cells inhibits cell proliferation via upregulation of p27 and p21 and not apoptosis. Cardiovascular Research, 2000, 47, 697-706.	3.8	70
706	Asymmetric Dimethylarginine, Derangements of the Endothelial Nitric Oxide Synthase Pathway, and Cardiovascular Diseases. Seminars in Thrombosis and Hemostasis, 2000, 26, 539-546.	2.7	73
707	Exaggerated Vascular and Renal Pathology in Endothelin-B Receptor–Deficient Rats With Deoxycorticosterone Acetate–Salt Hypertension. Circulation, 2000, 102, 2765-2773.	1.6	60
708	Chronic <i>N</i> <sup>G</sup> -Nitro- <scp>I</scp> -Arginine Methyl Ester–Induced Hypertension. Circulation, 2000, 101, 423-429.	1.6	84
709	Effects of Aspirin-Like Drugs on Nitric Oxide Synthesis in Rat Vascular Smooth Muscle Cells. Hypertension, 2000, 35, 1085-1091.	2.7	32
710	Effect of Chronic Treatment With the Inducible Nitric Oxide Synthase Inhibitor N -Iminoethyl- I -Lysine or With I -Arginine on Progression of Coronary and Aortic Atherosclerosis in Hypercholesterolemic Rabbits. Circulation, 2000, 102, 1033-1038.	1.6	72
711	Adenovirus-Mediated Human Tissue Kallikrein Gene Delivery Inhibits Neointima Formation Induced by Interruption of Blood Flow in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 1459-1466.	2.4	28
712	Nitric Oxide Synthase in Atherosclerosis and Vascular Injury. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 1873-1881.	2.4	87

#	ARTICLE	IF	CITATIONS
713	The Mitogenic Effect of $17\hat{l}^2$ -Estradiol on in vitro Endothelial Cell Proliferation and on in vivo Reendothelialization Are Both Dependent on Vascular Endothelial Growth Factor. Journal of Vascular Research, 2000, 37, 202-208.	1.4	36
714	Nitric Oxide Modulates Expression of Cell Cycle Regulatory Proteins. Circulation, 2000, 101, 1982-1989.	1.6	207
715	Loss of Expression of the $\hat{l}^2$ Subunit of Soluble Guanylyl Cyclase Prevents Nitric Oxideâ $\in$ Mediated Inhibition of DNA Synthesis in Smooth Muscle Cells of Old Rats. Circulation Research, 2000, 86, 520-525.	<b>4.</b> 5	42
716	Diabetes in the Goto-Kakizaki rat is accompanied by impaired insulin-mediated myosin-bound phosphatase activation and vascular smooth muscle cell relaxation. Diabetes, 2000, 49, 2178-2189.	0.6	81
717	Ascorbic Acid Enhances Endothelial Nitric-oxide Synthase Activity by Increasing Intracellular Tetrahydrobiopterin. Journal of Biological Chemistry, 2000, 275, 17399-17406.	3.4	310
718	Angiotensin-Converting Enzyme Inhibitor Prevents Plasminogen Activator Inhibitor-1 Expression in a Rat Model with Cardiovascular Remodeling Induced by Chronic Inhibition of Nitric Oxide Synthesis. Journal of Molecular and Cellular Cardiology, 2000, 32, 73-83.	1.9	80
719	Suppression of Proliferation of Human Coronary Artery Smooth Muscle Cells by the Nitric Oxide Donor, S-Nitrosoglutathione, Is cGMP-Independent. Molecular Cell Biology Research Communications: MCBRC: Part B of Biochemical and Biophysical Research Communications, 2000, 4, 32-36.	1.6	15
720	The Gap Between Knowledge and Practice in the Treatment and Prevention of Cardiovascular Disease. Preventive Cardiology, 2000, 3, 167-171.	1.1	9
721	Angiotensin-(1–7): an update. Regulatory Peptides, 2000, 91, 45-62.	1.9	353
722	Effect of imidapril on myocardial remodeling in L-NAME-induced hypertensive rats is associated with gene expression of NOS and ACE mRNA. American Journal of Hypertension, 2000, 13, 199-207.	2.0	36
723	Atherosclerosis: from lesion formation to plaque activation and endothelial dysfunction. Molecular Aspects of Medicine, 2000, 21, 99-166.	6.4	83
724	Nitric oxide reactivity and mechanisms involved in its biological effects. Pharmacological Research, 2000, 42, 421-427.	7.1	70
725	Does ADMA Cause Endothelial Dysfunction?. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 2032-2037.	2.4	521
726	Nitric oxide prevents p21 degradation with the ubiquitin-proteasome pathway in vascular smooth muscle cells. Journal of Vascular Surgery, 2000, 31, 364-374.	1.1	31
727	Nitrovasodilators inhibit platelet-derived growth factor-induced proliferation and migration of activated human hepatic stellate cells. Gastroenterology, 2000, 119, 479-492.	1.3	108
728	Inhibition of endothelium-dependent arterial relaxation by oxidized phosphatidylcholine. Atherosclerosis, 2000, 152, 79-87.	0.8	18
729	Acute hemodynamic and neurohumoral effects of selective ETA receptor blockade in patients with congestive heart failure. Journal of the American College of Cardiology, 2000, 35, 1745-1752.	2.8	107
730	Diffuse intimal thickening of coronary arteries in patients with coronary spastic angina. Journal of the American College of Cardiology, 2000, 36, 432-437.	2.8	105

#	Article	IF	CITATIONS
731	Polymeric-based perivascular delivery of a nitric oxide donor inhibits intimal thickening after balloon denudation arterial injury: role of nuclear factor-kappaB11This work was supported by a grant from the Henry W. Wheeler Research Fund Journal of the American College of Cardiology, 2000, 35, 493-501.	2.8	70
732	Pulmonary blood flow alters nitric oxide production in patients undergoing device closure of atrial septal defects. Journal of the American College of Cardiology, 2000, 35, 463-467.	2.8	33
733	Vascular actions of brain natriuretic peptide: modulation by atherosclerosis and neutral endopeptidase inhibition. Journal of the American College of Cardiology, 2000, 35, 796-801.	2.8	51
734	Local adenovirus-mediated transfer of C-type natriuretic peptide suppresses vascular remodeling in porcine coronary arteries in vivo. Journal of the American College of Cardiology, 2000, 35, 1040-1047.	2.8	51
735	Endothelium-derived relaxing factors: A focus on endothelium-derived hyperpolarizing factor(s). Canadian Journal of Physiology and Pharmacology, 2001, 79, 443-470.	1.4	146
736	Polymorphisms in endothelial nitric oxide synthase and atherogenesis. Atherosclerosis, 2001, 154, 521-527.	0.8	115
737	Therapeutic modification of the l-arginine-eNOS pathway in cardiovascular diseases. Atherosclerosis, 2001, 154, 255-267.	0.8	48
738	Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis, 2001, 158, 425-430.	0.8	185
739	Prevention of intimal hyperplasia with recombinant soluble P-selectin glycoprotein ligand-immunoglobulin in the porcine coronary artery balloon injury model. Journal of the American College of Cardiology, 2001, 38, 577-582.	2.8	51
740	Mechanisms of Cell Signaling by Nitric Oxide and Peroxynitrite: From Mitochondria to MAP Kinases. Antioxidants and Redox Signaling, 2001, 3, 215-229.	5.4	112
741	Involvement of PKC and NF-κB in Nitric Oxide Induced Apoptosis in Human Coronary Artery Smooth Muscle Cells. Cellular Physiology and Biochemistry, 2001, 11, 231-240.	1.6	16
742	Anti-oxidants - a protective role in cardiovascular disease?. Expert Opinion on Pharmacotherapy, 2001, 2, 1737-1750.	1.8	30
743	Reduced Expression of Endothelial Nitric Oxide Synthase in Pulmonary Arteries of Smokers. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 709-713.	5.6	185
744	THECLINICALPHARMACOLOGY OFL-ARGININE. Annual Review of Pharmacology and Toxicology, 2001, 41, 79-99.	9.4	276
745	Maintaining the Endothelium: Preventive Strategies for Vessel Integrity. Preventive Cardiology, 2001, 4, 28-37.	1.1	2
746	Nitric Oxide Regulates Smooth-muscle-specific Myosin Heavy Chain Gene Expression at the Transcriptional Levelâ€"Possible Role of SRF and YY1 Through CArG Element. Journal of Molecular and Cellular Cardiology, 2001, 33, 95-107.	1.9	28
747	Heterotypic Smooth Muscle Cell/Endothelial Cell Interactions Differ between Species. Journal of Surgical Research, 2001, 98, 85-88.	1.6	23
748	Coinduction of Endothelial Nitric Oxide Synthase and Arginine Recycling Enzymes in Aorta of Diabetic Rats. Nitric Oxide - Biology and Chemistry, 2001, 5, 252-260.	2.7	53

#	Article	IF	CITATIONS
749	Vascular Endothelial Growth Factor Receptor-2-Mediated Mitogenesis Is Negatively Regulated by Vascular Endothelial Growth Factor Receptor-1 in Tumor Epithelial Cells. American Journal of Pathology, 2001, 158, 265-273.	3.8	36
750	Enhanced gene expression of renin–angiotensin system, TGF-β1, endothelin-1 and nitric oxide synthase in right-ventricular hypertrophy. Pharmacological Research, 2001, 43, 265-273.	7.1	30
751	Cardiovascular implications of insulin resistance and non–insulin-dependent diabetes mellitus. Journal of Cardiothoracic and Vascular Anesthesia, 2001, 15, 768-777.	1.3	6
752	Relationship of the Glu298Asp polymorphism of the endothelial nitric oxide synthase gene and early-onset coronary artery disease. American Heart Journal, 2001, 142, 586-589.	2.7	52
753	Lipopolysaccharide-induced cell cycle arrest in macrophages occurs independently of nitric oxide synthase II induction. Biochimica Et Biophysica Acta - Molecular Cell Research, 2001, 1539, 140-146.	4.1	32
754	Effect of estrogen on endothelial dysfunction in postmenopausal women with diabetes. Diabetes Research and Clinical Practice, 2001, 54, S81-S92.	2.8	35
755	Mechanisms mediating the antiproliferative effects of nitric oxide in cultured human airway smooth muscle cells. FEBS Letters, 2001, 506, 91-96.	2.8	25
756	Direct measurement of nitric oxide release from saphenous vein: abolishment by surgical preparation. Annals of Thoracic Surgery, 2001, 71, 133-137.	1.3	124
757	Nitric oxide inhibition increases matrix metalloproteinase–9 expression by rat aortic smooth muscle cells in vitro. Journal of Vascular Surgery, 2001, 34, 76-83.	1.1	88
758	Adenovirus-mediated gene transfer of human inducible nitric oxide synthase in porcine vein grafts inhibits intimal hyperplasia. Journal of Vascular Surgery, 2001, 34, 156-165.	1.1	83
759	Dual cell seeding and the use of zymogen tissue plasminogen activator to improve cell retention on polytetrafluoroethylene grafts. Journal of Vascular Surgery, 2001, 34, 337-343.	1.1	14
760	Enhancement of neointima formation with tissue-type plasminogen activator. Journal of Vascular Surgery, 2001, 33, 821-828.	1.1	19
761	Expression of cell proliferationâ€related PCNA and E2F genes inDrosophilagut and inhibitory effect of nitric oxide. Korean Journal of Biological Sciences, 2001, 5, 59-64.	0.1	0
762	A Common Variant of Endothelial Nitric Oxide Synthase (Glu298Asp) Is an Independent Risk Factor for Carotid Atherosclerosis. Stroke, 2001, 32, 735-740.	2.0	163
763	Nitric oxide production in the hypoxic lung. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 280, L575-L582.	2.9	110
764	Vascular Smooth Muscle Growth: Autocrine Growth Mechanisms. Physiological Reviews, 2001, 81, 999-1030.	28.8	341
765	TNF-α inhibits flow and insulin signaling leading to NO production in aortic endothelial cells. American Journal of Physiology - Cell Physiology, 2001, 280, C1057-C1065.	4.6	127
766	Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. American Journal of Physiology - Cell Physiology, 2001, 280, C1375-C1386.	4.6	270

#	Article	IF	Citations
767	Cardioprotective actions of endogenous IL-10 are independent of iNOS. American Journal of Physiology - Heart and Circulatory Physiology, 2001, 281, H48-H52.	3.2	41
768	The NO donor molsidomine reduces endothelin-1 gene expression in chronic hypoxic rat lungs. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 280, L258-L263.	2.9	27
769	Invited Review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression. Journal of Applied Physiology, 2001, 91, 1421-1430.	2.5	452
770	Comparison of the lag time to initiation of flow-mediated vasodilation to endothelium-dependent vasodilation in early diagnosis of endothelial dysfunction. Sunhwan'gi, 2001, 31, 867.	0.3	1
771	Mechanisms of angiotensin- $(1\hat{a}\in "7)$ -induced inhibition of angiogenesis. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2001, 280, R994-R1000.	1.8	67
772	Overexpression of protein kinase G using adenovirus inhibits cyclin E transcription and mesangial cell cycle. American Journal of Physiology - Renal Physiology, 2001, 280, F851-F859.	2.7	14
773	Contrasting effects of thiol-modulating agents on endothelial NO bioactivity. American Journal of Physiology - Cell Physiology, 2001, 281, C719-C725.	4.6	28
774	Altered endothelium-dependent relaxations in lambs with high pulmonary blood flow and pulmonary hypertension. American Journal of Physiology - Heart and Circulatory Physiology, 2001, 280, H311-H317.	3.2	46
775	Cross talk between prostacyclin and nitric oxide under shear in smooth muscle cell: role in monocyte adhesion. American Journal of Physiology - Heart and Circulatory Physiology, 2001, 281, H177-H182.	3.2	17
776	Reduced endothelial nitric oxide synthase in lungs of chronically ventilated preterm lambs. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2001, 281, L1011-L1020.	2.9	85
777	Juxtacrine effects of IL-1 $\hat{l}$ ± precursor promote iNOS expression in vascular smooth muscle cells. American Journal of Physiology - Heart and Circulatory Physiology, 2001, 280, H1615-H1623.	3.2	8
778	Nitric Oxide Is an Essential Negative Regulator of Cell Proliferation in <i>Xenopus</i> Brain. Journal of Neuroscience, 2001, 21, 8809-8818.	3.6	111
779	Endovascular Research: Stents. , 2001, , 1001-1010.		0
780	Differential expression and synthesis of natriuretic peptides determines natriuretic peptide receptor expression in primary cultures of human proximal tubular cells. Journal of Hypertension, 2001, 19, 255-262.	0.5	12
781	Effect of chronic angiotensin II inhibition on the nitric oxide synthase in the normal rat during aging. Journal of Hypertension, 2001, 19, 1403-1409.	0.5	34
782	Oxidants and antioxidants in atherosclerosis. Current Opinion in Lipidology, 2001, 12, 411-418.	2.7	90
783	Chronic inhibition of NO synthesis per se promotes structural intimal remodeling of the rat aorta. Journal of Hypertension, 2001, 19, 1567-1579.	0.5	28
784	Title is missing!. European Journal of Cardiovascular Prevention and Rehabilitation, 2001, 8, 319-328.	1.5	135

#	Article	IF	CITATIONS
785	Regulation of Endothelial Nitric Oxide Synthase and Endothelin-1 Expression by Fluvastatin in Human Vascular Endothelial Cells. The Japanese Journal of Pharmacology, 2001, 85, 147-154.	1.2	17
786	Nitric Oxide Stimulates Elastin Expression in Chick Aortic Smooth Muscle Cells Biological and Pharmaceutical Bulletin, 2001, 24, 461-464.	1.4	21
787	Regulation of glucose transport in aortic smooth muscle cells by cAMP and cGMP. Biochemical Journal, 2001, 353, 513.	3.7	2
788	Inhibitory Effects of Nicorandil on Rat Mesangial Cell Proliferation via the Protein Kinase G Pathway. Nephron, 2001, 87, 263-268.	1.8	23
789	A Liposomal iNOS-Gene Therapy Approach to Prevent Neointimal Lesion Formation in Porcine Femoral Arteries., 0,, 75-86.		0
790	Impaired Release of ATP from Red Blood Cells of Humans with Primary Pulmonary Hypertension. Experimental Biology and Medicine, 2001, 226, 434-439.	2.4	77
791	Vasoresponsiveness of Sarcoidosis-Associated Pulmonary Hypertension. Chest, 2001, 120, 866-872.	0.8	121
792	Atherogenesis and the arginine hypothesis. Current Atherosclerosis Reports, 2001, 3, 252-259.	4.8	47
795	Inhibition of rat cardiac fibroblast growth by cAMP - but not by cGMP-dependent protein kinase. Basic Research in Cardiology, 2001, 96, 184-191.	5.9	7
796	Cardioprotective actions of acute HMGâ€CoA reductase inhibition in the setting of myocardial infarction. Acta Physiologica Scandinavica, 2001, 173, 139-143.	2.2	39
797	Urea-induced inducible nitric oxide synthase inhibition and macrophage proliferation. Kidney International, 2001, 59, S2-S8.	5,2	20
798	Endothelial nitric oxide in humans in health and disease. International Journal of Experimental Pathology, 2001, 80, 291-303.	1.3	33
799	Lack of association between polymorphisms of catalase, copper-zinc superoxide dismutase (SOD), extracellular SOD and endothelial nitric oxide synthase genes and macroangiopathy in patients with type 2 diabetes mellitus. Journal of Internal Medicine, 2001, 249, 451-459.	6.0	85
800	Antiangiogenesis efficacy of nitric oxide donors. Journal of Cellular Biochemistry, 2001, 80, 104-114.	2.6	36
801	Molecular pathways of cyclic nucleotide-induced inhibition of arterial smooth muscle cell proliferation. Journal of Cellular Physiology, 2001, 186, 1-10.	4.1	81
802	Regression of early events of atherosclerosis in hypercholesterolemic rabbits by prophylactic treatment with nitroderivative of acetyl salicylic acid. Drug Development Research, 2001, 53, 237-243.	2.9	0
803	Nitric Oxide Synthase in Filariae: Demonstration of Nitric Oxide Production by Embryos in Brugia malayi and Acanthocheilonema viteae. Experimental Parasitology, 2001, 97, 205-214.	1.2	21
804	Adeno-associated virus-mediated transfer of endothelial nitric oxide synthase gene inhibits protein synthesis of rat ventricular cardiomyocytes. Cardiovascular Drugs and Therapy, 2001, 15, 19-24.	2.6	8

#	Article	IF	CITATIONS
805	Role of endothelin in the control of peripheral vascular tone in human hypertension. Heart Failure Reviews, 2001, 6, 277-285.	3.9	38
806	Regulation of L-Arginine Transport and Metabolism in Vascular Smooth Muscle Cells. Cell Biochemistry and Biophysics, 2001, 35, 19-34.	1.8	33
808	Antihypertensive effects of the flavonoid quercetin in spontaneously hypertensive rats. British Journal of Pharmacology, 2001, 133, 117-124.	5.4	381
809	The human internal thoracic artery releases more nitric oxide in response to vascular endothelial growth factor than the human saphenous vein. Journal of Thoracic and Cardiovascular Surgery, 2001, 122, 305-309.	0.8	29
810	Current and future strategies in the treatment of childhood pulmonary hypertension. Progress in Pediatric Cardiology, 2001, 12, 289-318.	0.4	12
811	Inactivation of glutathione peroxidase by nitric oxide leads to the accumulation of H2O2and the induction of HBâ€EGF via câ€Jun NH2â€terminal kinase in rat aortic smooth muscle cells. FASEB Journal, 2001, 15, 1472-1474.	0.5	33
812	Endothelial Nitric Oxide Synthase Gene Polymorphism and Maternal Vascular Adaptation to Pregnancy. Hypertension, 2001, 38, 1289-1293.	2.7	89
813	Brachial Flow-Mediated Vasodilator Responses in Population-Based Research: Methods, Reproducibility and Effects of Age, Gender and Baseline Diameter. European Journal of Cardiovascular Prevention and Rehabilitation, 2001, 8, 319-328.	2.8	129
814	Reduced Hypoxic Pulmonary Vascular Remodeling by Nitric Oxide From the Endothelium. Hypertension, 2001, 37, 322-327.	2.7	107
815	Workshop:Endothelial Cell Dysfunction Leading to Diabetic Nephropathy. Hypertension, 2001, 37, 744-748.	2.7	131
816	Tumor Necrosis Factor-α Induces Fibronectin Synthesis in Coronary Artery Smooth Muscle Cells by a Nitric Oxide–Dependent Posttranscriptional Mechanism. Circulation Research, 2001, 89, 26-32.	4.5	12
817	Endothelial NO Synthase Overexpression Inhibits Lesion Formation in Mouse Model of Vascular Remodeling. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 201-207.	2.4	90
818	17Î <sup>2</sup> -Estradiol Increases Nitric Oxide and Prostaglandin I2 Production by Cultured Human Uterine Arteries Only in Histologically Normal Specimens. Journal of Cardiovascular Pharmacology, 2001, 38, 240-249.	1.9	10
819	Low-Dose Estrogen Supplementation Improves Vascular Function in Hypogonadal Men. Hypertension, 2001, 38, 1011-1016.	2.7	41
820	p11 Expression in Human Bronchial Epithelial Cells Is Increased by Nitric Oxide in a cGMP-dependent Pathway Involving Protein Kinase G Activation. Journal of Biological Chemistry, 2001, 276, 44613-44621.	3.4	22
821	Differential Effect of Chronic Antihypertensive Treatment on Vascular Smooth Muscle Cell Phenotype in Spontaneously Hypertensive Rats. Hypertension, 2001, 37, E4-E10.	2.7	24
822	NO Modulates Monocyte Chemotactic Protein-1 Expression in Endothelial Cells Under Cyclic Strain. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1941-1947.	2.4	59
823	Regression of Renal Vascular Fibrosis by Endothelin Receptor Antagonism. Hypertension, 2001, 37, 490-496.	2.7	88

#	Article	IF	Citations
824	Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 1712-1719.	2.4	1,182
825	Induction of NAD(P)H Oxidase by Oxidized Low-Density Lipoprotein in Human Endothelial Cells. Circulation, 2001, 104, 1767-1772.	1.6	250
826	Soluble Guanylate Cyclase $\hat{l}\pm \langle sub \rangle 1 \langle $	4.5	48
827	Improvements of renal lesions and function by angiotensin and endothelin receptor antagonism in nitric oxide-deficient rats. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2001, 2, S211-S216.	1.7	2
828	High Levels of Exhaled Nitric Oxide (NO) and NO Synthase III Expression in Lesional Smooth Muscle in Lymphangioleiomyomatosis. American Journal of Respiratory Cell and Molecular Biology, 2001, 24, 414-418.	2.9	28
829	Comparative Trial of Local Pharmacotherapy with <scp> </scp> -Arginine, r-Hirudin, and Molsidomine to Reduce Restenosis after Balloon Angioplasty of Stenotic Rabbit Iliac Arteries. Radiology, 2001, 219, 716-723.	7.3	23
830	Polyamines, NO and cGMP mediate stimulation of DNA synthesis by tumor necrosis factor and lipopolysaccharide in chick embryo cardiomyocytes. Cardiovascular Research, 2001, 49, 408-416.	3.8	12
831	Nitric oxide synthase inhibition increases aortic stiffness measured by pulse wave velocity in rats. Cardiovascular Research, 2001, 51, 351-358.	3.8	149
832	Inhibition of Major Histocompatibility Complex Class II Gene Transcription by Nitric Oxide and Antioxidants. Journal of Biological Chemistry, 2002, 277, 26460-26467.	3.4	23
833	Overexpression of a Constitutively Active Protein Kinase G Mutant Reduces Neointima Formation and In-Stent Restenosis. Circulation, 2002, 105, 2911-2916.	1.6	61
834	Insulin Activates CCAAT/Enhancer Binding Proteins and Proinflammatory Gene Expression through the Phosphatidylinositol 3-Kinase Pathway in Vascular Smooth Muscle Cells. Journal of Biological Chemistry, 2002, 277, 36631-36639.	3.4	67
835	Nitric Oxide and Angiogenesis in Cardiovascular Disease. Antioxidants and Redox Signaling, 2002, 4, 825-831.	5.4	57
836	NO Attenuates Insulin Signaling and Motility in Aortic Smooth Muscle Cells via Protein Tyrosine Phosphatase 18–Mediated Mechanism. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 1086-1092.	2.4	46
837	Hydrogen Peroxide Activates Endothelial Nitric-oxide Synthase through Coordinated Phosphorylation and Dephosphorylation via a Phosphoinositide 3-Kinase-dependent Signaling Pathway. Journal of Biological Chemistry, 2002, 277, 6017-6024.	3.4	339
838	cGMP-Dependent Protein Kinase Expression Restores Contractile Function in Cultured Vascular Smooth Muscle Cells. Journal of Vascular Research, 2002, 39, 95-103.	1.4	38
839	Nitric Oxide–Induced Motility in Aortic Smooth Muscle Cells. Circulation Research, 2002, 91, 390-397.	4.5	57
840	Statins and vascular protection: a â€~radical' view. Journal of Hypertension, 2002, 20, 359-361.	0.5	8
841	The endothelial nitric oxide synthase (Glu298Asp and –786T>C) gene polymorphisms are associated with coronary in-stent restenosis. European Heart Journal, 2002, 23, 1955-1962.	2.2	60

#	Article	IF	CITATIONS
842	Glu298Asp Endothelial Nitric Oxide Synthase Gene Polymorphism Interacts With Environmental and Dietary Factors to Influence Endothelial Function. Circulation Research, 2002, 90, 1153-1158.	4.5	190
843	Oral Administration of l-Arginine Prevents Congestive Heart Failure in Murine Viral Myocarditis. Journal of Cardiovascular Pharmacology, 2002, 40, 1-8.	1.9	5
844	Endothelial dysfunction in ischemic acute renal failure: rescue by transplanted endothelial cells. American Journal of Physiology - Renal Physiology, 2002, 282, F1140-F1149.	2.7	269
845	Alterations in Nitric Oxide Production in 8-Week-Old Lambs with Increased Pulmonary Blood Flow. Pediatric Research, 2002, 52, 233-244.	2.3	30
846	Vessel-Specific Stimulation of Protein Synthesis by Nitric Oxide Synthase Inhibition. Hypertension, 2002, 39, 16-21.	2.7	20
847	Structure of Cerebral Arterioles in Cystathionine $\hat{l}^2$ -Synthase-Deficient Mice. Circulation Research, 2002, 91, 931-937.	4.5	65
848	Overexpression of Endothelial Nitric Oxide Synthase Attenuates Cardiac Hypertrophy Induced by Chronic Isoproterenol Infusion Circulation Journal, 2002, 66, 851-856.	1.6	80
850	Long-Term Treatment With Perindopril Ameliorates Dobutamine-Induced Myocardial Ischemia in Patients With Coronary Artery Disease. The Japanese Journal of Pharmacology, 2002, 88, 100-107.	1.2	18
851	Kinetics of transplant arteriosclerosis in MHC-Class I mismatched and fully allogeneic mouse aortic allografts 1. Transplantation, 2002, 73, 1068-1074.	1.0	33
852	Pravastatin promotes coronary collateral circulation in patients with coronary artery disease. Coronary Artery Disease, 2002, 13, 377-381.	0.7	21
853	The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide. Journal of Hypertension, 2002, 20, 2023-2027.	0.5	221
854	Regulation of cell signalling by vitamin E. Proceedings of the Nutrition Society, 2002, 61, 415-425.	1.0	190
855	Endogenous Nitric Oxide Synthase Inhibitors in Endothelial Cells, Endothelin-1 Within the Vessel Wall, and Intimal Hyperplasia in Perimenopausal Human Uterine Arteries. Journal of Cardiovascular Pharmacology, 2002, 39, 192-200.	1.9	26
856	Overexpression of endothelial NO synthase induces angiogenesis in a co-culture model. Cardiovascular Research, 2002, 55, 190-200.	3.8	78
857	Effect of lower limb exercise on forearm vascular function: contribution of nitric oxide. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 283, H899-H907.	3.2	102
858	Short Polymers of Arginine Rapidly Translocate Into Vascular Cells. Circulation Journal, 2002, 66, 1155-1160.	1.6	11
859	Measurements of redox control of nitric oxide bioavailability. Methods in Enzymology, 2002, 359, 209-216.	1.0	3
860	Nitric oxide, gender and hypertension in humans. Advances in Cell Aging and Gerontology, 2002, , 145-163.	0.1	0

#	Article	IF	Citations
861	Comparison of angiotensin-converting enzyme (ACE), neutral endopeptidase (NEP) and dual ACE/NEP inhibition on blood pressure and resistance arteries of deoxycorticosterone acetate-salt hypertensive rats. Journal of Hypertension, 2002, 20, 899-907.	0.5	27
862	Platelet-endothelial cell adhesion molecule-1 (CD31) expression on donor endothelial cells attenuates the development of transplant arteriosclerosis1. Transplantation, 2002, 74, 1267-1273.	1.0	19
863	High prevalence of polymorphisms of angiotensin-converting enzyme (I/D) and endothelial nitric oxide synthase (Glu298Asp) in patients with systemic sclerosis. American Journal of Medicine, 2002, 112, 540-544.	1.5	69
864	Nitric Oxide Modulates Vascular Disease in the Remnant Kidney Model. American Journal of Pathology, 2002, 161, 239-248.	3.8	105
865	l-Arginine Impacts Pulmonary Vascular Structure in Rats with an Aortocaval Shunt. Journal of Surgical Research, 2002, 108, 20-31.	1.6	19
866	Mechanisms of Dysfunction of the Nitric Oxide Pathway in Vascular Diseases. Nitric Oxide - Biology and Chemistry, 2002, 6, 101-124.	2.7	115
867	Glycoxidized low-density lipoprotein downregulates endothelial nitricoxide synthase in human coronary cells. Journal of the American College of Cardiology, 2002, 40, 1515-1522.	2.8	41
868	The T allele of the missense Glu298Asp endothelial nitric oxide synthase gene polymorphism is associated with coronary heart disease in younger individuals with high atherosclerotic risk profile. Atherosclerosis, 2002, 160, 167-175.	0.8	78
869	Intraperitoneal infusion of homocysteine increases intimal hyperplasia in balloon-injured rat carotid arteries. Atherosclerosis, 2002, 160, 103-114.	0.8	15
870	$\hat{l}^2$ -very low density lipoprotein enhances inducible nitric oxide synthase expression in cytokine-stimulated vascular smooth muscle cells. Atherosclerosis, 2002, 162, 307-313.	0.8	18
871	Constitutive and Inducible Nitric Oxide Synthase: Role in Angiogenesis. Antioxidants and Redox Signaling, 2002, 4, 817-823.	5 <b>.</b> 4	85
872	Effects of Antihypertensive Drugs on Endothelial Dysfunction. Drugs, 2002, 62, 265-284.	10.9	150
873	Nitric oxide donor drugs: current status and future trends. Expert Opinion on Investigational Drugs, 2002, 11, 587-601.	4.1	79
874	T-786C Polymorphism in Endothelial NO Synthase Gene Affects Cerebral Circulation in Smokers. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 605-610.	2.4	45
875	Effects of enalapril on the vascular wall in an experimental model of syndrome X. American Journal of Hypertension, 2002, 15, 872-878.	2.0	30
876	Atherosclerosis and cancer: common pathways on the vascular endothelium. Biomedicine and Pharmacotherapy, 2002, 56, 317-324.	5.6	48
877	Dendroaspis natriuretic peptide-like immunoreactivity and its regulation in rat aortic vascular smooth muscle. Peptides, 2002, 23, 23-29.	2.4	20
878	The Glu298Asp polymorphism in endothelial nitric oxide synthase gene is associated with coronary in-stent restenosis. International Journal of Cardiology, 2002, 86, 71-76.	1.7	31

#	Article	IF	CITATIONS
879	Oral l-arginine prevents murine coxsackievirus B3 myocarditis. International Journal of Cardiology, 2002, 86, 273-279.	1.7	4
880	17Î <sup>2</sup> -Estradiol rapid stimulation of rat aorta NOS activity is prevented by oestrogen deficiency. Maturitas, 2002, 43, 55-64.	2.4	5
881	The bradykinin/soluble guanylate cyclase signaling pathway is impaired in androgen-independent prostate cancer cells. Cancer Letters, 2002, 177, 181-187.	7.2	10
882	Inhibition of Neointimal Hyperplasia by Heat Stress in an Experimental Model. Journal of Vascular and Interventional Radiology, 2002, 13, 1247-1253.	0.5	2
883	Intraluminal gene transfer of endothelial cell-nitric oxide synthase suppresses intimal hyperplasia of vein grafts in cholesterol-fed rabbit: A limited biological effect as a result of the loss of medial smooth muscle cells. Surgery, 2002, 131, 644-653.	1.9	41
884	Hypoxia-induced pulmonary endothelin-1 expression is unaltered by nitric oxide. Journal of Applied Physiology, 2002, 92, 1152-1158.	2.5	25
885	Expression of Nitric Oxide Synthase Isoforms after Endothelial Denudation of the Rat Carotid Artery. Sunhwan'gi, 2002, 32, 884.	0.3	0
886	Developmental differences in pulmonary eNOS expression in response to chronic hypoxia in the rat. Journal of Applied Physiology, 2002, 93, 311-318.	2.5	24
887	Expression and control of C-type natriuretic peptide in rat vascular smooth muscle cells. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2002, 282, R156-R165.	1.8	37
888	Long-term inhibition of nitric oxide synthesis increases arterial thrombogenecity in rat carotid artery. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 282, H1478-H1484.	3.2	28
889	Differential response to myocardial reperfusion injury in eNOS-deficient mice. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 282, H2422-H2426.	3.2	77
890	ecNOS gene polymorphism is associated with endothelium-dependent vasodilation in Type 2 diabetes. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 283, H557-H561.	3.2	26
891	Role of nitric oxide in heparin-induced attenuation of hypoxic pulmonary vascular remodeling. Journal of Applied Physiology, 2002, 92, 2012-2018.	2.5	7
892	Ultrasound Improves Tissue Perfusion in Ischemic Tissue through a Nitric Oxide Dependent Mechanism. Thrombosis and Haemostasis, 2002, 88, 865-870.	3.4	96
893	Effects of Choto-san on hemorheological factors and vascular function in stroke-prone spontaneously hypertensive rats. Phytomedicine, 2002, 9, 93-98.	5.3	17
894	Ethanol differentially modulates the expression and activity of cell cycle regulatory proteins in rat aortic smooth muscle cells. European Journal of Pharmacology, 2002, 445, 163-170.	3.5	8
895	Enalapril and quinapril improve endothelial vasodilator function and aortic eNOS gene expression in l-NAME-treated rats. European Journal of Pharmacology, 2002, 450, 61-66.	3.5	44
896	Effect of local delivery of l-arginine on in-stent restenosis in humans. American Journal of Cardiology, 2002, 89, 363-367.	1.6	36

#	Article	IF	CITATIONS
897	Beneficial effect of pentaerythrityl tetranitrate on functional and morphological changes in the rat thoracic aorta evoked by long-term nitric oxide synthase inhibition. Vascular Pharmacology, 2002, 38, 177-182.	2.1	10
898	Local Delivery of NO-Donor Molsidomine Post-PTA Improves Haemodynamics, Wall Mechanics and Histomorphometry in Atherosclerotic Porcine SFA. European Journal of Vascular and Endovascular Surgery, 2002, 23, 226-233.	1.5	5
899	Mitochondria, nitric oxide, and cardiovascular dysfunction. Free Radical Biology and Medicine, 2002, 33, 1465-1474.	2.9	139
900	Rapid vascular cell responses to estrogen and membrane receptors. Vascular Pharmacology, 2002, 38, 99-108.	2.1	57
901	Coronary revascularization in the 21ST century. General Thoracic and Cardiovascular Surgery, 2002, 50, 541-553.	0.4	2
902	Inducible Nitric Oxide Synthase: From Cloning to Therapeutic Applications. World Journal of Surgery, 2002, 26, 772-778.	1.6	33
904	Association of a polymorphism of the ecNOS gene with myocardial infarction in a subgroup of Turkish MI patients. Clinical Genetics, 2002, 61, 66-70.	2.0	24
905	Endothelial nitric oxide synthase gene Glu298Asp polymorphism and blood pressure, left ventricular mass and carotid artery atherosclerosis in a populationâ€based cohort. Journal of Internal Medicine, 2002, 251, 102-110.	6.0	80
906	Antiproliferative effect of nitric oxide on epidermal growth factor-responsive human neuroblastoma cells. Journal of Neurochemistry, 2002, 83, 119-131.	3.9	50
907	Free radicals, diabetes and endothelial dysfunction. Diabetes, Obesity and Metabolism, 2002, 4, 224-238.	4.4	83
908	Effects of VEGF and bFGF on Proliferation and Production of Steroids and Nitric Oxide in Porcine Granulosa Cells. Reproduction in Domestic Animals, 2002, 37, 362-368.	1.4	55
909	Effect of Perilla frutescens on nitric oxide production and DNA synthesis in cultured murine vascular smooth muscle cells. Phytotherapy Research, 2002, 16, 19-23.	5.8	23
910	Nitric Oxide–Releasing Aspirin Decreases Vascular Injury by Reducing Inflammation and Promoting Apoptosis. Laboratory Investigation, 2002, 82, 825-832.	3.7	30
911	Nitric oxide inhibits capacitative Ca2+entry and enhances endoplasmic reticulum Ca2+uptake in bovine vascular endothelial cells. Journal of Physiology, 2002, 539, 77-91.	2.9	122
912	Elevated mean arterial pressure in the ovariectomized rat was normalized by ETA receptor antagonist therapy: absence of cardiac hypertrophy and fibrosis. British Journal of Pharmacology, 2002, 136, 685-692.	5.4	19
913	Functional Analysis of Natriuretic Peptide Receptors in the Bladder of the Toad, Bufo marinus. General and Comparative Endocrinology, 2002, 125, 207-217.	1.8	8
914	A selective somatostatin type-2 receptor agonist inhibits neointimal thickening and enhances endothelial cell growth and morphology following aortic balloon injury in the rabbit. Molecular and Cellular Biochemistry, 2002, 240, 31-37.	3.1	7
915	Nitric oxide and cardioprotection during ischemia-reperfusion. Heart Failure Reviews, 2002, 7, 391-405.	3.9	118

#	Article	IF	CITATIONS
916	Nitric oxide, cell death, and heart failure. Heart Failure Reviews, 2002, 7, 327-334.	3.9	7
917	Nitric oxide and portal hypertension. Metabolic Brain Disease, 2002, 17, 311-324.	2.9	29
918	Regulation of Neuronal Proliferation and Differentiation by Nitric Oxide. Molecular Neurobiology, 2003, 27, 107-120.	4.0	123
919	The therapeutic effect of natriuretic peptides in heart failure; differential regulation of endothelial and inducible nitric oxide synthases. Heart Failure Reviews, 2003, 8, 55-70.	3.9	14
920	The role of the NO axis and its therapeutic implications in pulmonary arterial hypertension. Heart Failure Reviews, 2003, 8, 5-21.	3.9	57
921	Asymmetrical dimethylarginine: A novel risk factor for coronary artery disease. Clinical Cardiology, 2003, 26, 458-464.	1.8	71
922	Potential mechanisms of impaired endothelial function in arterial hypertension and hypercholesterolemia. Current Hypertension Reports, 2003, 5, 199-207.	3.5	77
923	Efficacy of Local Molsidomine Delivery from a Hydrogel-Coated Angioplasty Balloon Catheter in the Atherosclerotic Porcine Model. CardioVascular and Interventional Radiology, 2003, 26, 65-72.	2.0	15
924	Interaction of CA repeat polymorphism of the endothelial nitric oxide synthase and hyperhomocysteinemia in acute coronary syndromes: evidence of gender-specific differences. Journal of Molecular Medicine, 2003, 81, 305-309.	3.9	9
925	Beyond lipid-lowering: effects of statins on endothelial nitric oxide. European Journal of Clinical Pharmacology, 2003, 58, 719-731.	1.9	157
926	High plasma level of asymmetric dimethylarginine in patients with acutely exacerbated congestive heart failure: role in reduction of plasma nitric oxide level. Heart and Vessels, 2003, 18, 177-182.	1.2	58
927	Skeletonized radial artery: New technique for graft harvest with improved angiographic results. International Journal of Angiology, 2003, 12, 252-256.	0.6	0
928	Normalization by edaravone, a free radical scavenger, of irradiation-reduced endothelial nitric oxide synthase expression. European Journal of Pharmacology, 2003, 476, 131-137.	3.5	26
929	Endothelial nitric oxide synthase gene polymorphisms in giant cell arteritis. Arthritis and Rheumatism, 2003, 48, 3219-3223.	6.7	35
930	Nitric oxide-induced epidermal growth factor-dependent phosphorylations in A431 tumour cells. FEBS Journal, 2003, 270, 1828-1837.	0.2	28
931	Nitric oxide in vascular biology. Journal of Thrombosis and Haemostasis, 2003, 1, 2112-2118.	3.8	230
932	The effect of lipoproteins on endothelial nitric oxide synthase is modulated by lipoperoxides. European Journal of Clinical Investigation, 2003, 33, 117-125.	3.4	29
933	Protective role of endothelial nitric oxide synthase. Journal of Pathology, 2003, 199, 8-17.	4.5	327

#	Article	IF	Citations
934	Endothelial control of vasomotion and nitric oxide production. Cardiology Clinics, 2003, 21, 289-302.	2.2	58
935	Nitric oxide and wound repair. Surgical Clinics of North America, 2003, 83, 521-530.	1.5	79
936	Cytotoxicity of nitric oxide donors in smooth muscle cells is dependent on phenotype, and mainly due to apoptosis. Atherosclerosis, 2003, 166, 223-232.	0.8	28
937	The platelet-endothelium interaction mediated by lectin-like oxidized low-density lipoprotein receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells. Journal of the American College of Cardiology, 2003, 41, 499-507.	2.8	55
938	Red wine increases the expression of human endothelial nitric oxide synthase. Journal of the American College of Cardiology, 2003, 41, 471-478.	2.8	179
939	Functional Interplay Between Angiotensin II and Nitric Oxide. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 26-36.	2.4	163
940	Nitric oxide and vascular reactivity in African American patients with hypertension*1. Journal of Cardiac Failure, 2003, 9, S199-S204.	1.7	23
941	Insulin resistance and endothelial dysfunction. Best Practice and Research in Clinical Endocrinology and Metabolism, 2003, 17, 411-430.	4.7	58
942	Plasminogen activator inhibitor contributes to the coronary wall thickening in patients with angiographically normal coronary. Thrombosis Research, 2003, 112, 123-129.	1.7	6
943	Ghrelin improves endothelial dysfunction through growth hormone-independent mechanisms in rats. Biochemical and Biophysical Research Communications, 2003, 310, 830-835.	2.1	120
944	ADMA and oxidative stress. Atherosclerosis Supplements, 2003, 4, 41-51.	1.2	360
945	Inhibitory effect of brachytherapy on intimal hyperplasia in arteriovenous fistula1. Journal of Surgical Research, 2003, 115, 200-208.	1.6	27
946	Effect of the alpha-adrenergic blocker, doxazosin, on endothelial function and insulin action. Metabolism: Clinical and Experimental, 2003, 52, 1147-1152.	3.4	22
947	Nitric oxide acts in a positive feedback loop with BDNF to regulate neural progenitor cell proliferation and differentiation in the mammalian brain. Developmental Biology, 2003, 258, 319-333.	2.0	280
948	The chronic inhibition of nitric oxide synthase enhances cell proliferation in the adult rat hippocampus. Neuroscience Letters, 2003, 339, 9-12.	2.1	32
949	In vitro evaluation of vascular endothelial growth factor (VEGF)-eluting stents. International Journal of Cardiology, 2003, 92, 247-251.	1.7	26
950	Exercise and the Nitric Oxide Vasodilator System. Sports Medicine, 2003, 33, 1013-1035.	6.5	268
951	The potential of nitric oxide therapeutics in stroke. Expert Opinion on Investigational Drugs, 2003, 12, 455-470.	4.1	50

#	Article	IF	CITATIONS
952	Preclinical Evaluation of Inducible Nitric Oxide Synthase Lipoplex Gene Therapy for Inhibition of Stent-Induced Vascular Neointimal Lesion Formation. Human Gene Therapy, 2003, 14, 375-383.	2.7	43
953	Nitric Oxide Signaling and Clinical Alternatives to Nitric Oxide. Seminars in Cardiothoracic and Vascular Anesthesia, 2003, 7, 239-252.	1.0	1
954	Stretch Activates Nitric Oxide Production in Pulmonary Vascular Endothelial Cells <i>In Situ</i> American Journal of Respiratory and Critical Care Medicine, 2003, 168, 1391-1398.	5.6	111
955	Molecular Mechanisms of Inhibition of Vascular Growth by Angiotensin-(1-7). Hypertension, 2003, 42, 574-579.	2.7	158
956	Celiprolol Activates eNOS Through the PI3K-Akt Pathway and Inhibits VCAM-1 Via NF-κB Induced by Oxidative Stress. Hypertension, 2003, 42, 1004-1013.	2.7	81
957	Cyclic GMP-Dependent Protein Kinases and the Cardiovascular System. Circulation Research, 2003, 93, 907-916.	4.5	265
958	Cardiac Allograft Vasculopathy and Dysregulation of the NO Synthase Pathway. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 567-575.	2.4	68
959	Probucol Promotes Functional Reendothelialization in Balloon-Injured Rabbit Aortas. Circulation, 2003, 107, 2031-2036.	1.6	104
960	Folate Improves Endothelial Function in Patients with Coronary Heart Disease. Clinical Chemistry and Laboratory Medicine, 2003, 41, 1505-12.	2.3	27
961	NADPH Oxidase in Endothelial Cells: Impact on Atherosclerosis. Antioxidants and Redox Signaling, 2003, 5, 171-180.	5.4	86
962	Insulin-Stimulated Hydrogen Peroxide Increases Guanylate Cyclase Activity in Vascular Smooth Muscle. Hypertension, 2003, 42, 569-573.	2.7	13
963	L-4F, an Apolipoprotein A-1 Mimetic, Restores Nitric Oxide and Superoxide Anion Balance in Low-Density Lipoprotein-Treated Endothelial Cells. Circulation, 2003, 107, 1520-1524.	1.6	92
964	Both estrogen and raloxifene cause G1 arrest of vascular smooth muscle cells. Journal of Endocrinology, 2003, 178, 319-329.	2.6	53
965	The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovascular Research, 2003, 59, 824-833.	3.8	323
966	Adrenomedullin Overexpression to Inhibit Cuff-Induced Arterial Intimal Formation. Hypertension, 2003, 41, 302-307.	2.7	24
967	Peroxisome Proliferator-Activated Receptor Î <sup>3</sup> Ligands Increase Release of Nitric Oxide From Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 52-57.	2.4	278
968	Potentiation of C-type natriuretic peptide with ultrasound and microbubbles to prevent neointimal formation after vascular injury in rats. Cardiovascular Research, 2003, 58, 231-238.	3.8	14
969	Exogenous nitric oxide causes overexpression of TGF- $\hat{l}^21$ and overproduction of extracellular matrix in human coronary smooth muscle cells. Cardiovascular Research, 2003, 58, 671-678.	3.8	25

#	Article	IF	Citations
970	Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. European Heart Journal, 2003, 24, 1912-1919.	2.2	164
971	Deficiency of Nitric Oxide Synthase 2 Results in Increased Neointima Formation in a Mouse Model of Vascular Injury. Journal of Cardiovascular Pharmacology, 2003, 41, 897-902.	1.9	9
972	Possible Involvement of Facilitated Polyol Pathway in Augmentation of Intimal Hyperplasia in Rabbits with Alloxan-induced Hyperglycemia. Journal of Cardiovascular Pharmacology, 2003, 41, 265-275.	1.9	6
973	Endothelium-Dependent Effects of Statins. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 729-736.	2.4	372
974	Cardiac allograft vasculopathy: central role of endothelial injury leading to transplant ???atheroma???. Transplantation, 2003, 76, 891-899.	1.0	138
975	ETA Receptors Mediate Vasoconstriction of Large Conduit Arteries During Reduced Flow in Humans. Journal of Cardiovascular Pharmacology, 2003, 42, 315-318.	1.9	62
976	Interrelationship of Free Oxygen Radicals and Endothelial Dysfunction–Modulation by Statins. Endothelium: Journal of Endothelial Cell Research, 2003, 10, 23-33.	1.7	58
977	Local adenoviral-mediated inducible nitric oxide synthase gene transfer inhibits neointimal formation in the porcine coronary stented model. Molecular Therapy, 2003, 7, 597-603.	8.2	42
978	Mechanism of eNOS gene transfer inhibition of vascular smooth muscle cell proliferation. American Journal of Physiology - Cell Physiology, 2003, 284, C191-C199.	4.6	31
979	Pulmonary vascular dysfunction in preterm lambs with chronic lung disease. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2003, 285, L76-L85.	2.9	57
980	Effects of ET-A receptor blockade on eNOS gene expression in chronic hypoxic rat lungs. Journal of Applied Physiology, 2003, 94, 446-452.	2.5	23
981	Reduced Endothelial Vasomotor Function and Enhanced Neointimal Formation after Vascular Injury in a Rat Model of Blood Pressure Lability. Hypertension Research, 2003, 26, 991-998.	2.7	74
982	Alterations in ET-1, not nitric oxide, in 1-week-old lambs with increased pulmonary blood flow. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 284, H480-H490.	3.2	28
983	Intrauterine hypertension decreases lung VEGF expression and VEGF inhibition causes pulmonary hypertension in the ovine fetus. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2003, 284, L508-L517.	2.9	86
984	NOS inhibition accelerates atherogenesis: reversal by exercise. American Journal of Physiology - Heart and Circulatory Physiology, 2003, 285, H535-H540.	3.2	39
985	Nitric Oxide and Cardioprotection During Ischemia-Reperfusion. , 2004, , 231-245.		1
986	Developmental Physiology of the Pulmonary Circulation. , 2004, , 105-117.		2
987	In-Stent Restenosis Limitation with Stent-based Controlled-Release Nitric Oxide: Initial Results in Rabbits. Radiology, 2004, 230, 377-382.	7.3	33

#	Article	IF	CITATIONS
988	Endothelial Function and Oxidative Stress. Endothelium: Journal of Endothelial Cell Research, 2004, 11, 123-132.	1.7	145
989	Structure of Cerebral Arterioles in Mice Deficient in Expression of the Gene for Endothelial Nitric Oxide Synthase. Circulation Research, 2004, 95, 822-829.	4.5	66
990	Nitric Oxide Is a Physiological Inhibitor of Neurogenesis in the Adult Mouse Subventricular Zone and Olfactory Bulb. Journal of Neuroscience, 2004, 24, 85-95.	3.6	211
991	Actin Cytoskeleton Organization and Posttranscriptional Regulation of Endothelial Nitric Oxide Synthase During Cell Growth. Circulation Research, 2004, 95, 488-495.	4.5	66
992	Regulation of cGMP-dependent Protein Kinase Expression by Soluble Guanylyl Cyclase in Vascular Smooth Muscle Cells. Journal of Biological Chemistry, 2004, 279, 46631-46636.	3.4	44
993	Exogenous Nitric Oxide Upregulates p21 <sup>waf1/cip1</sup> in Pulmonary Microvascular Smooth Muscle Cells. Journal of Vascular Research, 2004, 41, 211-219.	1.4	26
994	Vascular Effects of Improving Metabolic Control With Metformin or Rosiglitazone in Type 2 Diabetes. Diabetes Care, 2004, 27, 1349-1357.	8.6	170
995	Tumor Necrosis Factor-α Inhibits Endothelial Nitric-oxide Synthase Gene Promoter Activity in Bovine Aortic Endothelial Cells. Journal of Biological Chemistry, 2004, 279, 963-969.	3.4	148
996	Nitric oxide attenuates insulin- or IGF-I-stimulated aortic smooth muscle cell motility by decreasing H2O2 levels: essential role of cGMP. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 286, H2103-H2112.	3.2	30
997	Endothelial Nitric Oxide Gene Haplotypes and Risk of Cerebral Small-Vessel Disease. Stroke, 2004, 35, 654-659.	2.0	142
998	Nitric Oxide, Cell Death, and Heart Failure. , 2004, , 93-100.		0
999	The Role of the NO Axis and its Therapeutic Implications in Pulmonary Arterial Hypertension. , 2004, , 213-229.		21
1000	Modulatory effects of HMC oA reductase inhibitors in diabetic microangiopathy. FASEB Journal, 2004, 18, 805-815.	0.5	73
1001	Effects of Indapamide, a Thiazide-Like Diuretic, on Structure of Cerebral Arterioles in Hypertensive Rats. Hypertension, 2004, 43, 1092-1097.	2.7	24
1002	Nitric oxide negatively regulates proliferation and promotes neuronal differentiation through N-Myc downregulation. Journal of Cell Science, 2004, 117, 4727-4737.	2.0	69
1003	YC-1 prevents sodium nitroprusside-mediated apoptosis in vascular smooth muscle cells. Cardiovascular Research, 2004, 61, 152-158.	3.8	34
1004	Endothelium-derived microparticles impair endothelial function in vitro. American Journal of Physiology - Heart and Circulatory Physiology, 2004, 286, H1910-H1915.	3.2	329
1005	Nitric oxide: inhibitory effects on endothelial cell calcium signaling, prostaglandin I2 production and nitric oxide synthase expression. Cardiovascular Research, 2004, 62, 194-201.	3.8	34

#	ARTICLE	IF	Citations
1006	Do incremental increases in blood pressure elicit neointimal plaques through endothelial injury?. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2004, 287, R1486-R1493.	1.8	4
1007	High glucose mediates proâ€oxidant and antioxidant enzyme activities in coronary endothelial cells. Diabetes, Obesity and Metabolism, 2004, 6, 432-441.	4.4	75
1008	Low-intensity ultrasound increases endothelial cell nitric oxide synthase activity and nitric oxide synthesis. Journal of Thrombosis and Haemostasis, 2004, 2, 637-643.	3.8	85
1009	Effect of advanced glycation end-products on gene expression and synthesis of TNF- $\hat{l}_{\pm}$ and endothelial nitric oxide synthase by endothelial cells. Kidney International, 2004, 66, 1099-1106.	5.2	104
1010	Synergistic interaction between enalapril, L -arginine and tetrahydrobiopterin in smooth muscle cell apoptosis and aortic remodeling induction in SHR. British Journal of Pharmacology, 2004, 142, 912-918.	5.4	5
1011	iNOS Gene Transfer for Graft Disease. Trends in Cardiovascular Medicine, 2004, 14, 267-272.	4.9	10
1012	Gene therapy for muscular disease. Drug Discovery Today, 2004, 9, 777.	6.4	0
1013	Role of endothelin ETB receptor in partial ablation-induced chronic renal failure in rats. European Journal of Pharmacology, 2004, 494, 63-71.	3.5	12
1014	The Role of Statins in Vascular Disease. European Journal of Vascular and Endovascular Surgery, 2004, 27, 6-16.	1.5	48
1015	Influence of eNOS Gene Polymorphisms on Carotid Atherosclerosis. European Journal of Vascular and Endovascular Surgery, 2004, 27, 540-544.	1.5	34
1016	Nitric oxide, an iceberg in cardiovascular physiology:. Archives of Medical Research, 2004, 35, 1-11.	3.3	40
1017	Nitric oxide synthesis inhibition increases proliferation of neural precursors isolated from the postnatal mouse subventricular zone. Brain Research, 2004, 995, 274-284.	2.2	77
1018	Nitric oxide synthase gene G298 allele. Cardiovascular Radiation Medicine, 2004, 5, 113-118.	0.6	11
1019	High-Speed Detection of the G894T Polymorphism in Exon 7 of the eNOS Gene by Real-Time Fluorescence PCR with the Light-Cycler. Biochemical Genetics, 2004, 42, 121-127.	1.7	6
1020	Nitric oxide signaling during myocardial angiogenesis. Molecular and Cellular Biochemistry, 2004, 264, 25-34.	3.1	24
1021	Nitric oxide insufficiency and atherothrombosis. Histochemistry and Cell Biology, 2004, 122, 353-367.	1.7	99
1023	The upregulation of endothelial nitric oxide synthase and urotensin-II is associated with pulmonary hypertension and vascular diseases in rats produced by aortocaval shunting. Heart and Vessels, 2004, 19, 81-88.	1.2	39
1024	The possible role of hydrogen sulfide as a smooth muscle cell proliferation inhibitor in rat cultured cells. Heart and Vessels, 2004, 19, 75-80.	1.2	166

#	Article	IF	CITATIONS
1025	Adrenomedullin in vascular diseases. Current Hypertension Reports, 2004, 6, 55-59.	3.5	10
1026	Effect of cell passage and density on protein kinase G expression and activation in vascular smooth muscle cells. Journal of Cellular Biochemistry, 2004, 92, 104-112.	2.6	22
1027	Aortic wall remodeling in rats with nitric oxide deficiency treated by enalapril or verapamil. Pathology Research and Practice, 2004, 200, 211-217.	2.3	23
1028	Inhibitory effects of l-arginine derivatives on endothelium-dependent vasorelaxing response to acetylcholine of the rat aorta. European Journal of Medicinal Chemistry, 2004, 39, 611-617.	5 <b>.</b> 5	3
1029	Evolving Pathophysiological Perspectives in Endothelial Dysfunction. High Blood Pressure and Cardiovascular Prevention, 2004, 11, 47-53.	2.2	0
1030	Transduction of peptide analogs of the small heat shock–related protein HSP20 inhibits intimal hyperplasia. Journal of Vascular Surgery, 2004, 40, 106-114.	1.1	39
1031	Role of the endothelium in modulating neointimal formation. Journal of the American College of Cardiology, 2004, 44, 733-739.	2.8	171
1032	Nipradilol inhibits atmospheric pressure-induced cell proliferation in human aortic smooth muscle cells. Pharmacological Research, 2004, 49, 217-225.	7.1	13
1033	Pharmacologic inhibition of nitric oxide synthases and cyclooxygenases enhances intimal hyperplasia in balloon-injured rat carotid arteries. Journal of Vascular Surgery, 2004, 40, 115-122.	1.1	16
1034	Restoring the endothelium of cryopreserved arterial grafts: co-culture of venous and arterial endothelial cells. Cryobiology, 2004, 49, 272-285.	0.7	16
1035	Impact of hydrogen sulfide on carbon monoxide/heme oxygenase pathway in the pathogenesis of hypoxic pulmonary hypertension. Biochemical and Biophysical Research Communications, 2004, 317, 30-37.	2.1	124
1036	Atrial natriuretic peptide inhibits cardiomyocyte hypertrophy through mitogen-activated protein kinase phosphatase-1. Biochemical and Biophysical Research Communications, 2004, 322, 310-319.	2.1	64
1037	Nitric oxide synthase and NAD(P)H oxidase modulate coronary endothelial cell growth. Journal of Molecular and Cellular Cardiology, 2004, 36, 277-286.	1.9	20
1038	Nitric oxide: a potential inducer of adhesion-related apoptosis—anoikis. Nitric Oxide - Biology and Chemistry, 2004, 10, 1-10.	2.7	47
1039	Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine. Metabolism: Clinical and Experimental, 2004, 53, 1574-1579.	3.4	128
1040	Influence of endothelial nitric oxide synthase gene polymorphisms (G894T, 4a4b, T-786C) and hyperhomocysteinemia on the predisposition to acute coronary syndromes. American Heart Journal, 2004, 147, 516-521.	2.7	76
1041	Nitric oxide synthase gene polymorphism (G894T) influences arterial stiffness in adults*1The Bogalusa Heart Study. American Journal of Hypertension, 2004, 17, 553-559.	2.0	31
1042	Neuromuscular electric stimulation enhances endothelial vascular control and hemodynamic function in paretic upper extremities of patients with stroke. Archives of Physical Medicine and Rehabilitation, 2004, 85, 1112-1116.	0.9	13

#	Article	IF	CITATIONS
1043	Lipids and atherosclerosis. Biochemistry and Cell Biology, 2004, 82, 212-224.	2.0	91
1044	L-arginine supplementation does not inhibit neointimal formation after coronary stenting in human beings: an intravascular ultrasound study. American Heart Journal, 2004, 147, 668.	2.7	15
1045	Endothelin-1(1?31) levels are increased in atherosclerotic lesions of the thoracic aorta of hypercholesterolemic hamsters. Atherosclerosis, 2004, 175, 203-212.	0.8	25
1046	The isoflavone metabolite dehydroequol produces vasodilatation in human resistance arteries via a nitric oxide-dependent mechanism. Atherosclerosis, 2004, 176, 45-48.	0.8	34
1047	Adenovirus Mediated Endothelial Nitric Oxide Synthase Gene Transfer Prevents Restenosis of Vein Grafts. ASAIO Journal, 2004, 50, 272-277.	1.6	10
1048	Caveolin-1 and caveolae in atherosclerosis: differential roles in fatty streak formation and neointimal hyperplasia. Current Opinion in Lipidology, 2004, 15, 523-529.	2.7	72
1049	Effects of chronic nitric oxide synthase inhibition on cerebral arterioles in Wistar???Kyoto rats. Journal of Hypertension, 2004, 22, 529-534.	0.5	13
1050	Statins Induce the Regression of Left Ventricular Mass in Patients With Angina. Circulation Journal, 2004, 68, 121-125.	1.6	30
1051	Cyclic nucleotide signaling in vascular and cavernous smooth muscle: aging-related changes. Advances in Cell Aging and Gerontology, 2004, 16, 57-106.	0.1	1
1052	Increase in the transcriptional activity of the endothelial nitric oxide synthase gene with fluvastatin: a relation with the ???786T>C polymorphism. Pharmacogenetics and Genomics, 2005, 15, 329-336.	1.5	48
1053	Randomized controlled trial of the effects of soy protein containing isoflavones on vascular function in postmenopausal women. American Journal of Clinical Nutrition, 2005, 81, 189-195.	4.7	103
1054	Angiotensin II as the link between nitric oxide and neuroadrenergic function. Journal of Hypertension, 2005, 23, 935-937.	0.5	14
1055	Inducible Nitric Oxide Synthase Has Divergent Effects on Vascular and Metabolic Function in Obesity. Diabetes, 2005, 54, 1082-1089.	0.6	137
1056	Endothelial nitric oxide synthase Glu298â†'Asp polymorphism, carotid atherosclerosis and intima-media thickness in a general population sample. Clinical Science, 2005, 109, 475-481.	<b>4.</b> 3	23
1057	Chapter 10 Caveolae and Caveolins in the Vascular System: Functional Roles in Endothelia, Macrophages, and Smooth Muscle Cells. Advances in Molecular and Cell Biology, 2005, 36, 187-209.	0.1	0
1058	Fundamental role of nitric oxide in neuritogenesis of PC12h cells. British Journal of Pharmacology, 2005, 146, 662-669.	5.4	29
1059	Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms. Nature Reviews Drug Discovery, 2005, 4, 977-987.	46.4	760
1060	Dietary copper supplements modulate aortic superoxide dismutase, nitric oxide and atherosclerosis. International Journal of Experimental Pathology, 2005, 86, 247-255.	1.3	21

#	Article	IF	CITATIONS
1061	Effects of Statins on 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition Beyond Low-Density Lipoprotein Cholesterol. American Journal of Cardiology, 2005, 96, 24-33.	1.6	243
1062	Pharmacological basis of different targets for the treatment of atherosclerosis. Journal of Cellular and Molecular Medicine, 2005, 9, 818-839.	3.6	23
1063	cGMP-independent nitric oxide signaling and regulation of the cell cycle. BMC Genomics, 2005, 6, 151.	2.8	45
1064	The Furoxan System: Design of Selective Nitric Oxide (NO) Donor Inhibitors of COX-2 Endowed with Anti-Aggregatory and Vasodilating Activities. Chemistry and Biodiversity, 2005, 2, 886-900.	2.1	32
1065	Infrainguinal vein graft stenosis. British Journal of Surgery, 2005, 80, 825-833.	0.3	62
1066	Pathobiology of intimal hyperplasia. British Journal of Surgery, 2005, 81, 1254-1269.	0.3	366
1067	Localized delivery of nitric oxide from hydrogels inhibits neointima formation in a rat carotid balloon injury model. Acta Biomaterialia, 2005, 1, 597-606.	8.3	50
1068	Effect of Nitric Oxide on Mitogen-Activated Protein Kinases in Neonatal Pulmonary Vascular Smooth Muscle. Lung, 2005, 183, 325-335.	3.3	11
1069	Pleiotropic effects of statins: Moving beyond cholesterol control. Current Atherosclerosis Reports, 2005, 7, 34-39.	4.8	19
1070	Chronic-arginine supplementation improves endothelial cell vasoactive functions in hypercholesterolemic and atherosclerotic monkeys. Molecular and Cellular Biochemistry, 2005, 269, 1-11.	3.1	27
1071	Regulation of Multimeric Structure of NO-synthase as a New Factor of Organogenesis. Russian Journal of Developmental Biology, 2005, 36, 285-291.	0.5	2
1072	Evidence for, and Importance of, cGMP-Independent Mechanisms with NO and NO Donors on Blood Vessels and Platelets. Current Vascular Pharmacology, 2005, 3, 41-53.	1.7	74
1073	Angiotensin II-induced hypertrophy is potentiated in mice overexpressing p22phox in vascular smooth muscle. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 288, H37-H42.	3.2	90
1074	Fetal origins of adult vascular dysfunction in mice lacking endothelial nitric oxide synthase. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2005, 288, R1114-R1121.	1.8	35
1075	Nitric oxide modulates vascular inflammation and intimal hyperplasia in insulin resistance and the metabolic syndrome. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 289, H228-H236.	3.2	54
1076	Bidirectional regulation of monocyte chemoattractant protein-1 gene at distinct sites of its promoter by nitric oxide in vascular smooth muscle cells. American Journal of Physiology - Cell Physiology, 2005, 289, C582-C590.	4.6	13
1077	Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly. Cardiovascular Research, 2005, 66, 276-285.	3.8	174
1078	rhVEGF treatment preserves pulmonary vascular reactivity and structure in an experimental model of pulmonary hypertension in fetal sheep. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2005, 289, L315-L321.	2.9	26

#	Article	IF	Citations
1079	Inhaled NO improves early pulmonary function and modifies lung growth and elastin deposition in a baboon model of neonatal chronic lung disease. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2005, 288, L450-L459.	2.9	201
1080	Ex vivo electroporation as a potent new strategy for nonviral gene transfer into autologous vein grafts. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 289, H1865-H1872.	3.2	8
1081	ADMA: its role in vascular disease. Vascular Medicine, 2005, 10, S11-S17.	1.5	22
1082	The Biology of Cyclic GMP-dependent Protein Kinases. Journal of Biological Chemistry, 2005, 280, 1-4.	3.4	212
1083	Nitric Oxide and Adult Neurogenesis in Health and Disease. Neuroscientist, 2005, 11, 294-307.	3.5	62
1084	Vascular Endothelium Has a Local Anti-Adenovirus Vector System and Glucocorticoid Optimizes Its Gene Transduction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1796-1803.	2.4	12
1085	Laminar Shear Stress and 3′ Polyadenylation of eNOS mRNA. Circulation Research, 2005, 96, 1161-1168.	4.5	50
1086	Modulation of Prostaglandin Biosynthesis by Nitric Oxide and Nitric Oxide Donors. Pharmacological Reviews, 2005, 57, 217-252.	16.0	321
1087	Inhaled Nitric Oxide Effects on Lung Structure and Function in Chronically Ventilated Preterm Lambs. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 899-906.	5.6	129
1088	Endothelial Nitric Oxide Synthase â^'786T>C, but Not 894G>T and 4a4b, Polymorphism Influences Plasma Homocysteine Concentrations in Persons with Normal Vitamin Status. Clinical Chemistry, 2005, 51, 1159-1164.	3.2	29
1089	ADMA: its role in vascular disease. Vascular Medicine, 2005, 10, S11-S17.	1.5	101
1090	Cytokine-Stimulated GTP Cyclohydrolase I Expression in Endothelial Cells Requires Coordinated Activation of Nuclear Factor-κB and Stat1/Stat3. Circulation Research, 2005, 96, 164-171.	4.5	74
1091	Nox1 Overexpression Potentiates Angiotensin II-Induced Hypertension and Vascular Smooth Muscle Hypertrophy in Transgenic Mice. Circulation, 2005, 112, 2668-2676.	1.6	396
1092	Induction of KLF2 by Fluid Shear Stress Requires a Novel Promoter Element Activated by a Phosphatidylinositol 3-Kinase-dependent Chromatin-remodeling Pathway. Journal of Biological Chemistry, 2005, 280, 23371-23379.	3.4	73
1093	Cardiopulmonary Effects of Chronic Administration of the NO Synthase Inhibitor L-NAME in the Chick Embryo. Neonatology, 2005, 88, 156-163.	2.0	4
1094	Peroxisome Proliferator-Activated Receptor γ Ligands Stimulate Endothelial Nitric Oxide Production Through Distinct Peroxisome Proliferator-Activated Receptor γ–Dependent Mechanisms. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1810-1816.	2.4	164
1095	Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events. European Heart Journal, 2005, 26, 1846-1851.	2.2	81
1096	Analysis of Pulmonary Vascular Response to Acute Alveolar Hypoxic Challenge in Young Rabbits Subjected to Chronic Hypoxia from Birth. Journal of Cardiovascular Pharmacology, 2005, 45, 431-438.	1.9	4

#	Article	IF	Citations
1097	Tratamiento de la insuficiencia cardÃaca en fase muy avanzada. FMC Formacion Medica Continuada En Atencion Primaria, 2005, 12, 315-324.	0.0	0
1098	Accumulated endogenous nitric oxide synthase inhibitors, enhanced arginase activity, attenuated dimethylarginine dimethylaminohydrolase activity and intimal hyperplasia in premenopausal human uterine arteries. Atherosclerosis, 2005, 178, 231-239.	0.8	31
1099	Antiproliferative Effects of Phosphodiesterase Type 5 Inhibition in Human Pulmonary Artery Cells. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 105-113.	5.6	316
1100	Neointimal hyperplasia on a cell-seeded polytetrafluoroethylene graft is promoted by transfer of tissue plasminogen activator gene and inhibited by transfer of nitric oxide synthase gene. Journal of Vascular Surgery, 2005, 41, 122-129.	1.1	8
1101	Hydrophilic statin suppresses vein graft intimal hyperplasia via endothelial cell-tropic Rho-kinase inhibition. Journal of Vascular Surgery, 2005, 42, 757-764.	1.1	52
1102	Vascular Consequences of Endothelial Nitric Oxide Synthase Uncoupling for the Activity and Expression of the Soluble Guanylyl Cyclase and the cGMP-Dependent Protein Kinase. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1551-1557.	2.4	345
1103	Glyceryl trinitrate-induced angiotensin-converting enzyme (ACE) inhibition in healthy volunteers is dependent on ACE genotype. Canadian Journal of Physiology and Pharmacology, 2005, 83, 1117-1122.	1.4	6
1104	eNOS Gene Affects Red Cell Deformability: Role of T-786C, G894T, and 4a/4b Polymorphisms. Clinical and Applied Thrombosis/Hemostasis, 2005, 11, 481-488.	1.7	14
1105	Chunghyuldan activates NOS mRNA expression and suppresses VCAM-1 mRNA expression in human endothelial cells. Canadian Journal of Physiology and Pharmacology, 2005, 83, 1101-1108.	1.4	11
1106	ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. Circulation, 2005, 112, e154-235.	1.6	2,179
1107	Inhibition of rat vascular smooth muscle cell proliferation by extract of Ligusticum chuanxiong and Angelica sinensis. Journal of Ethnopharmacology, 2005, 100, 140-144.	4.1	47
1108	Endothelial dysfunction and activation as an expression of disease: role of prostacyclin analogs. International Immunopharmacology, 2005, 5, 437-459.	3.8	41
1109	The role of nitric oxide in cardiovascular diseases. Molecular Aspects of Medicine, 2005, 26, 33-65.	6.4	436
1110	Association between the eNOS (Glu298Asp) and the RAS genes polymorphisms and premature coronary artery disease in a Turkish population. Clinica Chimica Acta, 2005, 351, 87-94.	1.1	57
1111	Role of nitric oxide in subventricular zone neurogenesis. Brain Research Reviews, 2005, 49, 355-366.	9.0	44
1112	A blend of polyphenolic compounds explains the stimulatory effect of red wine on human endothelial NO synthase. Nitric Oxide - Biology and Chemistry, 2005, 12, 97-104.	2.7	164
1113	Multiple potassium channels mediate nitric oxide-induced inhibition of rat vascular smooth muscle cell proliferation. Nitric Oxide - Biology and Chemistry, 2005, 13, 145-151.	2.7	15
1115	Nitric Oxide and Its Role in Diabetes Mellitus. , 2005, , 201-224.		2

#	Article	IF	CITATIONS
1116	ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. Journal of the American College of Cardiology, 2005, 46, e1-e82.	2.8	1,860
1117	PLEIOTROPIC EFFECTS OF STATINS. Annual Review of Pharmacology and Toxicology, 2005, 45, 89-118.	9.4	1,574
1118	eNOS G894T polymorphism as a mild predisposing factor for abdominal aortic aneurysm. Journal of Vascular Surgery, 2005, 42, 415-419.	1.1	41
1119	Reactive Species-Mediated Regulation of Cell Signaling and the Cell Cycle: The Role of MAPK. Antioxidants and Redox Signaling, 2005, 7, 726-740.	5.4	56
1120	Mining literature for a comprehensive pathway analysis: A case study for retrieval of homocysteine related genes for genetic and epigenetic studies. Lipids in Health and Disease, 2006, 5, 1.	3.0	129
1121	Diabetes Mellitus-Associated Atherosclerosis. American Journal of Cardiovascular Drugs, 2006, 6, 15-40.	2.2	26
1122	The cell cycle: A critical therapeutic target to prevent vascular proliferative disease. Canadian Journal of Cardiology, 2006, 22, 41B-55B.	1.7	29
1123	Does the method of harvesting the saphenous vein for coronary artery bypass surgery affect venous smooth muscle cells? iNOS immunolabelling and ultrastructural findings. International Journal of Surgery, 2006, 4, 20-29.	2.7	16
1124	Lipoplex gene transfer of inducible nitric oxide synthase inhibits the reactive intimal hyperplasia after expanded polytetrafluoroethylene bypass grafting. Journal of Vascular Surgery, 2006, 43, 1021-1027.	1.1	22
1125	Effect of diet and omega-3 fatty acid intervention on asymmetric dimethylarginine. Nutrition and Metabolism, 2006, 3, 4.	3.0	26
1126	Vascular Protection in Brain Ischemia. Cerebrovascular Diseases, 2006, 21, 21-29.	1.7	38
1127	Subcellular localization and regulation of type-1C and type-5 phosphodiesterases. Biochemical and Biophysical Research Communications, 2006, 341, 837-846.	2.1	45
1128	Hydrogen sulfide potentiates interleukin- $1\hat{1}^2$ -induced nitric oxide production via enhancement of extracellular signal-regulated kinase activation in rat vascular smooth muscle cells. Biochemical and Biophysical Research Communications, 2006, 345, 938-944.	2.1	80
1129	Association of the endothelial nitric oxide synthase (ecNOS) gene polymorphism with carotid atherosclerosis in type 2 diabetes. Diabetes Research and Clinical Practice, 2006, 72, 322-327.	2.8	7
1130	Janus-faced role of endothelial NO synthase in vascular disease: uncoupling of oxygen reduction from NO synthesis and its pharmacological reversal. Biological Chemistry, 2006, 387, 1521-33.	2.5	134
1131	Regulation of vascular smooth muscle cell phenotype by cyclic GMP and cyclic GMP-dependent protein kinase. Frontiers in Bioscience - Landmark, 2006, 11, 356.	3.0	118
1132	Significance of Plaque Disruption Sites in Acute Coronary Syndrome. Journal of Nippon Medical School, 2006, 73, 141-148.	0.9	3
1133	Nitric Oxide Pathway Activation and Impaired Red Blood Cell Deformability with Hypercholesterolemia. Journal of Atherosclerosis and Thrombosis, 2006, 13, 286-294.	2.0	19

#	Article	IF	CITATIONS
1134	The Basic Science of Wound Healing. Plastic and Reconstructive Surgery, 2006, 117, 12S-34S.	1.4	1,144
1135	A â~786T>C polymorphism in the endothelial nitric oxide synthase gene reduces serum nitrite/nitrate levels from the heart due to an intracoronary injection of acetylcholine. Pharmacogenetics and Genomics, 2006, 16, 339-345.	1.5	27
1136	Mechanisms Underlying Nano-Sized Air-Pollution-Mediated Progression of Atherosclerosis Carbon Black Causes Cytotoxic Injury/Inflammation and Inhibits Cell Growth in Vascular Endothelial Cells. Circulation Journal, 2006, 70, 129-140.	1.6	131
1137	Preclinical Profile of PF9404C, a Nitric Oxide Donor with $\hat{l}^2$ Receptor Blocking Properties. Cardiovascular Drug Reviews, 2006, 23, 149-160.	4.1	6
1138	Nitric oxide and cell proliferation. FEBS Journal, 2006, 273, 2329-2344.	4.7	151
1139	Biological fate and clinical implications of arginine metabolism in tissue healing. Wound Repair and Regeneration, 2006, 14, 376-386.	3.0	63
1140	PACAP Augments Nitric Oxide Synthesis in Rat Vascular Smooth Muscle Cells Stimulated with ILâ€1α. Annals of the New York Academy of Sciences, 2000, 921, 415-419.	3.8	2
1141	Effect of L-Arginine on Pulmonary Artery Smooth Muscle Cell Apoptosis in Rats with Hypoxic Pulmonary Vascular Structural Remodeling. Acta Biochimica Et Biophysica Sinica, 2006, 38, 15-21.	2.0	8
1142	Impaired flow-dependent control of vascular tone and remodeling in P2X4-deficient mice. Nature Medicine, 2006, 12, 133-137.	30.7	311
1143	Nitric oxide suppresses EPO-induced monocyte chemoattractant protein-1 in endothelial cells: implications for atherogenesis in chronic renal disease. Laboratory Investigation, 2006, 86, 369-379.	3.7	21
1144	The Role of Endothelial Nitric Oxide Synthase <i>(eNOS)</i> Genetic Variants in European Patients with Intracranial Aneurysms. Journal of Cerebral Blood Flow and Metabolism, 2006, 26, 1250-1255.	4.3	28
1145	Hemostasis and aging. Critical Reviews in Oncology/Hematology, 2006, 60, 144-151.	4.4	128
1146	Inhalation of nebulized nitroglycerin, a nitric oxide donor, for the treatment of pulmonary hypertension induced by high pulmonary blood flow. Heart and Vessels, 2006, 21, 169-179.	1.2	13
1147	Endothelial NO synthase as a source of NO and superoxide. European Journal of Clinical Pharmacology, 2006, 62, 5-12.	1.9	71
1148	Nitric oxide synthase gene transfer and treatment of restenosis: from bench to bedside. European Journal of Clinical Pharmacology, 2006, 62, 83-89.	1.9	3
1149	$\hat{l}^2$ -Adrenergic receptors and nitric oxide generation in the cardiovascular system. Cellular and Molecular Life Sciences, 2006, 63, 1070-1083.	5.4	39
1150	Should all diabetic patients receive statins?. Current Atherosclerosis Reports, 2006, 8, 13-18.	4.8	3
1151	Oxidative and nitrosative stress in pediatric pulmonary hypertension: Roles of endothelin-1 and nitric oxide. Vascular Pharmacology, 2006, 45, 308-316.	2.1	37

#	Article	IF	CITATIONS
1152	Oxidative stress and diabetic cardiovascular complications. Free Radical Biology and Medicine, 2006, 40, 183-192.	2.9	392
1153	Hydrogen peroxide restrains endothelium-derived nitric oxide bioactivity—Role for iron-dependent oxidative stress. Free Radical Biology and Medicine, 2006, 41, 681-688.	2.9	35
1154	Sildenafil reduces cardiovascular remodeling associated with hypertensive cardiomyopathy in NOS inhibitor-treated rats. European Journal of Pharmacology, 2006, 542, 141-147.	3.5	38
1155	BAY 41-2272, a Direct Activator of Soluble Guanylate Cyclase, Reduces Right Ventricular Hypertrophy and Prevents Pulmonary Vascular Remodeling during Chronic Hypoxia in Neonatal Rats. Neonatology, 2006, 90, 135-144.	2.0	61
1156	Hypertrophy of Cerebral Arterioles in Mice Deficient in Expression of the Gene for CuZn Superoxide Dismutase. Stroke, 2006, 37, 1850-1855.	2.0	58
1157	Insulin Resistance and Atherosclerosis. Endocrine Reviews, 2006, 27, 242-259.	20.1	275
1158	Sex-specific differences in cerebral arterial myogenic tone in hypertensive and normotensive rats. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 290, H1081-H1089.	3.2	31
1159	Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression. American Journal of Physiology - Cell Physiology, 2006, 291, C803-C816.	4.6	171
1160	Kinins and Cardiovascular Diseases. Current Pharmaceutical Design, 2006, 12, 3423-3435.	1.9	34
1161	Nitric oxide attenuates IGF-I-induced aortic smooth muscle cell motility by decreasing Rac1 activity: essential role of PTP-PEST and p130cas. American Journal of Physiology - Cell Physiology, 2006, 290, C1263-C1270.	4.6	18
1162	Lack of endothelial nitric oxide synthase decreases cardiomyocyte proliferation and delays cardiac maturation. American Journal of Physiology - Cell Physiology, 2006, 291, C1240-C1246.	4.6	31
1163	Beneficial Effects of Neuronal Nitric Oxide Synthase in Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 1417-1418.	2.4	7
1164	Adventures in vascular biology: a tale of two mediators. Philosophical Transactions of the Royal Society B: Biological Sciences, 2006, 361, 735-759.	4.0	89
1165	Altered S-Phase Kinase-Associated Protein-2 Levels Are a Major Mediator of Cyclic Nucleotide–Induced Inhibition of Vascular Smooth Muscle Cell Proliferation. Circulation Research, 2006, 98, 1141-1150.	4.5	71
1166	Cardiomyocyte-Specific Overexpression of NO Synthase-3 Protects Against Myocardial Ischemia-Reperfusion Injury. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 1517-1523.	2.4	91
1167	Salt Loading on Plasma Asymmetrical Dimethylarginine and the Protective Role of Potassium Supplement in Normotensive Salt-Sensitive Asians. Hypertension, 2006, 48, 724-729.	2.7	78
1168	Adenoviral-Mediated Gene Transfer of Nitric Oxide Synthase Isoforms and Vascular Cell Proliferation. Journal of Vascular Research, 2006, 43, 462-472.	1.4	28
1169	Caveolin-1 Expression Is Associated with Plaque Formation in Hypercholesterolemic Rabbits. Journal of Histochemistry and Cytochemistry, 2006, 54, 897-904.	2.5	19

#	Article	IF	CITATIONS
1170	Nitric Oxide and the Vascular Endothelium. , 2006, , 213-254.		295
1171	Chunghyul-Dan (Qingxie-Dan) Improves Arterial Stiffness in Patients with Increased baPWV. The American Journal of Chinese Medicine, 2006, 34, 553-563.	3.8	19
1173	Pharmacologic Induction of Heme Oxygenase-1. Antioxidants and Redox Signaling, 2007, 9, 2227-2240.	5.4	82
1174	Nitric oxide and vascular remodeling: Spotlight on the kidney. Kidney International, 2007, 72, S9-S16.	5.2	19
1175	Profound biopterin oxidation and protein tyrosine nitration in tissues of ApoE-null mice on an atherogenic diet: contribution of inducible nitric oxide synthase. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H2878-H2887.	3.2	32
1176	Roles of accumulated endogenous nitric oxide synthase inhibitors, enhanced arginase activity, and attenuated nitric oxide synthase activity in endothelial cells for pulmonary hypertension in rats. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2007, 292, L1480-L1487.	2.9	55
1177	iNOS regulation by calcium/calmodulin-dependent protein kinase II in vascular smooth muscle. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 292, H2634-H2642.	3.2	47
1178	Tumor necrosis factor-α reduces argininosuccinate synthase expression and nitric oxide production in aortic endothelial cells. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H1115-H1121.	3.2	98
1179	cGMP-dependent protein kinase I interacts with TRIM39R, a novel Rpp21 domain-containing TRIM protein. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2007, 293, L903-L912.	2.9	15
1180	The Role of Peroxisome Proliferator-Activated Receptors in Pulmonary Vascular Disease. PPAR Research, 2007, 2007, 1-10.	2.4	24
1181	Chronic Kidney Disease Is Associated With White Matter Hyperintensity Volume. Stroke, 2007, 38, 3121-3126.	2.0	216
1182	Intrauterine Pulmonary Hypertension Impairs AngiogenesisIn Vitro. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 1146-1153.	5.6	59
1183	Antioxidant Activity of Plicatin B on Cultured Human Microvascular Endothelial Cells Exposed to H2O2. Drug and Chemical Toxicology, 2007, 30, 311-325.	2.3	5
1184	Inhaled nitric oxide in infants >1500 g and <34 weeks gestation with severe respiratory failure. Journal of Perinatology, 2007, 27, 347-352.	2.0	31
1185	Nitric Oxide: What a Vascular Surgeon Needs to Know. Vascular, 2007, 15, 324-335.	0.9	18
1186	Secondary Prevention of Stroke and Transient Ischemic Attack. Circulation, 2007, 115, 1615-1621.	1.6	53
1187	Mechanisms of ET-1-induced Endothelial Dysfunction. Journal of Cardiovascular Pharmacology, 2007, 50, 621-628.	1.9	128
1188	Association of a 27-bp repeat polymorphism in intron 4 of endothelial constitutive nitric oxide synthase gene with myocardial infarction in Tunisian patients. Clinical Chemistry and Laboratory Medicine, 2007, 45, 1476-80.	2.3	11

#	Article	IF	CITATIONS
1189	Histamine Upregulates the Expression of Inducible Nitric Oxide Synthase in Human Intimal Smooth Muscle Cells via Histamine H1 Receptor and NF-κB Signaling Pathway. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 1556-1561.	2.4	27
1191	Cholesterol And The Cerebral Circulation. Future Lipidology, 2007, 2, 211-230.	0.5	2
1192	Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: Discordant in vitro and in vivo dose-effects: A review. Pulmonary Pharmacology and Therapeutics, 2007, 20, 9-22.	2.6	273
1193	Influence of endothelial nitric oxide synthase gene polymorphisms (â^'786T>C, 4a4b, 894G>T) in Korean patients with coronary artery disease. Thrombosis Research, 2007, 119, 579-585.	1.7	80
1194	Vasodilatation of sulfur dioxide derivatives and signal transduction. Archives of Biochemistry and Biophysics, 2007, 467, 291-296.	3.0	58
1195	Vascular endothelial dysfunction in cirrhosis. Journal of Hepatology, 2007, 46, 927-934.	3.7	273
1196	The regulatory effect of endogenous hydrogen sulfide on pulmonary vascular structure and gasotransmitters in rats with high pulmonary blood flow. Life Sciences, 2007, 81, 841-849.	4.3	24
1197	The relationship between the metabolic syndrome and energy-utilization deficit in the pathogenesis of obesity-induced osteoarthritis. Medical Hypotheses, 2007, 69, 860-868.	1.5	40
1198	Abnormal endothelial function in female patients with hypothyroidism and borderline thyroid function. International Journal of Cardiology, 2007, 114, 332-338.	1.7	41
1199	The relationship between endothelial function in the brachial artery and intima plus media thickening of the coronary arteries in patients with chest pain syndrome. Atherosclerosis, 2007, 195, 361-366.	0.8	6
1200	Influence of nitric oxide synthase gene polymorphism (G894T) on carotid artery intima-media thickness in adults: the Bogalusa Heart Study. Journal of the American Society of Hypertension, 2007, 1, 362-368.	2.3	4
1201	Nitric oxide homeostasis as a target for drug additives to cardioplegia. British Journal of Pharmacology, 2007, 151, 930-940.	5.4	25
1202	Superoxide counteracts low-density lipoprotein-induced human aortic smooth muscle cell proliferation. Journal of Bioscience and Bioengineering, 2007, 104, 157-162.	2.2	3
1203	Reactive oxygen species, cell growth, cell cycle progression and vascular remodeling in hypertension. Future Cardiology, 2007, 3, 53-63.	1.2	18
1204	Fixed-Dose Combination Antihypertensives and Reduction in Target Organ Damage. American Journal of Cardiovascular Drugs, 2007, 7, 413-422.	2.2	20
1205	The Nitric Oxide/cGMP Signaling Pathway in Pulmonary Hypertension. Clinics in Chest Medicine, 2007, 28, 143-167.	2.1	74
1206	Celiprolol reduces the intimal thickening of autogenous vein grafts via an enhancement of nitric oxide function through an inhibition of superoxide production. Journal of Vascular Surgery, 2007, 46, 116-123.	1.1	19
1207	The role of nitric oxide in the pathophysiology of intimal hyperplasia. Journal of Vascular Surgery, 2007, 45, A64-A73.	1.1	89

#	Article	IF	CITATIONS
1208	Role of HMG-CoA Reductase Inhibitors in Neurological Disorders. Drugs, 2007, 67, 2111-2120.	10.9	34
1209	Dimethylarginine Dimethylaminohydrolase Promotes Endothelial Repair After Vascular Injury. Journal of the American College of Cardiology, 2007, 49, 1099-1105.	2.8	72
1210	Signal transduction and oxidative processes in sinonasal polyposis. Journal of Allergy and Clinical Immunology, 2007, 120, 1346-1353.	2.9	13
1211	The diverse role of inhaled nitric oxide in experimental BPD: reduced fibrin deposition and improved lung growth. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2007, 293, L33-L34.	2.9	1
1212	Neutrophil-activating protein-2- and interleukin-8-mediated angiogenesis. Journal of Cellular Biochemistry, 2007, 102, 412-420.	2.6	16
1213	Effects of venous needle turbulence during ex vivo hemodialysis on endothelial morphology and nitric oxide formation. Journal of Biomechanics, 2007, 40, 2158-2166.	2.1	36
1214	Simulated hyperglycemia in rat cardiomyocytes: A proteomics approach for improved analysis of cellular alterations. Proteomics, 2007, 7, 2570-2590.	2.2	13
1215	Effect of gene delivery of NOS isoforms on intimal hyperplasia and endothelial regeneration after balloon injury. Gene Therapy, 2007, 14, 396-404.	4.5	68
1216	ENDOTHELIUMâ€TARGETED TRANSGENIC GTP YCLOHYDROLASE I OVEREXPRESSION INHIBITS NEOINTIMA FORMATION IN MOUSE CAROTID ARTERY. Clinical and Experimental Pharmacology and Physiology, 2007, 34, 1260-1266.	1.9	13
1217	Vascular injury and modulation of MAPKs: A targeted approach to therapy of restenosis. Cellular Signalling, 2007, 19, 1359-1371.	3.6	26
1218	Role of eNOS phosphorylation at Ser-116 in regulation of eNOS activity in endothelial cells. Vascular Pharmacology, 2007, 47, 257-264.	2.1	38
1219	The pharmacology of particulate matter air pollution-induced cardiovascular dysfunction., 2007, 113, 16-29.		135
1220	Prostacyclin in sepsis: A systematic review. Prostaglandins and Other Lipid Mediators, 2007, 83, 1-24.	1.9	28
1221	Photoactivation of Vascular iNOS and Elevation of cGMP In Vivo: Possible Mechanism for Photovasorelaxation and Inhibition of Restenosis in an Atherosclerotic Rabbit Model¶. Photochemistry and Photobiology, 2007, 72, 579-582.	2.5	1
1222	Endothelial nitric oxide synthase gene haplotypes and diabetic nephropathy among Asian Indians. Molecular and Cellular Biochemistry, 2008, 314, 9-17.	3.1	70
1223	Should a statin be prescribed to every patient with heart failure?. Heart Failure Reviews, 2008, 13, 211-225.	3.9	17
1224	Nutrigenomics: a case for the common soil between cardiovascular disease and cancer. Genes and Nutrition, 2008, 3, 19-24.	2.5	24
1225	Tissueâ€engineered blood vessels with endothelial nitric oxide synthase activity. Journal of Biomedical Materials Research - Part B Applied Biomaterials, 2008, 85B, 537-546.	3.4	30

#	Article	IF	CITATIONS
1226	Effects of endogenous sulfur dioxide on monocrotaline-induced pulmonary hypertension in rats <sup>1</sup> . Acta Pharmacologica Sinica, 2008, 29, 1157-1166.	6.1	84
1227	Additive Effects of Statin and Dipyridamole on Cerebral Blood Flow and Stroke Protection. Journal of Cerebral Blood Flow and Metabolism, 2008, 28, 1285-1293.	4.3	43
1228	The role of IGF†and its binding proteins in the development of type 2 diabetes and cardiovascular disease. Diabetes, Obesity and Metabolism, 2008, 10, 198-211.	4.4	79
1229	Beneficial effect of a short-acting NO donor for the prevention of neointimal hyperplasia. Free Radical Biology and Medicine, 2008, 44, 73-81.	2.9	67
1230	Nitric oxide and nanotechnology: A novel approach to inhibit neointimal hyperplasia. Journal of Vascular Surgery, 2008, 47, 173-182.	1.1	122
1231	Vascular endothelial function in health and diseases. Pathophysiology, 2008, 15, 49-67.	2.2	76
1232	Sildenafil augments the beneficial hemodynamic and histopathological effects of amlodipine in nitric oxide-deficient hypertensive rats: Role of nitric oxide–cyclic GMP pathway. Pharmacological Research, 2008, 57, 456-463.	7.1	9
1233	Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Annals of Medicine, 2008, 40, 180-196.	3.8	330
1234	Beyond Oncogenesis: The Role of S-Phase Kinase-Associated Protein-2 (SKP2) In Vascular Restenosis. International Journal of Gerontology, 2008, 2, 158-166.	0.6	2
1235	Chapter 3 Natriuretic Peptides in Vascular Physiology and Pathology. International Review of Cell and Molecular Biology, 2008, 268, 59-93.	3.2	99
1236	Involvement of altered arginase activity, arginase I expression and NO production in accelerated intimal hyperplasia following cigarette smoke extract. Life Sciences, 2008, 83, 453-459.	4.3	4
1237	Modulation by bradykinin and nitric oxide of angiotensin II-induced apoptosis in a vascular smooth muscle cell phenotype. International Immunopharmacology, 2008, 8, 231-236.	3.8	6
1238	Regulation of transcription factors by nitric oxide in neurons and in neural-derived tumor cells. Progress in Neurobiology, 2008, 84, 317-328.	5.7	80
1239	Nitric Oxide, Tetrahydrobiopterin, Oxidative Stress, and Endothelial Dysfunction in Hypertension. Antioxidants and Redox Signaling, 2008, 10, 1115-1126.	5.4	361
1240	Glyoxal causes inflammatory injury in human vascular endothelial cells. Biochemical and Biophysical Research Communications, 2008, 369, 1155-1159.	2.1	22
1241	Vascular Senescence at the Crossroad between Oxidative Stress and Nitric Oxide Pathways. High Blood Pressure and Cardiovascular Prevention, 2008, 15, 17-22.	2.2	1
1242	Role of IGF-1 in glucose regulation and cardiovascular disease. Expert Review of Cardiovascular Therapy, 2008, 6, 1135-1149.	1.5	51
1243	Redox Control of Endothelial Function and Dysfunction: Molecular Mechanisms and Therapeutic Opportunities. Antioxidants and Redox Signaling, 2008, 10, 1713-1766.	5.4	339

#	Article	IF	CITATIONS
1244	Characterization of the Human $\hat{l}\pm 1\hat{l}^21$ Soluble Guanylyl Cyclase Promoter. Journal of Biological Chemistry, 2008, 283, 20027-20036.	3.4	23
1245	Cyclic Guanosine Monophosphate-dependent Protein Kinase I Promotes Adhesion of Primary Vascular Smooth Muscle Cells. Molecular Biology of the Cell, 2008, 19, 4434-4441.	2.1	29
1246	Inhibition of Restenosis Formation Without Compromising Reendothelialization as a Potential Solution to Thrombosis Following Angioplasty?. Endothelium: Journal of Endothelial Cell Research, 2008, 15, 85-92.	1.7	13
1247	Statin Potentiates Human Platelet eNOS Activity without Enhancing eNOS mRNA and Protein Levels. Cerebrovascular Diseases, 2008, 26, 190-198.	1.7	16
1248	Pravastatin Attenuates Left Ventricular Remodeling and Diastolic Dysfunction in Angiotensin II-Induced Hypertensive Mice. Journal of Cardiovascular Pharmacology, 2008, 51, 62-70.	1.9	55
1249	Thrombin mediates mitogenesis and survival of human endothelial cells through distinct mechanisms. American Journal of Physiology - Cell Physiology, 2008, 294, C1215-C1226.	4.6	22
1250	Translational Therapeutics of Dipyridamole. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, s39-42.	2.4	112
1251	Heightened efficacy of nitric oxide-based therapies in type II diabetes mellitus and metabolic syndrome. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 295, H2388-H2398.	3.2	31
1252	Interaction of G-protein Â3 Subunit and Nitric Oxide Synthase Gene Polymorphisms on Carotid Artery Intima-media Thickness in Young Adults: The Bogalusa Heart Study. American Journal of Hypertension, 2008, 21, 917-921.	2.0	3
1253	Racial Differences in Nitric Oxide—Dependent Vasorelaxation. Reproductive Sciences, 2008, 15, 9-25.	2.5	48
1254	Nitric oxide regulates vascular calcification by interfering with TGF- $\hat{l}^2$ signalling. Cardiovascular Research, 2008, 77, 221-230.	3.8	129
1255	Role of Smooth Muscle cGMP/cGKI Signaling in Murine Vascular Restenosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 1244-1250.	2.4	32
1256	Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition. European Respiratory Journal, 2008, 31, 599-610.	6.7	28
1257	Gene-eluting Stents: Adenovirus-mediated Delivery of eNOS to the Blood Vessel Wall Accelerates Re-endothelialization and Inhibits Restenosis. Molecular Therapy, 2008, 16, 1674-1680.	8.2	78
1258	Gene Expression in Chronic High Altitude Diseases. High Altitude Medicine and Biology, 2008, 9, 130-139.	0.9	54
1259	Possible Involvement of Altered Arginase Activity, Arginase Type I and Type II Expressions, and Nitric Oxide Production in Occurrence of Intimal Hyperplasia in Premenopausal Human Uterine Arteries. Journal of Pharmacological Sciences, 2008, 106, 385-393.	2.5	20
1260	Exaggerated Renal Pathology of Partial Ablation-Induced Chronic Renal Failure in eNOS Deficient Mice. Biological and Pharmaceutical Bulletin, 2008, 31, 1029-1031.	1.4	9
1261	Intimal Hyperplasia in Murine Models. Current Drug Targets, 2008, 9, 251-260.	2.1	69

#	Article	IF	CITATIONS
1262	Nitric oxide metabolism and the acute chest syndrome of sickle cell anemia. Pediatric Critical Care Medicine, 2008, 9, 159-168.	0.5	17
1263	Effects of nitric oxide and hydrogen sulfide on the relaxation of pulmonary arteries in rats. Chinese Medical Journal, 2008, 121, 420-423.	2.3	43
1264	Gene therapy for coronary and peripheral artery disease. Expert Opinion on Therapeutic Patents, 2008, 18, 903-927.	5.0	1
1265	Effect of Udenafil on Vascular Smooth Muscle Cell Proliferation and Neointimal Hyperplasia in Rat Carotid Artery Injury Model. Korean Circulation Journal, 2008, 38, 320.	1.9	1
1266	Pulmonary Hypertension in Peritoneal Dialysis Patients: Prevalence and Risk Factors. Peritoneal Dialysis International, 2009, 29, 191-198.	2.3	54
1267	Effect of Dietary Alpha-Linolenic Acid on Vascular Reactivity in Aorta of Spontaneously Hypertensive Rats. Journal of Oleo Science, 2009, 58, 221-225.	1.4	4
1268	2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. Circulation, 2009, 119, e391-479.	1.6	2,001
1269	Proatherosclerotic effects of chronic stress in male rats: Altered phenylephrine sensitivity and nitric oxide synthase activity of aorta and circulating lipids. Stress, 2009, 12, 320-327.	1.8	51
1270	Fixed Dose Combination of Perindopril and Indapamide Improves Peripheral Vascular Function in Essential Hypertensive Patients. American Journal of Hypertension, 2009, 22, 506-512.	2.0	31
1271	Mechanisms Underlying the Vascular Actions of Endothelin 1, Angiotensin II and Bradykinin in the Rat Carotid. Pharmacology, 2009, 84, 111-126.	2.2	25
1272	Analysis of haemodynamic factors involved in carotid atherosclerosis using computational fluid dynamics. British Journal of Radiology, 2009, 82, S33-S38.	2.2	29
1273	Association between arterial stiffness and variations in oestrogen-related genes. Journal of Human Hypertension, 2009, 23, 636-644.	2.2	26
1274	Progress and Challenges in Metabolic Syndrome in Children and Adolescents. Circulation, 2009, 119, 628-647.	1.6	605
1275	Regulation of soluble guanylyl cyclase- $\hat{l}\pm 1$ expression in chronic hypoxia-induced pulmonary hypertension: role of NFATc3 and HuR. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2009, 297, L475-L486.	2.9	30
1276	Inhibition of Endothelin ET <sub>B</sub> Receptor System Aggravates Neointimal Hyperplasia after Balloon Injury of Rat Carotid Artery. Journal of Pharmacology and Experimental Therapeutics, 2009, 331, 998-1004.	2.5	21
1277	Postmyocardial infarction remodeling and coronary reserve: effects of ivabradine and beta blockade therapy. American Journal of Physiology - Heart and Circulatory Physiology, 2009, 297, H322-H330.	3.2	27
1278	Hydrogen sulfide is an endogenous stimulator of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 21972-21977.	7.1	768
1279	Effect of Hydroxysafflor yellow A on human umbilical vein endothelial cells under hypoxia. Vascular Pharmacology, 2009, 50, 137-145.	2.1	60

#	Article	IF	CITATIONS
1280	Combination Antiplatelet Therapy for Secondary Stroke Prevention: Enhanced Efficacy or Double Trouble?. American Journal of Cardiology, 2009, 103, 1107-1112.	1.6	45
1281	S-Nitrosylation of the epidermal growth factor receptor: A regulatory mechanism of receptor tyrosine kinase activity. Free Radical Biology and Medicine, 2009, 46, 471-479.	2.9	49
1282	Cyclic GMP specifically suppresses Type-lÎ $\pm$ cGMP-dependent protein kinase expression by ubiquitination. Cellular Signalling, 2009, 21, 859-866.	3.6	22
1285	Estrogen-Eluting Stents. Journal of Cardiovascular Translational Research, 2009, 2, 240-244.	2.4	10
1286	Soyâ€diet has beneficial effects on cardiovascular parameters that are independent of its lipid effect in male hypercholesterolemic rats. Phytotherapy Research, 2009, 23, 624-627.	5.8	3
1287	Cilostazol suppresses neointimal hyperplasia in canine vein grafts. Surgery Today, 2009, 39, 128-132.	1.5	13
1288	NADPH Oxidase-Dependent Signaling in Endothelial Cells: Role in Physiology and Pathophysiology. Antioxidants and Redox Signaling, 2009, 11, 791-810.	5.4	355
1289	Visfatin causes endothelium-dependent relaxation in isolated blood vessels. Biochemical and Biophysical Research Communications, 2009, 383, 503-508.	2.1	74
1290	Nitric oxide regulates the 26S proteasome in vascular smooth muscle cells. Nitric Oxide - Biology and Chemistry, 2009, 20, 279-288.	2.7	54
1291	Non-genomic regulation of vascular cell function and growth by estrogen. Molecular and Cellular Endocrinology, 2009, 308, 9-16.	3.2	103
1292	Sarpogrelate hydrochloride reduced intimal hyperplasia in experimental rabbit vein graft. Journal of Vascular Surgery, 2009, 49, 1272-1281.	1.1	30
1293	Nitric Oxide-Releasing Nonsteroidal Anti-Inflammatory Drugs: Gastrointestinal-Sparing Potential Drugs. Journal of Medicinal Food, 2009, 12, 208-218.	1.5	8
1294	Nitric Oxide, NAD(P)H Oxidase, and Atherosclerosis. Antioxidants and Redox Signaling, 2009, 11, 1711-1731.	5.4	82
1295	The biological relevance and measurement of plasma markers of oxidative stress in diabetes and cardiovascular disease. Atherosclerosis, 2009, 202, 321-329.	0.8	218
1296	Exogenous in vivo NO-donor treatment preserves p53 levels and protects vascular cells from apoptosis. Atherosclerosis, 2009, 205, 101-106.	0.8	11
1297	Oxidative Stress and Compartment of Gene Expression Determine Proatherosclerotic Effects of Inducible Nitric Oxide Synthase. American Journal of Pathology, 2009, 174, 2400-2410.	3.8	52
1298	2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. Journal of the American College of Cardiology, 2009, 53, e1-e90.	2.8	1,386
1299	Effect of Chronic Inhibition of Nitric Oxide on Hypertension, Insulin Resistance, and Cardiovascular Remodeling in Glucose-fed Rats. Journal of Cardiovascular Pharmacology, 2009, 53, 405-413.	1.9	7

#	Article	IF	CITATIONS
1300	Lack of association between endothelial constitutive nitric oxide synthase (ecNOS 4 b/a) gene polymorphism and rheumatic heart disease. Modern Rheumatology, 2009, 19, 670-674.	1.8	2
1301	Statins and Cardiovascular Diseases: From Cholesterol Lowering to Pleiotropy. Current Pharmaceutical Design, 2009, 15, 467-478.	1.9	232
1302	Nitric oxide dysfunction in vascular endothelium and platelets: role in essential hypertension. Journal of Hypertension, 2009, 27, 2310-2320.	0.5	62
1303	Nitric Oxide Control of MYCN Expression and Multi Drug Resistance Genes in Tumours of Neural Origin. Current Pharmaceutical Design, 2010, 16, 431-439.	1.9	13
1304	Association of endothelial nitric oxide synthase polymorphisms with coronary artery disease in Korean individuals with or without diabetes mellitus. Experimental and Therapeutic Medicine, 2010, 1, 719-724.	1.8	16
1305	Gaseous Therapeutics in Acute Lung Injury. , 2011, 1, 105-121.		14
1306	Gene therapy via inducible nitric oxide synthase: a tool for the treatment of a diverse range of pathological conditions. Journal of Pharmacy and Pharmacology, 2010, 60, 999-1017.	2.4	31
1307	A novel predictor of restenosis and adverse cardiac events: asymmetric dimethylarginine. Heart and Vessels, 2010, 25, 19-26.	1.2	31
1308	Obesity and aging: determinants of endothelial cell dysfunction and atherosclerosis. Pflugers Archiv European Journal of Physiology, 2010, 460, 825-837.	2.8	88
1309	Pulmonary hypertension in chronic neonatal lung disease. Paediatric Respiratory Reviews, 2010, 11, 149-153.	1.8	74
1310	Rutin inhibits hydrogen peroxide-induced apoptosis through regulating reactive oxygen species mediated mitochondrial dysfunction pathway in human umbilical vein endothelial cells. European Journal of Pharmacology, 2010, 628, 27-35.	3.5	92
1311	Hydrogen sulfide: Regulatory role on blood pressure in hyperhomocysteinemia. Vascular Pharmacology, 2010, 53, 138-143.	2.1	30
1312	Collagen/heparin coating on titanium surface improves the biocompatibility of titanium applied as a bloodâ€contacting biomaterial. Journal of Biomedical Materials Research - Part A, 2010, 95A, 341-349.	4.0	74
1313	VASP phosphorylation at serine239 regulates the effects of NO on smooth muscle cell invasion and contraction of collagen. Journal of Cellular Physiology, 2010, 222, 230-237.	4.1	16
1314	Inhibitory effect of S-nitroso-glutathione on Eimeria tenella oocysts was mainly limited to the early stages of sporogony. Veterinary Parasitology, 2010, 173, 64-69.	1.8	11
1315	Association of the eNOS E298D polymorphism and the risk of myocardial infarction in the Greek population. BMC Medical Genetics, 2010, 11, 133.	2.1	13
1316	Nitric Oxide and Endothelium-Derived Hyperpolarizing Factor in Human Arteries and Veins. Journal of Cardiac Surgery, 2010, 17, 317-323.	0.7	9
1317	Risk of "silent stroke" in patients older than 60 years: risk assessment and clinical perspectives. Clinical Interventions in Aging, 2010, 5, 239.	2.9	29

#	Article	IF	CITATIONS
1318	The vessel wall: A forgotten player in post thrombotic syndrome. Thrombosis and Haemostasis, 2010, 104, 681-692.	3.4	48
1319	Role of NAD(P)H Oxidase in Superoxide Generation and Endothelial Dysfunction in Goto-Kakizaki (GK) Rats as a Model of Nonobese NIDDM. PLoS ONE, 2010, 5, e11800.	2.5	42
1320	Uncoupling of Endothelial Nitric Oxide Synthase in Cardiovascular Disease and its Pharmacological Reversal., 2010,, 139-167.		5
1321	Future outlook for drug eluting stents. , 2010, , 117-153.		3
1322	PPARÎ <sup>3</sup> as a potential therapeutic target in pulmonary hypertension. Therapeutic Advances in Respiratory Disease, 2010, 4, 143-160.	2.6	43
1323	Plasma Kallikrein Promotes Epidermal Growth Factor Receptor Transactivation and Signaling in Vascular Smooth Muscle through Direct Activation of Protease-activated Receptors. Journal of Biological Chemistry, 2010, 285, 35206-35215.	3.4	46
1324	Assessment of endothelial dysfunction. Expert Review of Cardiovascular Therapy, 2010, 8, 557-571.	1.5	17
1325	Insulin enhances the effect of nitric oxide at inhibiting neointimal hyperplasia in a rat model of type 1 diabetes. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 299, H772-H779.	3.2	17
1326	The Role of Endothelial Dysfunction on Development and Progression of Atherosclerosis and Methods to Assess Vascular Function and Structure. American Journal of Lifestyle Medicine, 2010, 4, 445-456.	1.9	10
1327	Regulation of reactive oxygen species by p53: implications for nitric oxide-mediated apoptosis. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 298, H2192-H2200.	3.2	36
1328	Sympathetic activity is not increased in l-NAME hypertensive rats. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2010, 298, R89-R95.	1.8	13
1329	cGMP-dependent protein kinase and the regulation of vascular smooth muscle cell gene expression: possible involvement of Elk-1 sumoylation. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 299, H1660-H1670.	3.2	20
1330	Adiponectin resistance and vascular dysfunction in the hyperlipidemic state. Acta Pharmacologica Sinica, 2010, 31, 1258-1266.	6.1	17
1331	Is oxidative stress a therapeutic target in cardiovascular disease?. European Heart Journal, 2010, 31, 2741-2748.	2.2	380
1332	Molecular targets and regulators of cardiac hypertrophy. Pharmacological Research, 2010, 61, 269-280.	7.1	254
1333	Isopropylamine NONOate (IPA/NO) moderates neointimal hyperplasia following vascular injury. Journal of Vascular Surgery, 2010, 51, 1248-1259.	1.1	52
1334	Endothelial nitric oxide synthase gene polymorphisms (â^'786T>C, 4a4b, 894G>T) and haplotypes in Korean patients with recurrent spontaneous abortion. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2010, 152, 64-67.	1.1	31
1335	Hexarelin suppresses high lipid diet and vitamin D3-induced atherosclerosis in the rat. Peptides, 2010, 31, 630-638.	2.4	51

#	Article	IF	CITATIONS
1336	Influence of cholesterol and fish oil dietary intake on nitric oxide-induced apoptosis in vascular smooth muscle cells. Nitric Oxide - Biology and Chemistry, 2010, 22, 205-212.	2.7	12
1337	Direct, real-time measurement of shear stress-induced nitric oxide produced from endothelial cells in vitro. Nitric Oxide - Biology and Chemistry, 2010, 23, 335-342.	2.7	73
1338	Basic Science Review: Statin Therapy-Part I: The Pleiotropic Effects of Statins in Cardiovascular Disease. Vascular and Endovascular Surgery, 2010, 44, 241-251.	0.7	121
1339	A Prospective, Single-Blind, Multicenter, Dose Escalation Study of Intracoronary iNOS Lipoplex (CAR-MP583) Gene Therapy for the Prevention of Restenosis in Patients with de novo or Restenotic Coronary Artery Lesion (REGENT I Extension). Human Gene Therapy, 2011, 22, 951-958.	2.7	16
1340	Reduced nitrate level in individuals with hypertension and diabetes. Journal of Cardiovascular Disease Research (discontinued), 2011, 2, 172-176.	0.1	38
1341	Gaseous nitric oxide exhibits minimal effect on skin fibroblast extracellular matrix gene expression and immune cell viability. Cell Biology International, 2011, 35, 407-415.	3.0	16
1342	Oxidative stress and endothelial dysfunction in hypertension. Hypertension Research, 2011, 34, 665-673.	2.7	368
1343	Tissue Engineering of Blood Vessels: How to Make a Graft. , 2011, , 263-278.		6
1344	Caloric restriction: powerful protection for the aging heart and vasculature. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 301, H1205-H1219.	3.2	162
1345	Ginkgolide A-Gold Nanoparticles Inhibit Vascular Smooth Muscle Proliferation and Migration In Vitro and Reduce Neointimal Hyperplasia in a Mouse Model. Journal of Surgical Research, 2011, 171, 31-39.	1.6	15
1346	Phosphorylated Endothelial NOS Ser1177 via the PI3K/Akt Pathway Is Depressed in the Brain of Stroke-Prone Spontaneously Hypertensive Rat. Journal of Stroke and Cerebrovascular Diseases, 2011, 20, 406-412.	1.6	17
1347	Post-challenge hyperglycaemia, nitric oxide production and endothelial dysfunction: The putative role of asymmetric dimethylarginine (ADMA). Nutrition, Metabolism and Cardiovascular Diseases, 2011, 21, 1-10.	2.6	41
1348	Postprandial Endothelial Function, Inflammation, and Oxidative Stress in Obese Children and Adolescents. Obesity, 2011, 19, 1279-1283.	3.0	20
1349	Hemodialysis Vascular Access Dysfunction. , 2011, , .		0
1350	Risk factors and metabolic mechanisms in the pathogenesis of uraemic cardiac disease. Frontiers in Bioscience - Landmark, 2011, 16, 1364.	3.0	20
1351	Plasma asymmetric dimethylarginine predicts restenosis after coronary angioplasty. Archives of Medical Science, 2011, 3, 444-448.	0.9	10
1352	Clinical Application of Inhaled Nitric Oxide., 2011,, 43-55.		2
1353	Soluble Guanylate Cyclase Activation With Cinaciguat. Cardiology in Review, 2011, 19, 23-29.	1.4	6

#	Article	IF	CITATIONS
1354	Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling. British Journal of Pharmacology, 2011, 164, 213-223.	5.4	245
1355	Effects of Slow, Sustained, and Rate‶unable Nitric Oxide Donors on Human Aortic Smooth Muscle Cells Proliferation. Chemical Biology and Drug Design, 2011, 78, 527-534.	3.2	25
1356	Titanium nitride oxide coating on rough titanium stimulates the proliferation of human primary osteoblasts. Clinical Oral Implants Research, 2011, 22, 552-559.	4.5	29
1357	Blue and Red Lightâ€Induced Germination of Resting Spores in the Redâ€Tide Diatom <i>Leptocylindrus danicus</i> <sup>â€</sup> . Photochemistry and Photobiology, 2011, 87, 590-597.	2.5	15
1358	Mechanisms underlying impairment of endothelium-dependent relaxation by fetal bovine serum in organ-cultured rat mesenteric artery. European Journal of Pharmacology, 2011, 668, 401-406.	3.5	17
1359	Clinical Science Review Article: Understanding the Implications of Diabetes on the Vascular System. Vascular and Endovascular Surgery, 2011, 45, 481-489.	0.7	1
1360	Antiproliferative effect of estrogen in vascular smooth muscle cells is mediated by Kruppel-like factor-4 and manganese superoxide dismutase. Basic Research in Cardiology, 2011, 106, 563-575.	5.9	34
1361	NADPH oxidases in cardiovascular disease: insights from in vivo models and clinical studies. Basic Research in Cardiology, 2011, 106, 735-747.	5.9	153
1362	Beneficial effect of Sparassis crispa on stroke through activation of Akt/eNOS pathway in brain of SHRSP. Journal of Natural Medicines, 2011, 65, 135-141.	2.3	17
1363	Antiangiogenic properties of Koetjapic acid, a natural triterpene isolated from Sandoricum koetjaoe Merr. Cancer Cell International, 2011, 11, 12.	4.1	25
1364	Atheroprotective effects of dietary <scp>l</scp> -arginine increase with age in cholesterol-fed rabbits. British Journal of Nutrition, 2011, 105, 1439-1447.	2.3	15
1365	Nitric oxide (NO) and asymmetric dimethylarginine (ADMA): their pathophysiological role and involvement in intracerebral hemorrhage. Neurological Research, 2011, 33, 541-548.	1.3	31
1366	Is Peroxisome Proliferatorâ€Activated Receptor Gamma (PPARγ) a Therapeutic Target for the Treatment of Pulmonary Hypertension?. Pulmonary Circulation, 2011, 1, 33-47.	1.7	42
1367	Mechanisms related to NO-induced motility in differentiated rat aortic smooth muscle cells. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 300, H101-H108.	3.2	4
1368	Restoring Soluble Guanylyl Cyclase Expression and Function Blocks the Aggressive Course of Glioma. Molecular Pharmacology, 2011, 80, 1076-1084.	2.3	29
1369	Stabilization of cGMP-dependent protein kinase G (PKG) expression in vascular smooth muscle cells: contribution of 3'UTR of its mRNA. Journal of Biochemistry, 2011, 149, 433-441.	1.7	2
1370	Effects of Statins on Cardiorenal Syndrome. International Journal of Vascular Medicine, 2012, 2012, 1-7.	1.0	9
1371	Intracellular Nitric Oxide Mediates Neuroproliferative Effect of Neuropeptide Y on Postnatal Hippocampal Precursor Cells. Journal of Biological Chemistry, 2012, 287, 20187-20196.	3.4	29

#	Article	IF	CITATIONS
1372	Changes in ADMA and TAFI levels after stenting in coronary artery disease patients. Molecular Medicine Reports, 2012, 6, 855-859.	2.4	7
1373	Emerging role of PKA/eNOS pathway in therapeutic angiogenesis for ischaemic tissue diseases. Cardiovascular Research, 2012, 95, 7-18.	3.8	88
1374	Pathophysiological Roles of Endothelin Receptors in Cardiovascular Diseases. Journal of Pharmacological Sciences, 2012, 119, 302-313.	2.5	69
1375	The endothelium: influencing vascular smooth muscle in many ways. Canadian Journal of Physiology and Pharmacology, 2012, 90, 713-738.	1.4	188
1376	Endothelial nitric oxide synthase gene polymorphism and type 2 diabetic retinopathy among Asian Indians. Acta Diabetologica, 2012, 49, 481-488.	2.5	27
1377	Possible involvement of Cyclic-GMP-dependent protein kinase on matrix metalloproteinase-2 expression in rat aortic smooth muscle cells. Molecular and Cellular Biochemistry, 2012, 368, 27-35.	3.1	16
1378	Association between polymorphisms of eNOS and GPx-1 genes, activity of free-radical processes and in-stent restenosis. Molecular and Cellular Biochemistry, 2012, 370, 241-249.	3.1	20
1379	Endothelial Nitric Oxide Synthase Expression in Postmenopausal Women: A Sex-Specific Risk Factor in Coronary Surgery. Annals of Thoracic Surgery, 2012, 94, 1934-1939.	1.3	27
1380	Increased Superoxide and Endothelial NO Synthase Uncoupling in Blood Vessels of Bmal1-Knockout Mice. Circulation Research, 2012, 111, 1157-1165.	4.5	103
1382	Lowâ€levelâ€laser irradiation induces photorelaxation in coronary arteries and overcomes vasospasm of internal thoracic arteries. Lasers in Surgery and Medicine, 2012, 44, 705-711.	2.1	10
1383	On the epigenetics of vascular regulation and disease. Clinical Epigenetics, 2012, 4, 7.	4.1	49
1384	Nitric Oxide: Biological Synthesis and Functions. , 2012, , 1-36.		0
1385	Restenosis after PCI. Part 1: pathophysiology and risk factors. Nature Reviews Cardiology, 2012, 9, 53-62.	13.7	233
1386	Ezetimibe reduces intimal hyperplasia in rabbit jugular vein graft. Journal of Vascular Surgery, 2012, 56, 1689-1697.	1.1	8
1387	Oxidative Stress, Endothelial Dysfunction, and Its Impact on Smooth Muscle Signaling. , 2012, , 1219-1229.		0
1388	Diabetic Vascular Disease. , 2012, , 1321-1328.		0
1389	Phosphodiesterases Regulate BAY 41-2272-Induced VASP Phosphorylation in Vascular Smooth Muscle Cells. Frontiers in Pharmacology, 2012, 3, 10.	3.5	16
1390	Alcohol and Cardiovascular Diseaseâ€"Modulation of Vascular Cell Function. Nutrients, 2012, 4, 297-318.	4.1	42

#	Article	IF	CITATIONS
1391	Changes of Gene Expressions in Spontaneously Hypertensive Rat Model After Losartan Treatment. Korean Circulation Journal, 2012, 42, 761.	1.9	7
1392	Effects of male silkworm pupa powder on the erectile dysfunction by chronic ethanol consumption in rats. Laboratory Animal Research, 2012, 28, 83.	2.5	18
1393	Nitric oxide synthases: regulation and function. European Heart Journal, 2012, 33, 829-837.	2.2	3,036
1394	HIF-mediated endothelial response during cancer progression. International Journal of Hematology, 2012, 95, 471-477.	1.6	17
1395	The role of perivascular adipose tissue in vascular smooth muscle cell growth. British Journal of Pharmacology, 2012, 165, 643-658.	5.4	131
1396	Carvedilol‣isinopril Combination Therapy and Endothelial Function in Obese Individuals With Hypertension. Journal of Clinical Hypertension, 2012, 14, 85-91.	2.0	23
1397	The Relation between Chronic Kidney Disease and Cerebral Microbleeds: Difference between Patients with and without Diabetes. International Journal of Stroke, 2012, 7, 551-557.	5.9	21
1398	Exhaled nitric oxide and atherosclerosis. European Journal of Clinical Investigation, 2012, 42, 873-880.	3.4	14
1399	Polymorphisms of the NOS3 gene and risk of myocardial infarction in the Tunisian population. Cytokine, 2013, 64, 646-651.	3.2	9
1400	Nitric oxide, a protective molecule in the cardiovascular system. Nitric Oxide - Biology and Chemistry, 2013, 35, 175-185.	2.7	148
1401	The Arrestin-selective Angiotensin AT1 Receptor Agonist [Sar1,lle4,lle8]-AngII Negatively Regulates Bradykinin B2 Receptor Signaling via AT1-B2 Receptor Heterodimers. Journal of Biological Chemistry, 2013, 288, 18872-18884.	3.4	46
1402	Neutralization of B. anthracis toxins during ex vivo phagocytosis. Glycoconjugate Journal, 2013, 30, 473-484.	2.7	0
1403	The eNOS 894G/T gene polymorphism and its influence on early and long-term mortality after on-pump cardiac surgery. Journal of Cardiothoracic Surgery, 2013, 8, 199.	1.1	2
1404	XJP-1 protects endothelial cells from oxidized low-density lipoprotein-induced apoptosis by inhibiting NADPH oxidase subunit expression and modulating the Pl3K/Akt/eNOS pathway. Vascular Pharmacology, 2013, 58, 78-86.	2.1	23
1405	Citrulline: pharmacological perspectives and its role as an emerging biomarker in future. Fundamental and Clinical Pharmacology, 2013, 27, 35-50.	1.9	71
1406	Cyclic stretch stimulates nitric oxide synthase-1-dependent peroxynitrite formation by neonatal rat pulmonary artery smooth muscle. Free Radical Biology and Medicine, 2013, 61, 310-319.	2.9	21
1407	Endothelial dysfunction predicts regression of hypertensive cardiac mass. International Journal of Cardiology, 2013, 167, 1188-1192.	1.7	12
1408	The impact of acute mental stress on vascular endothelial function: Evidence, mechanisms and importance. International Journal of Psychophysiology, 2013, 88, 124-135.	1.0	71

#	Article	IF	CITATIONS
1409	Surface-mediated functional gene delivery: An effective strategy for enhancing competitiveness of endothelial cells over smooth muscle cells. Biomaterials, 2013, 34, 3345-3354.	11.4	47
1410	Redox signaling in cardiovascular health and disease. Free Radical Biology and Medicine, 2013, 61, 473-501.	2.9	172
1411	Life-long caloric restriction reduces oxidative stress and preserves nitric oxide bioavailability and function in arteries of old mice. Aging Cell, 2013, 12, 772-783.	6.7	146
1412	Diversity in Mechanisms of Endotheliumâ€Dependent Vasodilation in Health and Disease. Microcirculation, 2013, 20, 239-247.	1.8	147
1413	α-Melanocyte-stimulating hormone regulates vascular NO availability and protects against endothelial dysfunction. Cardiovascular Research, 2013, 97, 360-368.	3.8	21
1414	Endothelial Dysfunction Exacerbates Renal Interstitial Fibrosis through Enhancing Fibroblast Smad3 Linker Phosphorylation in the Mouse Obstructed Kidney. PLoS ONE, 2013, 8, e84063.	2.5	29
1415	Nox2 Deficiency Prevents Hypertension-Induced Vascular Dysfunction and Hypertrophy in Cerebral Arterioles. International Journal of Hypertension, 2013, 2013, 1-8.	1.3	21
1416	Proprotein convertases play an important role in regulating PKGI endoproteolytic cleavage and nuclear transport. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2013, 305, L130-L140.	2.9	9
1417	Cell-permeant peptide inhibitors of vasospasm and intimal hyperplasia. Vascular, 2013, 21, 46-53.	0.9	0
1418	Role of Arginase in Vessel Wall Remodeling. Frontiers in Immunology, 2013, 4, 111.	4.8	67
1419	Tissue-engineered endothelial cell layers on surface-modified Ti for inhibiting in vitro platelet adhesion. Science and Technology of Advanced Materials, 2013, 14, 035002.	6.1	4
1420	Therapeutic Potential of the Nitrite-Generated NO Pathway in Vascular Dysfunction. Frontiers in Immunology, 2013, 4, 174.	4.8	39
1421	Nitric Oxide Deficiency in Pulmonary Hypertension: Pathobiology and Implications for Therapy. Pulmonary Circulation, 2013, 3, 20-30.	1.7	67
1422	Relationship between endothelial nitric oxide synthase gene polymorphisms and ischemic stroke: a meta-analysis. Acta Neurologica Scandinavica, 2013, 128, 202-212.	2.1	19
1423	Generation of nitric oxide gradients in microfluidic devices for cell culture using spatially controlled chemical reactions. Biomicrofluidics, 2013, 7, 64104.	2.4	7
1424	Nitric Oxide- and Heme-Independent Activation of Soluble Guanylate Cyclase Attenuates Peroxynitrite-Induced Endothelial Dysfunction in Rat Aorta. Journal of Cardiovascular Pharmacology and Therapeutics, 2013, 18, 70-77.	2.0	24
1425	Endothelial Dysfunction Is Associated With Graft Loss in Renal Transplant Recipients. Transplantation, 2013, 95, 733-739.	1.0	12
1426	Preclinical Evaluation of Coronary Stents: Focus on Safety Issues. Current Vascular Pharmacology, 2013, 11, 74-99.	1.7	17

#	Article	IF	CITATIONS
1428	Endothelin Receptor Signaling: New Insight Into Its Regulatory Mechanisms. Journal of Pharmacological Sciences, 2013, 123, 85-101.	2.5	92
1429	Nitric Oxide in Pathophysiology and Treatment of Pulmonary Hypertension. , 0, , .		1
1430	Vitamin E Is a Nephroprotectant Agent in Male but Not in Female in a Model of Cisplatin-Induced Nephrotoxicity. ISRN Nephrology, 2013, 2013, 1-6.	1.2	20
1431	Endovascular Gene Delivery from a Stent Platform: Gene- Eluting Stents. Angiology: Open Access, 2013, 01, .	0.1	4
1432	Endothelium Aging and Vascular Diseases. , 0, , .		2
1433	Effect of Nitric Oxide on Adhesion and Migration of Trabecular Meshwork Cells. Journal of Korean Ophthalmological Society, 2013, 54, 639.	0.2	0
1434	Adaptation of Endothelial Cells to Physiologically-Modeled, Variable Shear Stress. PLoS ONE, 2013, 8, e57004.	2.5	60
1435	Oxidative Stress in Cardiovascular Diseases and Obesity: Role of p66Shc and Protein Kinase C. Oxidative Medicine and Cellular Longevity, 2013, 2013, 1-11.	4.0	103
1436	Transcriptional Responses of Olive Flounder (Paralichthys olivaceus) to Low Temperature. PLoS ONE, 2014, 9, e108582.	2.5	57
1437	Developmental Physiology of the Pulmonary Circulation. , 2014, , 121-136.		3
1438	Association Between Urinary 6-Sulfatoxymelatonin Excretion and Arterial Stiffness in the General Elderly Population: The HEIJO-KYO Cohort. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3233-3239.	3.6	19
1439	Could plasma asymmetric dimethylarginine level be a novel predictor beyond the classic predictors of stent restenosis?. Anatolian Journal of Cardiology, 2014, 14, 491-497.	0.4	8
1440	sGC-cGMP Signaling: Target for Anticancer Therapy. Advances in Experimental Medicine and Biology, 2014, 814, 5-13.	1.6	22
1441	Are Microparticles the Missing Link between Thrombosis and Autoimmune Diseases? Involvement in Selected Rheumatologic Diseases. Seminars in Thrombosis and Hemostasis, 2014, 40, 675-681.	2.7	13
1442	Effects of atorvastatin loading prior to primary percutaneous coronary intervention on endothelial function and inflammatory factors in patients with ST-segment elevation myocardial infarction. Experimental and Therapeutic Medicine, 2014, 7, 316-322.	1.8	7
1443	Vessel wall, not platelet, P2Y12 potentiates early atherogenesis. Cardiovascular Research, 2014, 102, 429-435.	3.8	45
1444	Role of Nitric Oxide in Pathophysiology and Treatment of Pulmonary Hypertension. Vitamins and Hormones, 2014, 96, 407-424.	1.7	12
1445	Shear Stress-Induced NO Production is Dependent on ATP Autocrine Signaling and Capacitative Calcium Entry. Cellular and Molecular Bioengineering, 2014, 7, 510-520.	2.1	18

#	Article	IF	CITATIONS
1446	Characterization of a Fluorescent Probe for Imaging Nitric Oxide. Journal of Vascular Research, 2014, 51, 68-79.	1.4	8
1447	Description of a utrophin associated protein complex in lipid raft domains of human artery smooth muscle cells. Biochimica Et Biophysica Acta - Biomembranes, 2014, 1838, 1047-1054.	2.6	6
1448	Adipocyte-derived factors impair insulin signaling in differentiated human vascular smooth muscle cells via the upregulation of miR-143. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 275-283.	3.8	25
1449	Nox2 targets SERCA in response to a high fat high sugar diet. Journal of Molecular and Cellular Cardiology, 2014, 72, 228-230.	1.9	O
1450	Genetic association studies of endothelial nitric oxide synthase gene polymorphisms in women with unexplained recurrent pregnancy loss: a systematic and meta-analysis. Molecular Biology Reports, 2014, 41, 3981-3989.	2.3	8
1451	Potential Therapeutic Role of Phosphodiesterase Type 5 Inhibition in Hypertension and Chronic Kidney Disease. Hypertension, 2014, 63, 5-11.	2.7	35
1452	A Fluorescence Switch for the Detection of Nitric Oxide and Histidine and Its Application in Live Cell Imaging. ChemPlusChem, 2014, 79, 1761-1766.	2.8	26
1453	Nitric Oxide Regulation of Adult Neurogenesis. Vitamins and Hormones, 2014, 96, 59-77.	1.7	9
1454	Nitric Oxide in the Nervous System. Vitamins and Hormones, 2014, 96, 79-125.	1.7	67
1455	Screening of the NOS3 gene identifies the variants 894G/T, 1998C/G and 2479G/A to be associated with acute onset ischemic stroke in young Asian Indians. Journal of the Neurological Sciences, 2014, 344, 69-75.	0.6	4
1456	Chemical activation and changes in surface morphology of poly(ε-caprolactone) modulate VEGF responsiveness of human endothelial cells. Journal of Materials Science: Materials in Medicine, 2014, 25, 2003-2015.	3.6	7
1457	Creatinine metabolite, HMH (5-hydroxy-1-methylhydantoin; NZ-419), modulates bradykinin-induced changes in vascular smooth muscle cells. Journal of Receptor and Signal Transduction Research, 2014, 34, 195-200.	2.5	3
1458	Rho/Rho-Associated Coiled-Coil Forming Kinase Pathway as Therapeutic Targets for Statins in Atherosclerosis. Antioxidants and Redox Signaling, 2014, 20, 1251-1267.	5.4	68
1459	Contractile protein expression is upregulated by reactive oxygen species in aorta of Goto-Kakizaki rat. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 306, H214-H224.	3.2	39
1460	Induction of inducible nitric oxide synthase (iNOS) expression by oxLDL inhibits macrophage derived foam cell migration. Atherosclerosis, 2014, 235, 213-222.	0.8	39
1461	The current approach into signaling pathways in pulmonary arterial hypertension and their implication in novel therapeutic strategies. Pharmacological Reports, 2014, 66, 552-564.	3.3	9
1462	Inhibition of vascular calcification by block of intermediate conductance calcium-activated potassium channels with TRAM-34. Pharmacological Research, 2014, 85, 6-14.	7.1	28
1463	The Eternal Tale of Dialysis Access Vessels and Restenosis: Are Drug-Eluting Balloons the Solution?. Journal of Vascular Access, 2014, 15, 439-447.	0.9	35

#	Article	IF	CITATIONS
1465	Prenatal glucocorticoid contributed to rat lung dysplasia is related to asymmetric dimethylarginine/nitric oxide pathway. Science Bulletin, 2015, 60, 1416-1425.	9.0	5
1466	Topological control of nitric oxide secretion by tantalum oxide nanodot arrays. Journal of Nanobiotechnology, 2015, 13, 79.	9.1	7
1467	Nitric oxide regulates cell behavior on an interactive cellâ€derived extracellular matrix scaffold. Journal of Biomedical Materials Research - Part A, 2015, 103, 3807-3814.	4.0	12
1468	Asiatic acid alleviates cardiovascular remodelling in rats with Lâ€∢scp>NAME⟨/scp>â€induced hypertension. Clinical and Experimental Pharmacology and Physiology, 2015, 42, 1189-1197.	1.9	47
1469	Association between eNOS polymorphisms and risk of coronary artery disease in a Korean population: a meta-analysis. Genetics and Molecular Research, 2015, 14, 16508-16520.	0.2	8
1470	Estetrol Modulates Endothelial Nitric Oxide Synthesis in Human Endothelial Cells. Frontiers in Endocrinology, 2015, 6, 111.	3.5	7
1471	Contribution of <i>eNOS </i> Variants to the Genetic Susceptibility of Coronary Artery Disease in a Tunisian Population. Genetic Testing and Molecular Biomarkers, 2015, 19, 203-208.	0.7	22
1472	Arginase inhibition prevents bleomycin-induced pulmonary hypertension, vascular remodeling, and collagen deposition in neonatal rat lungs. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 308, L503-L510.	2.9	42
1473	Functional behavior and gene expression of magnetic nanoparticle-loaded primary endothelial cells for targeting vascular stents. Nanomedicine, 2015, 10, 1391-1406.	3.3	14
1474	Reduction of no-reflow and reperfusion injury with the synthetic $17\hat{l}^2$ -aminoestrogen compound Prolame is associated with PI3K/Akt/eNOS signaling cascade. Basic Research in Cardiology, 2015, 110, 1.	5.9	33
1475	The Pulmonary Circulation. Respiratory Medicine, 2015, , 1-20.	0.1	1
1476	Arterial blood pressure and vascular function in human saphenous vein. Perfusion (United Kingdom), 2015, 30, 233-238.	1.0	4
1477	Physiologically Modeled Pulse Dynamics to Improve Function in <i>In Vitro</i> Small-Diameter Vascular Grafts. Tissue Engineering - Part C: Methods, 2015, 21, 1125-1134.	2.1	17
1478	Utility of large-animal models of BPD: chronically ventilated preterm lambs. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 308, L983-L1001.	2.9	66
1479	Role of sGC-dependent NO signalling and myocardial infarction risk. Journal of Molecular Medicine, 2015, 93, 383-394.	3.9	22
1480	Plasma-synthesised carbon-based coatings for cardiovascular applications. Biosurface and Biotribology, 2015, 1, 146-160.	1.5	29
1481	Nitric oxide based strategies for applications of biomedical devices. Biosurface and Biotribology, 2015, 1, 177-201.	1.5	66
1482	An Overview of VEGF-Mediated Signal Transduction. Methods in Molecular Biology, 2015, 1332, 91-120.	0.9	18

#	Article	IF	CITATIONS
1483	Effects of soluble guanylate cyclase activation on heart transplantation in a rat model. Journal of Heart and Lung Transplantation, 2015, 34, 1346-1353.	0.6	21
1484	eNOS transfection of adipose-derived stem cells yields bioactive nitric oxide production and improved results in vascular tissue engineering. Journal of Tissue Engineering and Regenerative Medicine, 2015, 9, 1277-1285.	2.7	30
1485	Molecular Ultrasound Imaging of $\hat{l}\pm v\hat{l}^2$ 3-Integrin Expression in Carotid Arteries of Pigs After Vessel Injury. Investigative Radiology, 2016, 51, 767-775.	6.2	19
1486	Asymmetric Dimethylarginine Limits the Efficacy of Simvastatin Activating Endothelial Nitric Oxide Synthase. Journal of the American Heart Association, 2016, 5, e003327.	3.7	21
1487	Drug Treatment of Hypertension: Focus on Vascular Health. Drugs, 2016, 76, 1529-1550.	10.9	53
1488	Nitrates for the prevention of cardiac morbidity and mortality in patients undergoing non-cardiac surgery. The Cochrane Library, 2016, 2016, CD010726.	2.8	11
1489	Insulin decreases atherosclerotic plaque burden and increases plaque stability via nitric oxide synthase in apolipoprotein E-null mice. American Journal of Physiology - Endocrinology and Metabolism, 2016, 311, E335-E345.	3.5	7
1491	Direct measurement of actual levels of nitric oxide (NO) in cell culture conditions using soluble NO donors. Redox Biology, 2016, 9, 1-14.	9.0	34
1492	Endothelin 1, ADMA and SDMA in pregnancies with obstetric and thrombotic antiphospholipid syndrome. Journal of Reproductive Immunology, 2016, 116, 86-92.	1.9	2
1493	Vascular endothelium – Gatekeeper of vessel health. Atherosclerosis, 2016, 248, 97-109.	0.8	371
1494	Effect of continuous positive airway pressure treatment on pulmonary artery pressure in patients with isolated obstructive sleep apnea: a meta-analysis. Heart Failure Reviews, 2016, 21, 591-598.	3.9	23
1495	Targeted Nitric Oxide Delivery by Supramolecular Nanofibers for the Prevention of Restenosis After Arterial Injury. Antioxidants and Redox Signaling, 2016, 24, 401-418.	5.4	50
1496	Hemodynamics in stented vertebral artery ostial stenosis based on computational fluid dynamics simulations. Computer Methods in Biomechanics and Biomedical Engineering, 2016, 19, 1190-1200.	1.6	6
1497	Targeted overexpression of endothelial nitric oxide synthase in endothelial cells improves cerebrovascular reactivity in Ins2 <sup>Akita</sup> -type-1 diabetic mice. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 1135-1142.	4.3	13
1498	Genetic and Pharmacological Modulation of Akt1 for Improving Ovarian Graft Revascularization in a Mouse Model1. Biology of Reproduction, 2016, 94, 14.	2.7	11
1499	Metabolic Syndrome as a Multifaceted Risk Factor for Oxidative Stress. Antioxidants and Redox Signaling, 2017, 26, 445-461.	5.4	92
1500	Interactive role of endothelial nitric oxide synthase gene polymorphisms in T2D with CAD and CAD patients of Punjab (North-West India). International Journal of Diabetes in Developing Countries, 2017, 37, 286-297.	0.8	0
1501	Gasotransmitter delivery via self-assembling peptides: Treating diseases with natural signaling gases. Advanced Drug Delivery Reviews, 2017, 110-111, 137-156.	13.7	69

#	Article	IF	CITATIONS
1502	Antiinflammatory actions of inorganic nitrate stabilize the atherosclerotic plaque. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E550-E559.	7.1	52
1503	A Tailorable In Situ Lightâ€Activated Biodegradable Vascular Scaffold. Advanced Materials Technologies, 2017, 2, 1600243.	5 <b>.</b> 8	4
1504	TiN $\langle i \rangle \langle sub \rangle x \langle  sub \rangle \langle  i \rangle O \langle i \rangle \langle sub \rangle y \langle  sub \rangle \langle  i \rangle$ coatings facilitate the initial adhesion of osteoblasts to create a suitable environment for their proliferation and the recruitment of endothelial cells. Biomedical Materials (Bristol), 2017, 12, 025001.	3.3	8
1505	Phenotypic switching prevention and proliferation/migration inhibition of vascular smooth muscle		

#	Article	IF	Citations
1521	Influence of Relative Residence Time on Side-Wall Aneurysm Inception. Neurosurgery, 2018, 83, 574-581.	1.1	21
1522	Nanoparticles in Medicine: A Focus on Vascular Oxidative Stress. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-20.	4.0	122
1523	Incretin drugs as modulators of atherosclerosis. Atherosclerosis, 2018, 278, 29-38.	0.8	34
1524	Action of Red Wine and Polyphenols Upon Endothelial Function and Clinical Events. , 2018, , 391-418.		2
1525	Heparinized PCL/keratin mats for vascular tissue engineering scaffold with potential of catalytic nitric oxide generation. Journal of Biomaterials Science, Polymer Edition, 2018, 29, 1785-1798.	3.5	10
1526	Nitric Oxide Sensors for Biological Applications. Chemosensors, 2018, 6, 8.	3.6	31
1527	cGMP Signaling and Vascular Smooth Muscle Cell Plasticity. Journal of Cardiovascular Development and Disease, 2018, 5, 20.	1.6	33
1528	Inhibition of Multidrug Resistance Proteins by MK 571 Enhances Bladder, Prostate, and Urethra Relaxation through cAMP or cGMP Accumulation. Journal of Pharmacology and Experimental Therapeutics, 2018, 367, 138-146.	2.5	10
1529	The clinical effects of <scp>I</scp> _arginine and asymmetric dimethylarginine: implications for treatment in secondary Raynaud's phenomenon. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 497-503.	2.4	13
1530	Nanotherapies for Treatment of Cardiovascular Disease: a Case for Antioxidant Targeted Delivery. Current Pathobiology Reports, 2019, 7, 47-60.	3.4	8
1531	Exposure to Blast Overpressure Impairs Cerebral Microvascular Responses and Alters Vascular and Astrocytic Structure. Journal of Neurotrauma, 2019, 36, 3138-3157.	3.4	18
1532	Inflammation, Immunity, and Oxidative Stress in Hypertensionâ€"Partners in Crime?. Advances in Chronic Kidney Disease, 2019, 26, 122-130.	1.4	66
1533	Mild NO preconditioning protects H9c2 cells against NO-induced apoptosis through activation of PI3K/Akt and PKA-dependent pathways. Molecular and Cellular Toxicology, 2019, 15, 297-305.	1.7	0
1534	Alterations in phenotype and gene expression of adult human aneurysmal smooth muscle cells by exogenous nitric oxide. Experimental Cell Research, 2019, 384, 111589.	2.6	15
1535	Anti-hypertensive Effect of Cereal Antioxidant Ferulic Acid and Its Mechanism of Action. Frontiers in Nutrition, 2019, 6, 121.	3.7	88
1536	Regulatory T cells: Possible mediators for the anti-inflammatory action of statins. Pharmacological Research, 2019, 149, 104469.	7.1	32
1537	Periodontal Disease: A Risk Factor for Diabetes and Cardiovascular Disease. International Journal of Molecular Sciences, 2019, 20, 1414.	4.1	229
1538	Eight antihypertensive peptides from the protein hydrolysate of Antarctic krill (Euphausia superba): Isolation, identification, and activity evaluation on human umbilical vein endothelial cells (HUVECs). Food Research International, 2019, 121, 197-204.	6.2	58

#	Article	IF	CITATIONS
1539	Nitric Oxide Reverses the Position of the Heart during Embryonic Development. International Journal of Molecular Sciences, 2019, 20, 1157.	4.1	13
1540	Fe in biosynthesis, translocation, and signal transduction of NO: toward bioinorganic engineering of dinitrosyl iron complexes into NO-delivery scaffolds for tissue engineering. Dalton Transactions, 2019, 48, 9431-9453.	3.3	53
1541	Redox Regulation of the Microcirculation. , 2019, 10, 229-259.		7
1542	Periodontitis and Tooth Loss Have Negative Systemic Impact on Circulating Progenitor Cell Levels: A Clinical Study. Genes, 2019, 10, 1022.	2.4	55
1543	Antihypertensive Drugs and Vascular Health. Updates in Hypertension and Cardiovascular Protection, 2019, , 585-605.	0.1	0
1544	Neutrophil-Initiated Myocardial Inflammation and Its Modulation by B-Type Natriuretic Peptide: A Potential Therapeutic Target. International Journal of Molecular Sciences, 2019, 20, 129.	4.1	6
1545	Inducible Knockdown of Endothelial Protein Tyrosine Phosphatase-1B Promotes Neointima Formation in Obese Mice by Enhancing Endothelial Senescence. Antioxidants and Redox Signaling, 2019, 30, 927-944.	5 <b>.</b> 4	13
1546	Phosphorylation and activation of endothelial nitric oxide synthase by red fruit (Pandanus conoideus) Tj ETQq $1\ 1$	0.784314	rgBT/Oved
1547	Multiplicity of Nitric Oxide and Natriuretic Peptide Signaling in Heart Failure. Journal of Cardiovascular Pharmacology, 2020, 75, 370-384.	1.9	16
1548	Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm. Journal of Thrombosis and Haemostasis, 2020, 18, 3359-3370.	3.8	21
1549	Inhibition of eNOS by L-NAME resulting in rat hind limb developmental defects through PFKFB3 mediated angiogenetic pathway. Scientific Reports, 2020, 10, 16754.	3.3	11
1550	Nitric Oxide and Oxidative Stress-Mediated Cardiovascular Functionality: From Molecular Mechanism to Cardiovascular Disease., 0, , .		3
1551	Interplay between Endoplasmic Reticulum Stress and Large Extracellular Vesicles (Microparticles) in Endothelial Cell Dysfunction. Biomedicines, 2020, 8, 409.	3.2	13
1552	Analysis of Vascular Inflammation against Bioresorbable Zn–Ag-Based Alloys. ACS Applied Bio Materials, 2020, 3, 6779-6789.	4.6	18
1553	Interactive and independent effects of early lipopolysaccharide and hyperoxia exposure on developing murine lungs. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 319, L981-L996.	2.9	12
1554	Prostate Cancer Cell Phenotypes Remain Stable Following PDE5 Inhibition in the Clinically Relevant Range. Translational Oncology, 2020, 13, 100797.	3.7	8
1555	RNA-Binding Proteins in Pulmonary Hypertension. International Journal of Molecular Sciences, 2020, 21, 3757.	4.1	6
1556	Inosine, an endogenous purine nucleoside, avoids early stages of atherosclerosis development associated to eNOS activation and p38 MAPK/NF-kB inhibition in rats. European Journal of Pharmacology, 2020, 882, 173289.	3.5	19

#	Article	IF	CITATIONS
1557	Endothelial Dysfunction: A Contributor to Adverse Cardiovascular Remodeling and Heart Failure Development in Type 2 Diabetes beyond Accelerated Atherogenesis. Journal of Clinical Medicine, 2020, 9, 2090.	2.4	19
1558	Adrenomedullin Is Necessary to Resolve Hyperoxia-Induced Experimental Bronchopulmonary Dysplasia and Pulmonary HypertensionÂin Mice. American Journal of Pathology, 2020, 190, 711-722.	3.8	13
1559	Endothelial function after pancreas transplantation—A singleâ€eenter observational study. Clinical Transplantation, 2020, 34, e13815.	1.6	0
1560	Catalytic Generation of Nitric Oxide from Poly(ε-caprolactone)/Phosphobetainized Keratin Mats for a Vascular Tissue Engineering Scaffold. Langmuir, 2020, 36, 4396-4404.	3.5	18
1561	Assessment of potential cardiovascular risk in trichloroethylene exposure by serum methylated arginine levels. International Journal of Environmental Health Research, 2021, 31, 63-74.	2.7	4
1562	Myeloperoxidase: A versatile mediator of endothelial dysfunction and therapeutic target during cardiovascular disease., 2021, 221, 107711.		38
1563	The homeostatic role of hydrogen peroxide, superoxide anion and nitric oxide in the vasculature. Free Radical Biology and Medicine, 2021, 162, 615-635.	2.9	57
1564	Age-Related Macular Degeneration: Role of Oxidative Stress and Blood Vessels. International Journal of Molecular Sciences, 2021, 22, 1296.	4.1	64
1565	A REVIEW ON THE THERAPEUTIC POTENTIAL OF DIPYRIDAMOLE IN THE TREATMENT OF COVID-19. Plant Archives, 2021, 21, 2072-2077.	0.2	0
1566	Nitric oxide attenuates microglia proliferation by sequentially facilitating calcium influx through TRPV2 channels, activating NFATC2, and increasing p21 transcription. Cell Cycle, 2021, 20, 417-433.	2.6	3
1567	Significance of Inorganic Nitrate Supplement in Cardiovascular Health. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2022, 20, 83-89.	1.0	2
1568	Electrospun fiber membrane with asymmetric NO release for the differential regulation of cell growth. Bio-Design and Manufacturing, 2021, 4, 469-478.	7.7	8
1569	Molecular Action of Hydroxytyrosol in Attenuation of Intimal Hyperplasia: A Scoping Review. Frontiers in Pharmacology, 2021, 12, 663266.	3.5	9
1570	Heparan sulfate proteoglycan glypican-1 and PECAM-1 cooperate in shear-induced endothelial nitric oxide production. Scientific Reports, 2021, 11, 11386.	3.3	25
1571	Role of TRPV4 channel in vasodilation and neovascularization. Microcirculation, 2021, 28, e12703.	1.8	15
1572	AMPK: Potential Therapeutic Target for Vascular Calcification. Frontiers in Cardiovascular Medicine, 2021, 8, 670222.	2.4	12
1573	Resilience of the Internal Mammary Artery to Atherogenesis: Shifting From Risk to Resistance to Address Unmet Needs. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 2237-2251.	2.4	16
1574	Substance P ameliorates TNFâ€Î±â€mediated impairment of human aortic vascular cells in vitro. Clinical and Experimental Pharmacology and Physiology, 2021, 48, 1288-1297.	1.9	3

#	Article	IF	Citations
1575	Pathophysiology of Delayed Cerebral Ischemia After Subarachnoid Hemorrhage: A Review. Journal of the American Heart Association, 2021, 10, e021845.	3.7	96
1576	Combined therapy of far infrared radiation, heat and castor oil, an alternative remedy against Covid-19 infection: A perspective. GSC Biological and Pharmaceutical Sciences, 2021, 16, 001-012.	0.3	0
1577	Flow-adapted vascular systems: mimicking the vascular network to predict clinical response to radiation. , $2021$ , , $129-146$ .		0
1578	Modification of Biochemical and Cellular Processes in the Development of Atherosclerosis by Red Wine., 2006,, 475-494.		2
1579	Smoking and Oxidative Stress: Vascular Damage. , 2006, , 339-364.		2
1580	The Role of Thrombin in Angiogenesis. , 2009, , 93-113.		1
1581	The NO â^' K+ Channel Axis in Pulmonary Arterial Hypertension. Advances in Experimental Medicine and Biology, 2003, 543, 293-322.	1.6	20
1582	Growth Factor Regulators of Placental Angiogenesis. , 2000, , 149-162.		8
1583	Endothelium-Derived Relaxing Factor., 1996,, 3-19.		4
1584	Effects of Hyperglycemia on Vascular Endothelium Nitric Oxide Metabolism. , 1996, , 145-156.		5
1586	In Vitro Coculture Models to Study Vessel Formation and Function. , 1996, , 131-140.		1
1587	Flow Effects on Endothelial Cell Signal Transduction, Function, and Mediator Release., 1995,, 85-116.		4
1588	Nitric Oxide and Endothelin in the Developing Pulmonary Circulation: Physiologic and Clinical Implications., 1999,, 196-220.		7
1589	Recruitment of Ventricular Function with Adjunctive Nitrate Therapy after Late Reperfusion. Developments in Cardiovascular Medicine, 1995, , 425-432.	0.1	1
1590	Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis., 1995,, 89-97.		1
1591	Atherosclerosis, Oxidative Stress, and Endothelial Function. Developments in Cardiovascular Medicine, 2000, , 155-181.	0.1	1
1592	Role of Angiotensin II Receptor Blockade During Remodeling After Myocardial Infarction. Progress in Experimental Cardiology, 1998, , 437-449.	0.0	1
1593	Oxidative Stress and Vascular Remodeling. Developments in Cardiovascular Medicine, 1997, , 277-304.	0.1	2

#	Article	IF	CITATIONS
1594	Nitric Oxide: A Promoter or Inhibitor of Angiogenesis. , 1998, , 307-319.		1
1595	The Role of Platelet-Activating Factor and Its Receptor in Endometrial Receptivity. Advances in Experimental Medicine and Biology, 1996, 416, 277-290.	1.6	5
1596	Vascular Aging. , 2005, , 517-547.		1
1597	Vascular Remodeling in Health and Disease., 2007,, 1541-1565.		3
1598	The Endothelial Cell Nitric Oxide Synthase: Is It Really Constitutively Expressed?., 1995, 45, 107-117.		23
1599	Roles of vasodilatory prostaglandins in mitogenesis of vascular smooth muscle cells., 1997, 48, 63-91.		23
1600	Trophic Factors and the Control of Smooth Muscle Development and Innervation. , 1994, , 1-39.		5
1601	Airways Smooth Muscle Cell Growth and Proliferation. , 1994, , 41-68.		7
1602	Nitric oxide: An endogenous cardioprotectant?., 1996, 76, 71-85.		2
1603	Soluble Guanylate Cyclase Stimulators in Pulmonary Hypertension. Handbook of Experimental Pharmacology, 2013, 218, 279-313.	1.8	80
1604	Nitric Oxide and Atherosclerosis. Handbook of Experimental Pharmacology, 2000, , 571-617.	1.8	1
1605	Endothelial Alterations in Atherosclerosis: The Role of Nitric Oxide. , 1997, , 29-38.		6
1606	Pathology and Pathogenesis of Renovascular Hypertension. , 1992, , 73-106.		1
1607	Endothelial dysfunction in hypercholesterolemia is corrected by L-arginine. , 1991, 86 Suppl 2, 173-181.		17
1608	Angiotensin, ACE-inhibitors and endothelial control of vasomotor tone., 1993, 88 Suppl 1, 15-24.		16
1609	Endothelium and Vascular Smooth Muscle Function of Coronary Bypass Grafts. , 1994, , 193-211.		5
1610	Nitric Oxide Formation in the Vascular Wall: Regulation and Functional Implications. Current Topics in Microbiology and Immunology, 1995, 196, 7-18.	1.1	20
1611	Inhaled Nitric Oxide in Acute Respiratory Failure. Yearbook of Intensive Care and Emergency Medicine, 1995, , 331-357.	0.1	6

#	Article	IF	CITATIONS
1612	The Endothelium as a Regulator of Vascular Tone and Growth. , 1995, , 1-24.		10
1613	Endothelin Receptor Antagonists as New Tools to Inhibit Endothelin induced Vasoconstriction in Humans: Comparison with Calcium Channel Blockers. , 1995, , 129-147.		5
1614	Pharmacologic Approach of Hypoxemia in ARDS Patients. Yearbook of Intensive Care and Emergency Medicine, 1996, , 434-465.	0.1	1
1615	Vascular renin-angiotensin-system, endothelial function and atherosclerosis?., 1994, 89 Suppl 1, 71-86.		12
1616	Hypoxia, Nitric Oxide and Vasoactive Gene Transcription. , 1997, , 75-115.		1
1617	Regulation of Endothelial Nitric Oxide Synthase by Estrogen. , 1997, , 217-232.		1
1618	Endothelium control of vascular tone and growth: Potential role in coronary artery disease. Developments in Cardiovascular Medicine, 1994, , 3-18.	0.1	2
1619	Endothelium: the main actor in the remodelling of the retinal microvasculature in diabetes. Diabetologia, 1996, 39, 739-744.	6.3	6
1620	Vasoactive Peptides and Their Receptors. Methods in Neurosciences, 1993, , 43-86.	0.5	3
1621	Cyclic GMP-Mediated Signaling Mechanisms in Smooth Muscle. , 2000, , 401-425.		4
1622	Nitric Oxide and Vascular Disease. , 2000, , 759-783.		4
1624	Autocrine regulation of rat chondrocyte proliferation by natriuretic peptide C and its receptor, natriuretic peptide receptor-B Journal of Biological Chemistry, 1994, 269, 10729-10733.	3.4	101
1625	Nitric oxide decreases cytosolic free calcium in Balb/c 3T3 fibroblasts by a cyclic GMP-independent mechanism Journal of Biological Chemistry, 1991, 266, 9-12.	3.4	98
1626	Inhibition of Gi proteins by low density lipoprotein attenuates bradykinin-stimulated release of endothelial-derived nitric oxide Journal of Biological Chemistry, 1994, 269, 12987-12992.	3.4	59
1627	Chronic Blockade of Nitric Oxide–Synthase and Endothelin Receptors During Pregnancy in the Rat: Effect on Pregnancy Outcome. Journal of the Society for Gynecologic Investigation, 1998, 5, 132-139.	1.7	21
1628	Chronic blockade of nitric oxide synthase and endothelin receptors during pregnancy in the rat: effect on reactivity of the uterine artery in vitro. Journal of the Society for Gynecologic Investigation, 1998, 5, 288-295.	1.7	8
1629	L-arginine plasma levels and severity of idiopathic pulmonary arterial hypertension. Vasa - European Journal of Vascular Medicine, 2008, 37, 61-67.	1.4	16
1630	Physiology and Pathophysiology of Nitric Oxide in Chronic Renal Disease. Proceedings of the Association of American Physicians, 1999, 111, 602-610.	2.0	39

#	Article	IF	CITATIONS
1631	The do's and don'ts of arginine supplementation. South African Journal of Clinical Nutrition, 2010, 23, 25-28.	0.7	1
1632	Endothelial Dysfunction in the Pulmonary Vascular Bed. American Journal of the Medical Sciences, 2000, 320, 223-232.	1.1	52
1633	Cardiovascular Hypertrophy: Role of Angiotensin II and Bradykinin. Journal of Cardiovascular Pharmacology, 1996, 27, 36-40.	1.9	39
1634	Enhanced Antiproliferative Effect of Nitric Oxide in Cultured Smooth Muscle Cells from Diabetic Rats. Journal of Cardiovascular Pharmacology, 1996, 27, 140-146.	1.9	15
1635	Therapeutic Effects of Nitric Oxide-Donor Isosorbide Dinitrate on Atherosclerosis-Induced Alterations in Hemodynamics and Arterial Viscoelasticity Are Independent of the Wall Elastic Component. Journal of Cardiovascular Pharmacology, 1996, 27, 752-759.	1.9	12
1636	Tranilast Restores Cytokine-Induced Nitric Oxide Production Against Platelet-Derived Growth Factor in Vascular Smooth Muscle Cells. Journal of Cardiovascular Pharmacology, 1996, 28, 200-207.	1.9	22
1637	Inhibitor of Angiotensin-Converting Enzyme Modifies Myointimal Origin in an Arterial Autograft Model. Journal of Cardiovascular Pharmacology, 1996, 28, 285-293.	1.9	4
1638	Combination of ACE Inhibitors and Calcium Antagonists: A Logical Approach. Journal of Cardiovascular Pharmacology, 1998, 31, S5-S16.	1.9	25
1639	Stereoisomer-Specific Inhibition of Superoxide Anion-Induced Rat Aortic Smooth-Muscle Cell Proliferation by $17\hat{l}^2$ -Estradiol is Estrogen Receptor Dependent. Journal of Cardiovascular Pharmacology, 1998, 31, 499-505.	1.9	17
1640	Divergent Effects of Angiotensin-Converting Enzyme Inhibition and Angiotensin II-Receptor Antagonism on Myocardial Cellular Proliferation and Collagen Deposition After Myocardial Infarction in Rats. Journal of Cardiovascular Pharmacology, 1998, 31, 654-660.	1.9	49
1641	Neurohormonal Activation and Progression of Heart Failure. Journal of Cardiovascular Pharmacology, 1998, 32, S16-S21.	1.9	29
1642	Pentoxifylline Inhibits Neointimal Formation and Stimulates Constrictive Vascular Remodeling After Arterial Injury. Journal of Cardiovascular Pharmacology, 1999, 34, 683-689.	1.9	7
1643	Nebivolol Induces NO-Mediated Relaxations of Rat Small Mesenteric But Not of Large Elastic Arteries. Journal of Cardiovascular Pharmacology, 2000, 36, 316-320.	1.9	39
1644	Endothelial Dysfunction and Coronary Risk Reduction. Journal of Cardiopulmonary Rehabilitation and Prevention, 1998, 18, 60-67.	0.5	10
1645	Genetic susceptibility and ischaemic stroke. Current Opinion in Neurology, 1999, 12, 47-55.	3.6	37
1646	Cholesterol, endothelial function and cardiovascular disease. Current Opinion in Lipidology, 1998, 9, 237-242.	2.7	47
1647	Nitric oxide synthase gene transfer to the vessel wall. Current Opinion in Nephrology and Hypertension, 1999, 8, 75-81.	2.0	16
1648	Hypertension, nitric oxide and end-organ damage. Current Opinion in Nephrology and Hypertension, 1999, 8, 237-241.	2.0	4

#	ARTICLE	IF	CITATIONS
1650	Title is missing!. Cold Spring Harbor Symposia on Quantitative Biology, 1996, 61, 417-426.	1.1	15
1651	Maintaining the Endothelium: Preventive Strategies for Vessel Integrity. Preventive Cardiology, 2000, 3, 172-177.	1.1	3
1652	Receptor-activating peptides distinguish thrombin receptor (PAR-1) and protease activated receptor 2 (PAR-2) mediated hemodynamic responses in vivo. Canadian Journal of Physiology and Pharmacology, 1998, 76, 16-25.	1.4	33
1653	Endothelium-derived relaxing factors: A focus on endothelium-derived hyperpolarizing factor(s). Canadian Journal of Physiology and Pharmacology, 2001, 79, 443-470.	1.4	72
1654	IL- $1\hat{l}^2$ dysregulates cGMP signaling in the newborn lung. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 319, L21-L34.	2.9	3
1655	Role of NO in Flow-Induced Remodeling of the Rabbit Common Carotid Artery. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 1256-1262.	2.4	286
1656	Monocyte-Induced Downregulation of Nitric Oxide Synthase in Cultured Aortic Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 1095-1103.	2.4	31
1657	Reduced Responsiveness of Hypercholesterolemic Rabbit Aortic Smooth Muscle Cells to Nitric Oxide. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 394-402.	2.4	42
1658	Lack of Evidence for Linkage of the Endothelial Cell Nitric Oxide Synthase Gene to Essential Hypertension. Circulation, 1995, 91, 96-102.	1.6	119
1659	Reduced Epicardial Coronary Vasodilator Capacity in Patients With Left Ventricular Hypertrophy. Circulation, 1995, 91, 2916-2923.	1.6	13
1660	Bradykinin Antagonism Inhibits the Antigrowth Effect of Converting Enzyme Inhibition in the Dog Myocardium After Discrete Transmural Myocardial Necrosis. Circulation, 1995, 91, 2043-2048.	1.6	124
1661	How Do We Explain the Clinical Benefits of Estrogen?. Circulation, 1995, 92, 5-8.	1.6	147
1662	Contribution of Nitric Oxide to Metabolic Coronary Vasodilation in the Human Heart. Circulation, 1995, 92, 320-326.	1.6	249
1663	Impact of Left Ventricular Unloading After Late Reperfusion of Canine Anterior Myocardial Infarction on Remodeling and Function Using Isosorbide-5-Mononitrate. Circulation, 1995, 92, 926-934.	1.6	37
1664	Chronic Inhibition of Endothelium-Derived Nitric Oxide Synthesis Causes Coronary Microvascular Structural Changes and Hyperreactivity to Serotonin in Pigs. Circulation, 1995, 92, 2636-2644.	1.6	75
1665	Basic Fibroblast Growth Factor Restores Endothelium-Dependent Responses After Balloon Injury of Rabbit Arteries. Circulation, 1996, 93, 18-22.	1.6	32
1666	Effects of Dietary <scp>l</scp> -Arginine on Atherosclerosis and Endothelium-Dependent Vasodilatationin the Hypercholesterolemic Rabbit. Circulation, 1996, 94, 498-506.	1.6	87
1667	Is There a Role for Endothelin in the Natural History of Heart Failure?. Circulation, 1996, 94, 604-606.	1.6	19

#	ARTICLE	IF	CITATIONS
1668	Nitric Oxide and Hypertension. Circulation, 1996, 94, 1197-1198.	1.6	24
1669	Vascular Endothelin-1 Gene Expression and Effect on Blood Pressure of Chronic ET A Endothelin Receptor Antagonism After Nitric Oxide Synthase Inhibition With L- NAME in Normal Rats. Circulation, 1997, 95, 240-244.	1.6	49
1670	Effect of the Direct Nitric Oxide Donors Linsidomine and Molsidomine on Angiographic Restenosis After Coronary Balloon Angioplasty. Circulation, 1997, 95, 83-89.	1.6	89
1671	Arginine: A New Therapy for Atherosclerosis?. Circulation, 1997, 95, 311-312.	1.6	72
1672	<scp> </scp> -Arginine Prevents Xanthoma Development and Inhibits Atherosclerosis in LDL Receptor Knockout Mice. Circulation, 1997, 95, 430-437.	1.6	124
1673	Vascular Endothelial Growth Factor/Vascular Permeability Factor Augments Nitric Oxide Release From Quiescent Rabbit and Human Vascular Endothelium. Circulation, 1997, 95, 1030-1037.	1.6	328
1674	cGMP-Elevating Agents Suppress Proliferation of Vascular Smooth Muscle Cells by Inhibiting the Activation of Epidermal Growth Factor Signaling Pathway. Circulation, 1997, 95, 1269-1277.	1.6	173
1675	Angiotensin AT 1 Receptor Inhibition. Circulation, 1997, 95, 1592-1600.	1.6	72
1676	Local Intramural Delivery of I-Arginine Enhances Nitric Oxide Generation and Inhibits Lesion Formation After Balloon Angioplasty. Circulation, 1997, 95, 1863-1869.	1.6	91
1677	Endothelial Dysfunction Is Associated With Cholesterol Levels in the High Normal Range in Humans. Circulation, 1997, 96, 3287-3293.	1.6	165
1678	Stimulated Activation of Platelet-Derived Growth Factor Receptor In Vivo in Balloon-Injured Arteries. Circulation, 1997, 96, 1906-1913.	1.6	44
1679	Adventitial Gene Transfer of Recombinant Endothelial Nitric Oxide Synthase to Rabbit Carotid Arteries Alters Vascular Reactivity. Circulation, 1997, 96, 2254-2261.	1.6	81
1680	Attenuated Progression of Coronary Artery Disease After 6 Years of Multifactorial Risk Intervention. Circulation, 1997, 96, 2534-2541.	1.6	294
1681	Vasculoprotective Role of Inducible Nitric Oxide Synthase at Inflammatory Coronary Lesions Induced by Chronic Treatment With Interleukin- $1\hat{l}^2$ in Pigs in Vivo. Circulation, 1997, 96, 3104-3111.	1.6	36
1682	Effects of Interleukin-1Î <sup>2</sup> and Nitric Oxide on Cardiac Myocytes. Hypertension, 1995, 25, 421-430.	2.7	39
1683	Influence of Endothelium on Cultured Vascular Smooth Muscle Cell Proliferation. Hypertension, 1995, 25, 748-751.	2.7	57
1684	Cyclosporin A Inhibits Nitric Oxide Synthase Induction in Vascular Smooth Muscle Cells. Hypertension, 1995, 25, 764-768.	2.7	79
1685	Nitric Oxide and Its Putative Role in Hypertension. Hypertension, 1995, 25, 1202-1211.	2.7	126

#	ARTICLE	IF	CITATIONS
1686	L-NAME Hypertension Alters Endothelial and Smooth Muscle Function in Rat Aorta. Hypertension, 1995, 26, 744-751.	2.7	94
1687	Chronic Inhibition of Nitric Oxide Synthesis Causes Coronary Microvascular Remodeling in Rats. Hypertension, 1995, 26, 957-962.	2.7	172
1688	Chronic <scp>l</scp> -Arginine Administration Attenuates Cardiac Hypertrophy in Spontaneously Hypertensive Rats. Hypertension, 1996, 27, 14-18.	2.7	99
1689	Vascular Structure and Expression of Endothelin-1 Gene in L-NAME–Treated Spontaneously Hypertensive Rats. Hypertension, 1996, 27, 49-55.	2.7	55
1690	cDNA Cloning and Gene Expression of Human Type l $\hat{l}_{\pm}$ cGMP-Dependent Protein Kinase. Hypertension, 1996, 27, 552-557.	2.7	63
1691	Vascular Smooth Muscle Polyploidy and Cardiac Hypertrophy in Genetic Hypertension. Hypertension, 1996, 27, 752-759.	2.7	23
1692	Aging Progressively Impairs Endothelium-Dependent Vasodilation in Forearm Resistance Vessels of Humans. Hypertension, 1996, 27, 849-853.	2.7	380
1693	Effects of Angiotensin II Infusion and Inhibition of Nitric Oxide Synthase on the Rat Aorta. Hypertension, 1996, 28, 153-158.	2.7	29
1694	Estrogen Enhances Basal Nitric Oxide Release in the Forearm Vasculature in Perimenopausal Women. Hypertension, 1996, 28, 330-334.	2.7	146
1695	Menopause Is Associated With Endothelial Dysfunction in Women. Hypertension, 1996, 28, 576-582.	2.7	365
1696	Cardiac Transplantation, Perindopril, and Left Ventricular Hypertrophy in Spontaneously Hypertensive Rats. Hypertension, 1996, 28, 622-626.	2.7	7
1697	Upregulation of Nitric Oxide Synthase Correlates Temporally With Onset of Pulmonary Vascular Remodeling in the Hypoxic Rat. Hypertension, 1996, 28, 743-753.	2.7	109
1698	In Vivo Gene Transfer and Gene Modulation in Hypertension Research. Hypertension, 1996, 28, 1132-1137.	2.7	8
1699	Mechanical Stress of the Carotid Artery at the Early Phase of Spontaneous Hypertension in Rats. Hypertension, 1997, 29, 992-998.	2.7	18
1700	Early Induction of Angiotensin I–Converting Enzyme in Rat Carotid Artery After Balloon Injury. Hypertension, 1997, 30, 272-277.	2.7	19
1701	Enhanced Endothelium-Dependent Relaxations After Gene Transfer of Recombinant Endothelial Nitric Oxide Synthase to Rabbit Carotid Arteries. Hypertension, 1997, 30, 314-320.	2.7	61
1702	Ramipril Prevents Endothelial Dysfunction Induced by Oxidized Low-Density Lipoproteins. Hypertension, 1997, 30, 371-376.	2.7	49
1703	Structure and Function of Small Arteries in Salt-Induced Hypertension. Hypertension, 1997, 30, 905-911.	2.7	91

#	Article	IF	CITATIONS
1704	Parathyroid Hormone–Related Protein Upregulates Interleukin-1β–Induced Nitric Oxide Synthesis. Hypertension, 1997, 30, 922-927.	2.7	5
1705	Effect of Nitric Oxide on DNA Replication Induced by Angiotensin II in Rat Cardiac Fibroblasts. Hypertension, 1997, 30, 1035-1040.	2.7	29
1706	Effects of Chronic Nitric Oxide Synthase Inhibition on Cerebral Arterioles in Rats. Hypertension, 1997, 30, 1097-1104.	2.7	21
1707	Continuous Nitric Oxide Inhalation Reduces Pulmonary Arterial Structural Changes, Right Ventricular Hypertrophy, and Growth Retardation in the Hypoxic Newborn Rat. Circulation Research, 1995, 76, 215-222.	4.5	102
1708	Nitric Oxide–Generating Compounds Inhibit Total Protein and Collagen Synthesis in Cultured Vascular Smooth Muscle Cells. Circulation Research, 1995, 76, 305-309.	4.5	225
1709	Nitric Oxide Synthesis by Cultured Endothelial Cells Is Modulated by Flow Conditions. Circulation Research, 1995, 76, 536-543.	4.5	442
1710	Nitric Oxide Modulates the Expression of Monocyte Chemoattractant Protein 1 in Cultured Human Endothelial Cells. Circulation Research, 1995, 76, 980-986.	4.5	342
1711	The Intima. Circulation Research, 1995, 77, 445-465.	4.5	755
1712	Adrenomedullin as a Novel Antimigration Factor of Vascular Smooth Muscle Cells. Circulation Research, 1995, 77, 660-664.	4.5	122
1713	Regional Expression of Natriuretic Peptide Receptors During the Formation of Arterial Neointima in the Rabbit. Circulation Research, 1995, 77, 906-918.	4.5	30
1714	Nitric Oxide Reversibly Inhibits the Migration of Cultured Vascular Smooth Muscle Cells. Circulation Research, 1996, 78, 225-230.	4.5	305
1715	Chronic Inhalation of Nitric Oxide Inhibits Neointimal Formation After Balloon-Induced Arterial Injury. Circulation Research, 1996, 78, 337-342.	4.5	99
1716	Regulation of Endothelial Production of C-Type Natriuretic Peptide in Coculture With Vascular Smooth Muscle Cells. Circulation Research, 1996, 78, 606-614.	4.5	83
1717	Differential Regulation of <scp> </scp> -Arginine Transport and Nitric Oxide Production by Vascular Smooth Muscle and Endothelium. Circulation Research, 1996, 78, 1075-1082.	4.5	55
1718	Shear Stress Modulates Expression of Cu/Zn Superoxide Dismutase in Human Aortic Endothelial Cells. Circulation Research, 1996, 79, 32-37.	4.5	230
1719	Acute Reductions in Blood Flow and Shear Stress Induce Platelet-Derived Growth Factor-A Expression in Baboon Prosthetic Grafts. Circulation Research, 1996, 79, 45-53.	4.5	88
1720	Vasoactive Substances Regulate Vascular Smooth Muscle Cell Apoptosis. Circulation Research, 1996, 79, 748-756.	4.5	266
1721	Wall Remodeling During Luminal Expansion of Mesenteric Arterial Collaterals in the Rat. Circulation Research, 1996, 79, 1015-1023.	4.5	99

#	Article	IF	CITATIONS
1722	Phosphorylation of Endothelial Nitric Oxide Synthase in Response to Fluid Shear Stress. Circulation Research, 1996, 79, 984-991.	4.5	385
1723	17Î <sup>2</sup> -Estradiol Regulation of Human Endothelial Cell Basal Nitric Oxide Release, Independent of Cytosolic Ca <sup>2+</sup> Mobilization. Circulation Research, 1997, 81, 885-892.	4.5	402
1724	Structure and Function of the Rat Basilar Artery During Chronic Nitric Oxide Synthase Inhibition. Stroke, 1995, 26, 1922-1929.	2.0	44
1725	Difference in Endothelium-Derived Hyperpolarizing Factor–Mediated Hyperpolarization and Nitric Oxide Release Between Human Internal Mammary Artery and Saphenous Vein. Circulation, 2000, 102, .	1.6	2
1726	Comparison of Nitric Oxide Release and Endothelium-Derived Hyperpolarizing Factor–Mediated Hyperpolarization Between Human Radial and Internal Mammary Arteries. Circulation, 2001, 104, .	1.6	5
1727	Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells Journal of Clinical Investigation, 1990, 86, 1690-1697.	8.2	316
1728	Platelet-derived growth factor receptors on macrovascular endothelial cells mediate relaxation via nitric oxide in rat aorta Journal of Clinical Investigation, 1992, 89, 878-882.	8.2	49
1729	Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. Role in the vascular and renal complications of diabetes mellitus Journal of Clinical Investigation, 1992, 90, 1110-1115.	8.2	190
1730	Nitric oxide, an endothelial cell relaxation factor, inhibits neutrophil superoxide anion production via a direct action on the NADPH oxidase Journal of Clinical Investigation, 1992, 90, 1116-1121.	8.2	631
1731	Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit Journal of Clinical Investigation, 1992, 90, 1168-1172.	8.2	639
1732	Heparin regulates endothelin production through endothelium-derived nitric oxide in human endothelial cells Journal of Clinical Investigation, 1993, 92, 2080-2085.	8.2	93
1733	Chronic nitric oxide inhibition in utero produces persistent pulmonary hypertension in newborn lambs Journal of Clinical Investigation, 1994, 93, 2675-2683.	8.2	151
1734	Continuous inhalation of nitric oxide protects against development of pulmonary hypertension in chronically hypoxic rats Journal of Clinical Investigation, 1994, 94, 578-584.	8.2	117
1735	Endothelial nitric oxide synthase is expressed in cultured human bronchiolar epithelium Journal of Clinical Investigation, 1994, 94, 2231-2236.	8.2	189
1736	Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis Journal of Clinical Investigation, 1995, 95, 1747-1755.	8.2	409
1737	Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. Role of cyclic-nucleotides and angiotensin1 receptors Journal of Clinical Investigation, 1995, 96, 141-149.	8.2	301
1738	Inhibition of neointimal proliferation in rabbits after vascular injury by a single treatment with a protein adduct of nitric oxide Journal of Clinical Investigation, 1995, 96, 2630-2638.	8.2	205
1739	Regulation of bovine endothelial constitutive nitric oxide synthase by oxygen Journal of Clinical Investigation, 1995, 96, 2661-2666.	8.2	186

#	Article	IF	CITATIONS
1740	Expression and localization of inducible and endothelial nitric oxide synthase in the rat ovary. Effects of gonadotropin stimulation in vivo Journal of Clinical Investigation, 1995, 96, 2719-2726.	8.2	109
1741	Adenoviral-mediated transfer of the human endothelial nitric oxide synthase gene reduces acute hypoxic pulmonary vasoconstriction in rats Journal of Clinical Investigation, 1996, 98, 317-324.	8.2	145
1742	Effect of age on kinetics of nitric oxide release in rat aorta and pulmonary artery Journal of Clinical Investigation, 1996, 98, 899-905.	8.2	240
1743	Significant reduction of the antiatherogenic effect of estrogen by long-term inhibition of nitric oxide synthesis in cholesterol-clamped rabbits Journal of Clinical Investigation, 1997, 100, 821-828.	8.2	63
1744	Nitric oxide induces heat-shock protein 70 expression in vascular smooth muscle cells via activation of heat shock factor 1 Journal of Clinical Investigation, 1997, 100, 1089-1097.	8.2	126
1745	Inhibition of rat vascular smooth muscle proliferation in vitro and in vivo by bone morphogenetic protein-2 Journal of Clinical Investigation, 1997, 100, 2824-2832.	8.2	143
1746	Role of nitric oxide in experimental obliterative bronchiolitis (chronic rejection) in the rat Journal of Clinical Investigation, 1997, 100, 2984-2994.	8.2	51
1747	Cellular localization of AT1 receptor mRNA and protein in normal placenta and its reduced expression in intrauterine growth restriction. Angiotensin II stimulates the release of vasorelaxants Journal of Clinical Investigation, 1998, 101, 442-454.	8.2	103
1748	Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts Journal of Clinical Investigation, 1998, 101, 812-818.	8.2	435
1749	Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. Journal of Clinical Investigation, 2003, 111, 1201-1209.	8.2	678
1750	Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. Journal of Clinical Investigation, 2003, 111, 1201-1209.	8.2	1,284
1751	Nitric oxide inhibition induces early activation of type I collagen gene in renal resistance vessels and glomeruli in transgenic mice. Role of endothelin Journal of Clinical Investigation, 1998, 101, 2780-2789.	8.2	124
1752	T cell–mediated vascular dysfunction of human allografts results from IFN-γ dysregulation of NO synthase. Journal of Clinical Investigation, 2004, 114, 846-856.	8.2	90
1753	Blasts from the past. Journal of Clinical Investigation, 2004, 114, 1017-1033.	8.2	3
1754	Renal cytochrome P450 i‰-hydroxylase and epoxygenase activity are differentially modified by nitric oxide and sodium chloride. Journal of Clinical Investigation, 1999, 104, 1131-1137.	8.2	95
1755	Cyclic-GMP-Binding, Cyclic-GMP-Specific Phosphodiesterase (PDE5) Gene Expression Is Regulated during Rat Pulmonary Development. Pediatric Research, 1998, 43, 163-168.	2.3	103
1756	Chronic Lung Injury in Preterm Lambs: Abnormalities of the Pulmonary Circulation and Lung Fluid Balance. Pediatric Research, 2000, 48, 64-74.	2.3	83
1757	Measuring dimensions: the regulation of size and shape. Development (Cambridge), 2000, 127, 2977-2987.	2.5	311

#	Article	IF	CITATIONS
1758	Ecdysteroid coordinates optic lobe neurogenesis via a nitric oxide signaling pathway. Development (Cambridge), 2000, 127, 3543-3551.	2.5	54
1759	Rising behind NO: cGMP-dependent protein kinases. Journal of Cell Science, 2000, 113, 1671-1676.	2.0	287
1760	Arginine Vasopressin Inhibits Nitric Oxide Synthesis in Cytokine-Stimulated Vascular Smooth Muscle Cells Hypertension Research, 1997, 20, 209-216.	2.7	22
1761	Gene Expression of Endothelial Type Isoform of Nitric Oxide Synthase in Various Tissues of Stroke-Prone Spontaneously Hypertensive Rats Hypertension Research, 1997, 20, 43-49.	2.7	20
1762	Elevation of Soluble Guanylate Cyclase Suppresses Proliferation and Survival of Human Breast Cancer Cells. PLoS ONE, 2015, 10, e0125518.	2.5	35
1763	Section Review: Cardiovascular & Energy Renal: Genetic therapies for vascular diseases and lipid disorders. Expert Opinion on Investigational Drugs, 1995, 4, 1129-1137.	4.1	3
1764	Anti-Atherosclerotic Effects of Tamoxifen in Cholesterol-fed Ovariectomized Rabbits International Heart Journal, 2002, 43, 545-558.	0.6	1
1765	Photoactivation of Vascular iNOS and Elevation of cGMP In Vivo: Possible Mechanism for Photovasorelaxation and Inhibition of Restenosis in an Atherosclerotic Rabbit Model¶. Photochemistry and Photobiology, 2000, 72, 579.	2.5	11
1768	l Diretriz Latino-Americana para avaliação e conduta na insuficiência cardÃaca descompensada. Arquivos Brasileiros De Cardiologia, 0, 85, .	0.8	34
1769	Effects of lipopolysaccharide on low- and high-density cultured rabbit vascular smooth muscle cells: differential modulation of nitric oxide release, ERK1/ERK2 MAP kinase activity, protein tyrosine phosphatase activity, and DNA synthesis. Brazilian Journal of Medical and Biological Research, 2002, 35, 181-190.	1.5	5
1770	Pharmacologic Modulators of Nitric Oxide Exacerbate Tubulointerstitial Inflammation in Proteinuric Rats. Journal of the American Society of Nephrology: JASN, 2001, 12, 1696-1705.	6.1	22
1771	Endothelial cell biology in relation to current concepts of vessel wall structure and function Journal of the American Society of Nephrology: JASN, 1991, 1, 931-948.	6.1	32
1772	Mechanisms of vascular injury: the emerging role of the endothelium. Journal of the American Society of Nephrology: JASN, 1991, 2, S2.	6.1	14
1773	Diabetes-induced endothelial dysfunction in streptozotocin-treated rats. Journal of the American Society of Nephrology: JASN, 1993, 4, 1327-1336.	6.1	91
1774	Dietary supplementation with L-arginine ameliorates glomerular hypertension in rats with subtotal nephrectomy Journal of the American Society of Nephrology: JASN, 1994, 4, 1690-1694.	6.1	49
1775	Role of nitric oxide in rat nephrotoxic nephritis: comparison between inducible and constitutive nitric oxide synthase Journal of the American Society of Nephrology: JASN, 1997, 8, 1712-1721.	6.1	46
1776	Proliferation of macrophages due to the inhibition of inducible nitric oxide synthesis by oxidized low-density lipoproteins. EXCLI Journal, 2015, 14, 439-51.	0.7	9
1777	The genetic basis for altered blood vessel function in disease: large artery stiffening. Vascular Health and Risk Management, 2005, 1, 333-344.	2.3	11

#	Article	IF	CITATIONS
1778	Endothelial effects of antihypertensive treatment: focus on irbesartan. Vascular Health and Risk Management, 2008, 4, 89-101.	2.3	36
1779	Insulin Resistance and Endothelial Dysfunction: A Mutual Relationship in Cardiometabolic Risk. Current Pharmaceutical Design, 2013, 19, 2420-2431.	1.9	37
1780	Vascular Stiffness: Measurements, Mechanisms and Implications. Current Vascular Pharmacology, 2004, 2, 379-384.	1.7	66
1781	The Effect of a Resistance Training Course on Blood Pressure and Nitric Oxide Levels in Elderly Women. Salmand: Iranian Journal of Ageing, 2018, 13, 16-27.	0.5	2
1782	Physiological and Clinical Significance of Nitric Oxide Keio Journal of Medicine, 1994, 43, 15-26.	1.1	5
1783	Nitric oxide signalling in the regulation of cardiovascular and platelet function. Frontiers in Bioscience - Landmark, 2011, 16, 1873.	3.0	101
1784	Long-term effect of losartan administration on blood pressure, heart and structure of coronary artery of young spontaneously hypertensive rats. Physiological Research, 2009, 58, 327-335.	0.9	38
1785	The Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Improves Hypoxia-Induced Pulmonary Hypertension in Mice Partly via Normalization of Reduced ETB Receptor Expression. Physiological Research, 2018, 67, S175-S184.	0.9	13
1786	Therapeutic Application of Nitric Oxide in Human Diseases. Biomolecules and Therapeutics, 2010, 18, 351-362.	2.4	6
1787	Sodium Nitroprusside inhibits HEK293 Cell Growth by cGMP-Dependent and Independent Mechanisms. Pharmacology & Pharmacy, 2014, 05, 262-271.	0.7	2
1788	The Relationship between Insulin Resistance and Polymorphisms of the Endothelial Nitric Oxide Synthase Gene in Patients with Coronary Artery Disease Journal of Atherosclerosis and Thrombosis, 2003, 10, 43-47.	2.0	20
1789	Effect of Modified LDL on the Release of NO and PGI2 from Rat Peritoneal Macrophages. Journal of Atherosclerosis and Thrombosis, 1995, 2, 41-45.	2.0	6
1790	Effects of Estrogen on Atherosclerosis Formation and Serum Nitrite/Nitrate Concentrations in Cholesterol-fed Ovariectomized Rabbits. Journal of Atherosclerosis and Thrombosis, 1996, 3, 114-119.	2.0	6
1791	Chronic thromboembolic pulmonary hypertension: the magic of pathophysiology. Annals of Cardiothoracic Surgery, 2022, 11, 106-119.	1.7	17
1792	Bioinspired NO release coating enhances endothelial cells and inhibits smooth muscle cells. Journal of Materials Chemistry B, 2022, 10, 2454-2462.	5.8	9
1793	The NO signalling pathway in aortic aneurysm and dissection. British Journal of Pharmacology, 2022, 179, 1287-1303.	5.4	9
1794	Covalently Bound <i>S</i> -Nitroso- <i>N</i> -Acetylpenicillamine to Electrospun Polyacrylonitrile Nanofibers for Multifunctional Tissue Engineering Applications. ACS Biomaterials Science and Engineering, 2021, 7, 5279-5287.	5.2	7
1795	Therapeutic Potential of Nitric Oxide Synthase Gene Manipulation. Handbook of Experimental Pharmacology, 2000, , 639-653.	1.8	0

#	Article	IF	CITATIONS
1796	Nitric Oxide Synthase Gene Transfer. , 2000, , 503-524.		0
1798	Circadian Variation in Myocardial Ischemia and Infarction. Developments in Cardiovascular Medicine, 2000, , 247-261.	0.1	O
1799	Advanced Glycosylation Endproducts and Diabetic Vascular Disease. Developments in Cardiovascular Medicine, 2000, , 287-303.	0.1	1
1800	Human Studies of Antioxidants and Vascular Function. Developments in Cardiovascular Medicine, 2000, , 213-243.	0.1	3
1801	Nitric Oxide Synthase Gene Transfer Inhibits Protein Synthesis of Rat Cardiac Mycocytes. Progress in Experimental Cardiology, 2000, , 399-407.	0.0	0
1802	Role of Nitric Oxide in the Antiatherosclerotic Effect of 17β-Estradiol. , 2000, , 193-210.		0
1803	The Role of Nuts in Cardiovascular Disease Prevention. Modern Nutrition, 2000, , .	0.1	1
1804	Nitric Oxide: Lessons Learned and Areas of Success. , 2001, , 47-52.		0
1805	Therapeutic Regulation of Leukocyte Adhesion Molecule Expression. , 2001, , 263-301.		0
1806	Transplantation-associated arteriosclerosis and inflammation. , 2001, , 61-78.		O
1807	Nitric oxide regulation of leukocyte adhesion molecule expression., 2001,, 99-116.		0
1808	Clinical Assessment of Endothelial Function. , 2002, , 691-700.		2
1809	Coronary Artery Function in Diabetes Mellitus. , 2002, , 1008-1015.		0
1810	Pleiotropic effects of HMG-CoA reductase inhibitors on cells of the vascular wall., 2002,, 81-98.		1
1811	Leukocyte-Endothelial Interactions Following Myocardial Ischemia., 2003,, 427-438.		0
1812	INTRAMYOCARDIAL GENE AND CELLULAR DELIVERY FOR MYOCARDIAL ANGIOGENESIS AND REGENERATION. , 2003, , 298-308.		O
1813	Nitric Oxide, Oxygen Radicals. , 2004, , 477-492.		0
1814	Pentaerithrityltetranitrat (PETN) schützt hänodynamische Funktionen und morphologische Strukturen in aortalen GefäŸpräarationen. , 2004, , 41-54.		O

#	Article	IF	CITATIONS
1817	The Medical Management of Heart Failure., 2007,, 1397-1416.		0
1818	Diseases of the Pulmonary Vascular System. , 2009, , 1-18.		0
1819	Renal Function in Congestive Heart Failure. , 2009, , 974-977.		0
1820	Neonatal Emergencies., 2009,, 747-766.		2
1821	Cardiovascular Disease in Women with Diabetes. , 2009, , 35-56.		1
1822	Chronic Lung Disease of Infancy. , 2009, , 1-27.		0
1823	Nitric Oxide Expression in Cancer. , 2010, , 59-82.		2
1824	Bewegungstherapie bei koronarer Herzkrankheit. , 2010, , 115-142.		1
1825	Sites of Injury: The Endothelium. , 2011, , 57-69.		1
1826	Placental Vascular Morphogenesis and Oxidative Stress. , 2013, , 95-113.		1
1827	eNOS Glu298Asp polymorphism is associated with development of complicated plaques in patients from Serbia with advanced carotid atherosclerosis. Archives of Biological Sciences, 2013, 65, 143-149.	0.5	2
1828	Senescence and Senescence-Related Disorders. , 2013, , .		3
1829	Phosphodiesterase-5 Inhibitors in Cardioprotection. , 2013, , 439-458.		0
1831	Pathogenic Mechanisms of Pulmonary Hypertension. , 2014, , 1-32.		0
1832	Pathophysiological Roles of Reactive Oxygen and Nitrogen Species. , 2014, , 171-206.		2
1833	Endothelium Function in Human Coronary Bypass Grafts. , 1991, , 139-155.		0
1834	Atherosclerasis and Vasoactive Substances. The Journal of Japan Atherosclerosis Society, 1992, 20, 459-467.	0.0	0
1835	Angiotensin, ACE-Inhibitoren und endotheliale Regulation des GefÃßtonus. , 1993, , 17-27.		0

#	Article	IF	Citations
1836	Growth factors and hypertension: Implications for a role in vascular remodelling. Developments in Cardiovascular Medicine, 1993, , 287-310.	0.1	0
1837	Signals regulating arterial contractile function and growth in hypertension. Developments in Cardiovascular Medicine, 1993, , 89-105.	0.1	O
1838	Modulation of Pulmonary Vascular Tone by Nitric Oxide in Health and Disease., 1993,, 465-473.		0
1839	Chronic Changes in Venous Grafts After Implantation. , 1994, , 228-244.		O
1840	The effect on coronary artery and heart muscle microstructure of a rat of N-nitro-L-arginine methylester chronic administration. The effect of ACE inhibitor Japanese Journal of Clinical Pharmacology and Therapeutics, 1994, 25, 35-36.	0.1	O
1842	Induction of Nitric Oxide Synthase after Protein Kinase C Activation by Phorbol Esters. , 1994, , 51-64.		0
1843	Nitric Oxide: An Endogenous Inhibitor of Balloon Catheter-Induced Intimal Hyperplasia. , 1995, , 175-180.		0
1844	Nitric Oxide: Friend and Foe in Myocardial Ischemia and Reperfusion. Developments in Cardiovascular Medicine, 1995, , 249-262.	0.1	0
1845	Physiologische, pharmakologische und klinische Aspekte der Nitrovasodilatatoren: Kurz- und Langzeitwirkungen von PETN auf das HÄ <b>m</b> odynamische System. , 1995, , 54-65.		1
1846	Cellular Actions of Nitric Oxide on the Circulatory System. Update in Intensive Care and Emergency Medicine, 1995, , 114-124.	0.6	0
1847	Characterization of Signals Leading to Clonal Expansion or to Cell Death During Lymphocyte B Cell Activation. Current Topics in Microbiology and Immunology, 1995, 200, 39-50.	1.1	6
1848	Ventricular remodeling: insights from pharmacologic interventions with angiotensin-converting enzyme inhibitors., 1995, 147, 51-55.		9
1849	Endothelial Cells and Cerebrovascular Disease. , 1995, , 173-183.		1
1850	Elevation of Circulating NO: Its Effects on Hemodynamics and Vascular Smooth Muscle Cell Proliferation in Rats., 1995, 45, 169-176.		3
1851	Effects of Nitric Oxide on Intestinal Epithelial Structure and Function. Update in Intensive Care and Emergency Medicine, 1995, , 181-198.	0.6	0
1852	Non-cGMP, Paracrine Effects of Nitric Oxide in the Vasculature. , 1996, , 37-47.		0
1853	Inhaled Nitric Oxide in Acute Respiratory Failure. , 1996, , 181-203.		9
1855	Gene therapy for the vulnerable atherosclerotic plaque. Developments in Cardiovascular Medicine, 1996, , 395-412.	0.1	0

#	ARTICLE	IF	CITATIONS
1856	The role of coronary vasomotor tone in coronary artery disease. Developments in Cardiovascular Medicine, 1996, , 219-236.	0.1	0
1857	Measurement of the metabolic products of nitric oxide in hemodialysis patients Nihon Toseki Igakkai Zasshi, 1996, 29, 29-35.	0.1	1
1858	Estrogen and Vascular Reactivity. , 1996, , 67-78.		2
1859	Estrogen, Nitric Oxide, and Primate Atherosclerosis. , 1997, , 233-245.		0
1860	Vascular Remodeling and Lesion Formation in Restenosis: Implications for Nitric Oxide-Based Therapeutics. Developments in Cardiovascular Medicine, 1997, , 255-276.	0.1	0
1862	Role of NO in Cell Locomotion. , 1997, , 86-110.		0
1863	Natriuretic Peptides as Antigrowth Factors. , 1997, , 223-237.		2
1864	Endothelial Dysfunction after Angioplasty: A Pathway for Remodelling?. Developments in Cardiovascular Medicine, 1997, , 231-252.	0.1	0
1865	Nitric Oxide Inhibits Growth of Vascular Smooth Muscle Cells In Vitro by Mechanisms Independent of Guanylate Cyclase. Advances in Experimental Medicine and Biology, 1997, 411, 519-525.	1.6	0
1866	Effects of NIDDM on Vascular Tone Regulation. , 1997, , 233-246.		0
1867	Coronary Vasomotor Responses: Role of Endothelium and Nitrovasodilators. , 1997, , 1-20.		0
1868	Effect of short-term treatment with a monoclonal antibody to P-selectin on balloon catheter-induced: Intimal hyperplasia, re-endothelialization, and attenuation of endothelial-dependent relaxation., 1997,, 13-20.		2
1869	Cardiac Hypertrophy and the Renin-Angiotensin System., 1997,, 47-66.		0
1870	Blood Flows in Cerebral Arteries After Suspension of Postmenopausal Hormone Replacement Therapy. A Randomized Crossover Study. Medical Science Symposia Series, 1997, , 141-144.	0.0	0
1871	Comparative study of Nitric Oxide(NO) and atherosclerotic change in patients on maintenance hemodialysis. with special reference to Aortic Calcification Index Nihon Toseki Igakkai Zasshi, 1997, 30, 45-51.	0.1	0
1872	Aging and Endothelial Function. , 1998, , 45-54.		0
1873	Das koronare GefÃßendothel. , 1998, , 69-89.		0
1874	Insulin and Insulin-Like Growth Factor I (IGF-I) Effects on Ca2+ and Nitric Oxide in Diabetes. Growth Hormone, 1998, , 139-158.	0.2	2

#	Article	IF	CITATIONS
1875	Neurohormonal Activation and Progression of Heart Failure: Hypothetical and Clinical Considerations. Journal of Cardiovascular Pharmacology, 1998, 32, S16-S21.	1.9	12
1876	Angiotensin II, Oxidative Stress, and Nitric Oxide. Growth Hormone, 1998, , 79-98.	0.2	0
1877	Protein Glycation and Diabetic Vascular Disease. Growth Hormone, 1998, , 159-180.	0.2	0
1878	Vascular Smooth Muscle Cell Biology and Restenosis. Perspectives in Antisense Science, 1999, , 45-69.	0.2	0
1879	The Role of Nitric Oxide in Coronary Disease. Developments in Cardiovascular Medicine, 1999, , 125-141.	0.1	0
1880	iNOS and COX-2 in atherosclerosis. , 1999, , 109-124.		0
1881	Reatividade vascular da art $\tilde{A}$ ©ria mam $\tilde{A}_i$ ria interna: estudos farmacol $\tilde{A}^3$ gicos comparativos entre art $\tilde{A}$ ©rias caninas direita e esquerda. Brazilian Journal of Cardiovascular Surgery, 1999, 14, .	0.6	0
1882	Enhanced Nitric Oxide–Mediated Vascular Relaxation in Radial Artery Compared With Internal Mammary Artery or Saphenous Vein. Circulation, 1999, 100, .	1.6	2
1883	Pathogenic Mechanisms of Pulmonary Hypertension. , 2015, , 4079-4104.		0
1884	Effect of Theobroma cacao Polyphenol on Isoproterenol-Induced Myocardial Infarction in Wistar Rats. Journal of Applied Pharmaceutical Science, 0, , 076-083.	1.0	3
1885	Obesity and Antiphospholipid Syndrome: A Particular Challenge in Pregnancy. Obesity Research - Open Journal, 2015, 2, 46-56.	0.4	1
1886	Serum nitric oxide levels in patients with coronary artery ectasia. Anatolian Journal of Cardiology, 2016, 16, 947-952.	0.9	5
1887	ACHIEVEMENTS AND PROSPECTS IN THE FIELD OF GENE-ELUTING CORONARY STENTS. Complex Issues of Cardiovascular Diseases, 2016, , 99-107.	0.5	0
1888	Cellular and Molecular Mechanisms of Atherosclerosis. Learning Materials in Biosciences, 2019, , 207-218.	0.4	0
1889	Inorganic Nitrate Supplementation for Cardiovascular Health. Methodist DeBakey Cardiovascular Journal, 2021, 15, 200.	1.0	12
1890	The role of endothelium in atherogenesis: dependence of atherosclerosis development on the properties of vessel endothelium. Meditsinskii Akademicheskii Zhurnal, 2020, 20, 23-36.	0.2	3
1893	Diabetische Herzmuskelerkrankung. , 2005, , 157-173.		0
1894	Gene Therapy and Cardiovascular Diseases. , 2005, , 57-69.		0

#	Article	IF	CITATIONS
1895	The Coronary Microcirculation and Angiogenesis. , 2005, , 65-105.		0
1896	Lack of association between endothelial constitutive nitric oxide synthase (ecNOS 4 b/a) gene polymorphism and rheumatic heart disease. Modern Rheumatology, 2009, 19, 670-674.	1.8	0
1897	Thromboembolic disease: a geriatric syndrome. Journal of Gerontology and Geriatrics, 2021, 69, 68-78.	0.5	0
1898	Regulation of smooth muscle cell growth by endothelium-derived factors. Texas Heart Institute Journal, 1994, 21, 91-7.	0.3	47
1899	Role of nitric oxide in insulin-dependent diabetes mellitus-related vascular complications. Western Journal of Medicine, 1995, 162, 439-45.	0.3	26
1900	Role of nitric oxide in progression and regression of atherosclerosis. Western Journal of Medicine, 1996, 164, 419-24.	0.3	23
1901	Immunohistochemical comparison of traditional and modified harvesting of the left internal mammary artery. Texas Heart Institute Journal, 2007, 34, 290-5.	0.3	3
1902	Vascular gene transfer of the human inducible nitric oxide synthase: characterization of activity and effects on myointimal hyperplasia. Molecular Medicine, 1996, 2, 211-25.	4.4	17
1903	L-arginine and Alzheimer's disease. International Journal of Clinical and Experimental Pathology, 2009, 2, 211-38.	0.5	36
1904	Potential role for angiotensin-converting enzyme inhibitors in the treatment of glaucoma. Clinical Ophthalmology, 2007, 1, 217-23.	1.8	27
1907	The prevention of cardiovascular disease in cancer survivors. Texas Heart Institute Journal, 2012, 39, 190-8.	0.3	50
1908	Pomegranate Flower Extract does not Prevent Cisplatin-Induced Nephrotoxicity in Female Rats. International Journal of Preventive Medicine, 2014, 5, 1621-5.	0.4	13
1909	The Contrary Impact Of Diabetes And Exercise On Endothelial Nitric Oxide Synthase Function. WebmedCentral, 2010, $1$ , .	0.0	1
1910	Vascular Endothelial Growth Factor Increases Endothelial Nitric Oxide Synthase Transcription In Huvec Cells. WebmedCentral, $2010,1,.$	0.0	2
1911	Antioxidant and anti-inflammatory medicinal plants have potential role in the treatment of cardiovascular disease: a review. American Journal of Cardiovascular Disease, 2017, 7, 19-32.	0.5	23
1912	Nitric oxide releasing nanomatrix gel treatment inhibits venous intimal hyperplasia and improves vascular remodeling in a rodent arteriovenous fistula. Biomaterials, 2022, 280, 121254.	11.4	15
1913	Exercise-Induced Pulmonary Hypertension: How to Define, Diagnose, and Treat At-Risk Patients. McGill Journal of Medicine, 2021, 20, .	0.1	0
1914	Effects of dipyridamole and its use in neurology. Meditsinskiy Sovet, 2021, , 41-48.	0.5	1

#	Article	IF	CITATIONS
1915	Morphological alterations and NO-synthase expression in the heart after continuous light exposure of rats. Physiological Research, 2007, 56 Suppl 2, S71-S76.	0.9	8
1916	Is NO the king? Pathophysiological benefit with uncertain clinical impact. Physiological Research, 2007, 56 Suppl 2, S1-S6.	0.9	16
1917	Nitric oxide: Clinical applications in critically ill patients. Nitric Oxide - Biology and Chemistry, 2022, 121, 20-33.	2.7	21
1918	Effect of short-term treatment with a monoclonal antibody to P-selectin on balloon catheter-induced: intimal hyperplasia, re-endothelialization, and attenuation of endothelial-dependent relaxation. Molecular and Cellular Biochemistry, 1997, 176, 13-20.	3.1	2
1919	Nitric Oxide Delivering Surfaces: An Overview of Functionalization Strategies and Efficiency Progress. Advanced Healthcare Materials, 2022, 11, e2102692.	7.6	11
1920	Coronary Artery Disease in Granulomatosis with Polyangiitis: a Review. SN Comprehensive Clinical Medicine, 2022, 4, 1.	0.6	1
1921	Endothelial Dysfunction and 6-Year Risk of Mortality in Kidney Transplant Recipients. Transplantation Direct, 2022, 8, e1262.	1.6	1
1922	Mechanisms underlying the effects of caloric restriction on hypertension. Biochemical Pharmacology, 2022, 200, 115035.	4.4	9
1923	Transplant Arteriopathy: Role of Nitric Oxide Synthase., 2006,, 435-454.		0
1931	Uncoupling of Endothelial Nitric Oxide Synthase in Atherosclerosis. , 0, , 275-299.		O
1932	Parallel regulation of arginine transport and nitric oxide synthesis by angiotensin II in vascular smooth muscle cells role of protein kinase C. Amino Acids, 1996, 11, 153-170.	2.7	7
1933	Effect of dietary supplementation with fish oil on cyclosporine A-induced vascular toxicity. Cardiovascular Drugs and Therapy, 1996, 10, 379-385.	2.6	2
1934	VEGFmRNA and eNOSmRNA expression in immature rabbits with bleomycin-induced pulmonary hypertension. Journal of Zhejiang University Science B, 2004, 5, 995-1000.	0.4	1
1937	Oligoglycine and fluoropolymer functionalized enzyme-responsive gene delivery surface for rapid in situ endothelialization of vascular grafts. Applied Materials Today, 2022, 27, 101476.	4.3	5
1941	Alterations in Nitric Oxide Production in 8-Week-Old Lambs with Increased Pulmonary Blood Flow. Pediatric Research, 2002, 52, 233-244.	2.3	0
1942	Endothelial dysfunction: basis for many local and systemic conditions., 2022,, 313-326.		0
1943	Inhaled nitric oxide: role in the pathophysiology of cardio-cerebrovascular and respiratory diseases. Intensive Care Medicine Experimental, 2022, 10, .	1.9	16
1944	Exercise-Induced Pulmonary Hypertension: How to Define, Diagnose, and Treat At-Risk Patients. McGill Journal of Medicine, 2022, 20, .	0.1	O

#	Article	IF	CITATIONS
1945	Chronic thromboembolic pulmonary hypertension: from pathogenesis to the choice of treatment tactics. Terapevticheskii Arkhiv, 2022, 94, 791-796.	0.8	2
1946	Endothelıal nıtrıc oxide synthase Glu298asp gene polymorphism in the cases of idiopathic thrombocytopenic purpura. Blood Research, 2022, , .	1.3	0
1947	The Impact of Tobacco Cigarettes, Vaping Products and Tobacco Heating Products on Oxidative Stress. Antioxidants, 2022, 11, 1829.	5.1	12
1948	Endothelial modulation of pulmonary vascular tone. European Respiratory Journal, 1992, 5, 757-762.	6.7	94
1949	Coronary artery disease, nitric oxide and oxidative stress: The "Yin-Yang" effect - a Chinese concept for a worldwide pandemic. Swiss Medical Weekly, 0, , .	1.6	13
1950	Vascular smooth muscle cell dysfunction in neurodegeneration. Frontiers in Neuroscience, 0, 16, .	2.8	14
1952	Endothelial-mesenchymal transition induced by metastatic 4T1 breast cancer cells in pulmonary endothelium in aged mice. Frontiers in Molecular Biosciences, 0, 9, .	3.5	1
1953	Arterial dissections: Common features and new perspectives. Frontiers in Cardiovascular Medicine, 0, 9, .	2.4	16
1954	Inducible Nitric Oxide: An Autoregulatory Feedback Inhibitor of Vascular Inflammation. Journal of Immunology, 1998, 161, 1970-1976.	0.8	140
1955	Melatonin in Health and Disease: A Perspective for Livestock Production. Biomolecules, 2023, 13, 490.	4.0	4
1956	Nitric Oxide and Cardiovascular Health. , 2023, , 15-39.		0
1957	Effect of hypoxia on HIF- $1\hat{l}_{\pm}$ and NOS3 expressions in CD34+ cells of JAK2V617F-positive myeloproliferative neoplasms. Advances in Medical Sciences, 2023, 68, 169-175.	2.1	0
1958	Inhaled Nitric Oxide in Acute Respiratory Distress Syndrome Subsets: Rationale and Clinical Applications. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2023, 36, 112-126.	1.4	3
1959	Nitric Oxide, Its Role in Diabetes Mellitus and Methods to Improve Endothelial Function. Contemporary Cardiology, 2023, , 159-200.	0.1	1
1961	Impact of Breaking up of Sitting Time on Anti-inflammatory Response Induced by Extracellular Vesicles. Current Pharmaceutical Design, 2023, 29, 2524-2533.	1.9	0
1962	Association between dietary intakes of Nitrate and Nitrite with Angina and atherogenic index in adults: A cross-sectional study from Tehran University of Medical Sciences employees` cohort (TEC) study. Current Problems in Cardiology, 2024, 49, 102206.	2.4	0
1963	Angiotensin II Receptor Blockers: Novel Therapy for Heart Failure?. Pharmacotherapy, 1996, 16, .	2.6	1
1964	VEGFmRNA and eNOSmRNA expression in immature rabbits with bleomycin-induced pulmonary hypertension. Journal of Zhejiang University: Science A, 2004, 5, 995-1000.	2.4	О

#	Article	IF	CITATIONS
1965	Nitric Oxide in the Developing Lung. Advances in Pediatrics, 1995, 42, 367-414.	1.4	1
1966	Nitric oxide in vascular biology: elegance in complexity. Journal of Clinical Investigation, 2024, 134, .	8.2	0
1967	Therapeutic potential of organosulfur compounds in pulmonary hypertension. PharmaNutrition, 2024, 27, 100382.	1.7	0